<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cbf70031" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Biochem Funct</journal-id><journal-id journal-id-type="iso-abbrev">Cell Biochem Funct</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">CBF</journal-id><journal-title-group><journal-title>Cell Biochemistry and Function</journal-title></journal-title-group><issn pub-type="ppub">0263-6484</issn><issn pub-type="epub">1099-0844</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11662099</article-id><article-id pub-id-type="pmcid-ver">PMC11662099.1</article-id><article-id pub-id-type="pmcaid">11662099</article-id><article-id pub-id-type="pmcaiid">11662099</article-id><article-id pub-id-type="pmid">39707603</article-id><article-id pub-id-type="doi">10.1002/cbf.70031</article-id><article-id pub-id-type="publisher-id">CBF70031</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Biotechnological Interventions for the Production of Subunit Vaccines Against Group A Rotavirus</article-title></title-group><contrib-group><contrib id="cbf70031-cr-0001" contrib-type="author"><name name-style="western"><surname>Prajapati</surname><given-names initials="M">Mukta</given-names></name><xref rid="cbf70031-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cbf70031-cr-0002" contrib-type="author"><name name-style="western"><surname>Malik</surname><given-names initials="P">Pooja</given-names></name><xref rid="cbf70031-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cbf70031-cr-0003" contrib-type="author"><name name-style="western"><surname>Sinha</surname><given-names initials="A">Astha</given-names></name><xref rid="cbf70031-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cbf70031-cr-0004" contrib-type="author"><name name-style="western"><surname>Yadav</surname><given-names initials="H">Honey</given-names></name><xref rid="cbf70031-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cbf70031-cr-0005" contrib-type="author"><name name-style="western"><surname>Jaiwal</surname><given-names initials="YK">Yachna K.</given-names></name><xref rid="cbf70031-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cbf70031-cr-0006" contrib-type="author"><name name-style="western"><surname>Ahlawat</surname><given-names initials="YK">Yogesh K.</given-names></name><xref rid="cbf70031-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cbf70031-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cbf70031-cr-0007" contrib-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names initials="D">Darshna</given-names></name><xref rid="cbf70031-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cbf70031-cr-0008" contrib-type="author"><name name-style="western"><surname>Jaiwal</surname><given-names initials="R">Ranjana</given-names></name><xref rid="cbf70031-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="cbf70031-cr-0009" contrib-type="author"><name name-style="western"><surname>Sharma</surname><given-names initials="N">Nisha</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3500-598X</contrib-id><xref rid="cbf70031-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="cbf70031-cr-0010" contrib-type="author" corresp="yes"><name name-style="western"><surname>Jaiwal</surname><given-names initials="PK">Pawan K.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3143-4103</contrib-id><xref rid="cbf70031-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>jaiwalpawan@rediffmail.com</email></address></contrib><contrib id="cbf70031-cr-0011" contrib-type="author" corresp="yes"><name name-style="western"><surname>Chattu</surname><given-names initials="VK">Vijay K.</given-names></name><xref rid="cbf70031-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><address><email>vijay.chattu@mail.utoronto.ca</email></address></contrib></contrib-group><aff id="cbf70031-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Centre for Biotechnology</named-content>
<institution>Maharshi Dayanand University</institution>
<city>Rohtak</city>
<country country="IN">India</country>
</aff><aff id="cbf70031-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Paediatrics</named-content>
<institution>Civil Hospital</institution>
<city>Rohtak</city>
<country country="IN">India</country>
</aff><aff id="cbf70031-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmaceutical Sciences</named-content>
<institution>Maharshi Dayanand University</institution>
<city>Rohtak</city>
<country country="IN">India</country>
</aff><aff id="cbf70031-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>University Centre for Research and Development, Chandigarh University</institution>
<city>Mohali</city>
<named-content content-type="country-part">Punjab</named-content>
<country country="IN">India</country>
</aff><aff id="cbf70031-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Centre for Research Impact and Outcome</named-content>
<institution>Chitkara University Institute of Engineering and Technology, Chitkara University</institution>
<city>Rajpura</city>
<named-content content-type="country-part">Punjab</named-content>
<country country="IN">India</country>
</aff><aff id="cbf70031-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Zoology</named-content>
<institution>Maharshi Dayanand University</institution>
<city>Rohtak</city>
<country country="IN">India</country>
</aff><aff id="cbf70031-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Biotechnology</named-content>
<institution>Graphic Era (Deemed to be University)</institution>
<city>Dehradun</city>
<country country="IN">India</country>
</aff><aff id="cbf70031-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of OS &amp; OT</named-content>
<institution>Temerty Faculty of Medicine, University of Toronto</institution>
<city>Toronto</city>
<named-content content-type="country-part">Ontario</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold> Pawan K. Jaiwal (<email>jaiwalpawan@rediffmail.com</email>)<break/>
Vijay K. Chattu (<email>vijay.chattu@mail.utoronto.ca</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2024</year></pub-date><volume>42</volume><issue seq="49">8</issue><issue-id pub-id-type="pmc-issue-id">477500</issue-id><issue-id pub-id-type="doi">10.1002/cbf.v42.8</issue-id><elocation-id>e70031</elocation-id><history><date date-type="rev-recd"><day>29</day><month>11</month><year>2024</year></date><date date-type="received"><day>09</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>02</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>22</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-22 12:25:36.317"><day>22</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Cell Biochemistry and Function</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CBF-42-e70031.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CBF-42-e70031.pdf"/><abstract><title>ABSTRACT</title><p>Group A rotavirus (RVA) is a major cause of severe gastroenteritis in infants and young children globally, despite the availability of live&#8208;attenuated vaccines. Challenges such as limited efficacy in low&#8208;income regions, safety concerns for immunocompromised individuals, and cold&#8208;chain dependency necessitate alternative vaccine strategies. Subunit vaccines, which use specific viral proteins to elicit immunity, provide a safer and more adaptable approach. This review highlights biotechnological advancements in producing subunit vaccines, focusing on recombinant expression systems like bacterial, yeast, insect, mammalian, and plant&#8208;based platforms for scalable and cost&#8208;effective production of viral proteins. Key innovations include molecular engineering, adjuvant development, and delivery system improvements to enhance vaccine immunogenicity and efficacy. Subunit vaccines and virus&#8208;like particles expressed in various systems have demonstrated promising preclinical and clinical results, with some candidates nearing commercial readiness. Reverse vaccinology, combined with Artificial Intelligence and Machine Learning, is driving the development of innovative multiepitope vaccines and antivirals. Strategies such as passive immunization, single&#8208;chain antibodies, immunobiotics, and novel antivirals are also explored as alternative management options. The review also underscores advanced genome editing and reverse genetics approaches to improve vaccine design and antiviral therapies. These biotechnological interventions offer hope for equitable and effective control of rotavirus diarrhea, particularly in resource&#8208;limited settings, and represent significant progress toward addressing current vaccine limitations.</p></abstract><abstract abstract-type="highlights"><title>Summary</title><p>The development of subunit vaccines against Group A rotavirus (RV&#8208;A) is a critical step in combating rotavirus&#8208;induced diarrhea, a leading cause of morbidity and mortality in children worldwide. This paper highlights biotechnological strategies for the efficient production of subunit vaccines, focusing on the use of recombinant DNA technology, plant&#8208;based expression systems, and viral vector platforms. By leveraging these advanced techniques, the study aims to provide a more cost&#8208;effective, scalable, and safe alternative to traditional vaccine production methods. The research offers insights into optimizing antigen expression, purification processes, and immune responses, potentially improving vaccine efficacy and accessibility in low&#8208;resource settings. These biotechnological innovations could revolutionize rotavirus vaccine development, significantly contributing to global efforts to reduce the burden of rotavirus infections.</p></abstract><kwd-group><kwd id="cbf70031-kwd-0001">bio&#8208;factories</kwd><kwd id="cbf70031-kwd-0002">conventional and subunit vaccines</kwd><kwd id="cbf70031-kwd-0003">genome editing and reverse genetics</kwd><kwd id="cbf70031-kwd-0004">Group A rotaviruses</kwd><kwd id="cbf70031-kwd-0005">management</kwd><kwd id="cbf70031-kwd-0006">novel antivirals</kwd><kwd id="cbf70031-kwd-0007">reverse vaccinology</kwd><kwd id="cbf70031-kwd-0008">virus&#8208;like particles</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Pawan K. Jaiwal is grateful to the University Grants Commission, New Delhi, for the financial support in the form of the BSR Faculty Fellowship (18&#8208;1/2011(BSR)).</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="21"/><word-count count="16112"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:21.12.2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="cbf70031-sec-0010"><label>1</label><title>Introduction</title><p>Group A rotaviruses (RVs) cause life&#8208;threatening gastroenteritis worldwide in young humans and animals under 5 years. Gastroenteritis is the intestinal inflammation that causes severe dehydrating diarrhea, increasing morbidity and mortality of children and calves. Globally, rotavirus causes about 215,000 deaths of children each year and hospitalized hundreds and thousands more [<xref rid="cbf70031-bib-0001" ref-type="bibr">1</xref>]. The high proportions of these deaths are from developing countries in Asia and sub&#8208;Saharan Africa. The global cost of rotavirus infections, including outpatient visits and hospitalizations, exceeds US$ 200 million annually (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://preventrotavirus.org/rotavirus-disease/economic-burden/" ext-link-type="uri">https://preventrotavirus.org/rotavirus-disease/economic-burden/</ext-link>). Rotavirus infection has also caused calves' mortality, leading to significant economic losses to farmers and the dairy and beef industry worldwide. As per one estimate, calves' mortality due to diarrhea causes economic losses of approximately one billion yen per year in Japan [<xref rid="cbf70031-bib-0002" ref-type="bibr">2</xref>]. In 2009, the World Health Organization (WHO) licensed two live&#8208;attenuated oral vaccines against rotavirus, Rotarix and RotaTeq, which have been introduced into the national immunization programs of 120 countries worldwide, of which 53 have accessed support from the global alliance for vaccines and immunization (GAVI) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/immunization/monitoring_surveillance/en/" ext-link-type="uri">https://www.who.int/immunization/monitoring_surveillance/en/</ext-link>). These vaccines have higher efficiency (85%&#8211;96%) in several high&#8208; and middle&#8208;income countries [<xref rid="cbf70031-bib-0003" ref-type="bibr">3</xref>] whereas their efficiency is lower(49%&#8211;72%) in developing countries, where the impact of rotavirus disease is higher [<xref rid="cbf70031-bib-0004" ref-type="bibr">4</xref>]. Several factors have been implicated in their lower efficacy in developing countries. These are the deficiency of micronutrients (vitamin A and Zn), high frequency of malnutrition, competition with enteric infections and concomitant disease at the time of vaccination, and interference by gut and milk microbes and maternal antibodies [<xref rid="cbf70031-bib-0005" ref-type="bibr">5</xref>, <xref rid="cbf70031-bib-0006" ref-type="bibr">6</xref>]. Further, these vaccines are not easily accessible to populations in developing countries due to their lengthy developmental procedures, high manufacturing costs, low biosafety and high risks of intussusception [<xref rid="cbf70031-bib-0006" ref-type="bibr">6</xref>, <xref rid="cbf70031-bib-0007" ref-type="bibr">7</xref>]. Efforts are being made to enhance the efficacy, manufacturing capacity, safety, and affordability of traditional vaccines (i.e., attenuated or inactivated live virus) to develop new non&#8208;replicating rotavirus recombinant subunit vaccines based on viral protein antigens, indispensable to decrease the disease load in greatly affected populations. Plant&#8208;based productions have now emerged as a highly potent platform over fermenters based on microbial (bacterial and yeast) and animal cells due to their intrinsic safety (that do not support the replication of human pathogens and are free from microbial toxins), simplicity (requires no sterility during production), greater scalability (can be grown in open fields), and low&#8208;cost (requires only sunlight, water, and minerals for growth and production) for vaccination [<xref rid="cbf70031-bib-0008" ref-type="bibr">8</xref>, <xref rid="cbf70031-bib-0009" ref-type="bibr">9</xref>, <xref rid="cbf70031-bib-0010" ref-type="bibr">10</xref>]. The recent plant&#8208;produced pharmaceuticals, taliglucerase alfa and ZMapp, have been approved by the US Food and Drug Administration (FDA), the Newcastle disease vaccine by the US Department of Agriculture (USDA), and Medicago's COVID&#8208;19 vaccine by Health Canada and the safety of some plant&#8208;derived vaccines for influenza, cholera, and <italic toggle="yes">Bacillus anthracis</italic> in clinical trials have also been demonstrated [<xref rid="cbf70031-bib-0011" ref-type="bibr">11</xref>]. Recombinant subunit vaccines, viral&#8208;based particles, and nanoparticles produced in plants via stable or transient viral antigen(s) expression could overcome the adverse consequences of live&#8208;inactivated or attenuated vaccines. The subunit vaccines have shown high specificity, high biosafety, and a reasonable cost but are low in immunogenicity compared to whole virus vaccines. However, introducing antigens from the most widely circulating rotavirus strains into plants would effectively develop a universal multivalent rotavirus vaccine, which may be safe, free from cold chain, and easy to transport for access to remote and difficult&#8208;to&#8208;reach populations at low cost. This study discusses the currently licensed rotavirus vaccines, along with the latest advances in the production of rotavirus subunit vaccines and virus&#8208;like particles (VLPs) in bacteria, yeast, insect, and mammalian cells, transient and stably transformed plants (derived from nuclear [transgenic] or chloroplast [transplastomic] transformations), DNA based and cell&#8208;free platforms for the first time [<xref rid="cbf70031-bib-0011" ref-type="bibr">11</xref>]. The expressed antigens have maintained their immunogenic properties, eliciting protective immune responses in animal and human models. Recent advances in reverse vaccinology (RV) have been presented in designing novel multiepitope rotavirus vaccines. Besides vaccines, an overview of the other management strategies like passive immunization, single chain antibodies, immunobiotics, and novel antivirals is also highlighted along with genome editing and reverse genetics (RG) approaches for the future improvement in vaccines and antivirals to sustainably control rotavirus diarrhea, especially in developing countries.</p></sec><sec id="cbf70031-sec-0020"><label>2</label><title>Structure of Rotavirus Virions</title><p>Bovine/human rotaviruses (HRVs) are members of the genus <italic toggle="yes">Rotavirus</italic> of the family Sedoreoviridae. The rotaviruses obtained their name from the Latin word &#8220;rota,&#8221; meaning wheel&#8208;like structure. These are comprised of the non&#8208;enveloped icosahedral capsid (80&#8201;nm isometric diameter) enclosing a total of ~18.55&#8201;kb long linear genome made of 11 double&#8208;stranded RNA (dsRNA) segments in the size of 0.6&#8211;3.3&#8201;kb with conserved 5&#8242; and 3&#8242; noncoding regions. Each segment is a gene that encodes for a protein, except the 11th segment, which encodes for two proteins. These RNA genomic segments are translated into six structural (VP1&#8211;VP4, VP6, and VP7) and six nonstructural (NSP1&#8211;NSP5 or NSP6) proteins [<xref rid="cbf70031-bib-0012" ref-type="bibr">12</xref>]. The six structural proteins form three concentric layers of the viral capsid. Core protein (VP2) forms an inner layer that encloses the RNA&#8208;dependent RNA polymerase (VP1), the capping enzyme (VP3), and the viral genome. A middle layer of VP6 protein further surrounds this to form a DLP (double&#8208;layered particle), which gains an outermost VP7 protein layer and spike&#8208;forming VP4 protein. VP4 protein consists of two subunits, VP5* at C&#8208;terminal and VP8* at N&#8208;terminal. These subunits facilitate virus entry by interacting with various receptors present on the cell surface [<xref rid="cbf70031-bib-0012" ref-type="bibr">12</xref>]. The host&#8211;cell attachment protein, VP7, is a glycoprotein (G antigen, G genotype), and the antibodies&#8208;neutralizing protein VP4 is a protease&#8208;sensitive protein (P antigen, P genotype). Both these proteins are located on the outer layer of the rotavirus [<xref rid="cbf70031-bib-0003" ref-type="bibr">3</xref>, <xref rid="cbf70031-bib-0012" ref-type="bibr">12</xref>]. The nonstructural proteins (NSP1&#8211;NSP6) participate in several virus functions like genome replication, particle assembly, viral gene expression stimulation, and host innate response regulation [<xref rid="cbf70031-bib-0012" ref-type="bibr">12</xref>]. Rotavirus transcriptase synthesizes a cap (m7GpppG) at 5&#8242; untranslated region (UTR) of their genome and contains a consensus sequence at 3&#8242; UTR but lacks a polyA tail. Rotavirus gene segments, their size, molecular weight, length of noncoding sequence, properties, and functions are represented in Table&#160;<xref rid="cbf70031-suppl-0001" ref-type="supplementary-material">S1</xref>.</p><p>Rotavirus strains have been identified as 10 serogroups/species (A to I or J) based on serological reactivity and genetic variability of VP6 inner capsid protein, and into various genotypes encoding VP7 (G type) and VP4 (P&#8208;type) within species (Table&#160;<xref rid="cbf70031-suppl-0001" ref-type="supplementary-material">S2</xref>). The A, B, and C serogroups cause disease in man and various animal species. The most widely studied virulent and frequently isolated rotavirus strains of serogroup A cause contagious diarrhea in children and various domestic mammals and bird species [<xref rid="cbf70031-bib-0003" ref-type="bibr">3</xref>]. Animal and human group A RV strains have been identified with 36G and 51P genotypes (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rega.kuleuven.be/cev/viralmetagenomics/virus-classification/rcwg" ext-link-type="uri">https://rega.kuleuven.be/cev/viralmetagenomics/virus-classification/rcwg</ext-link>). The most widely circulated HRV genotypes belong to six VP7 G (G1&#8211;G4, G9, G12) and three VP4 P (P4, P6, P8). Among them, six combo groups or serotypes G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], and G12P[8], are accountable for over 90% of the serious rotavirus infections [<xref rid="cbf70031-bib-0003" ref-type="bibr">3</xref>, <xref rid="cbf70031-bib-0007" ref-type="bibr">7</xref>]. Serotypes G1, G6, G8, and G10, together with P [1], P [5], and P [11], are most commonly found with bovine group A rotavirus infections (Table&#160;<xref rid="cbf70031-suppl-0001" ref-type="supplementary-material">S3</xref>).</p></sec><sec id="cbf70031-sec-0030"><label>3</label><title>Management of Rotavirus&#8208;Induced Diarrhea</title><p>Unfortunately, no specific treatment for rotavirus infection is available except supportive care with oral rehydration salts to prevent dehydration, zinc supplementation, and continued feeding [<xref rid="cbf70031-bib-0013" ref-type="bibr">13</xref>]. Some specific treatments are Rotavirus group A (RVA) specific bovine colostrum [<xref rid="cbf70031-bib-0014" ref-type="bibr">14</xref>], monoclonal antibodies (mAbs) [<xref rid="cbf70031-bib-0015" ref-type="bibr">15</xref>], egg yolk polyclonal immunoglobulins (Ig) YAbs [<xref rid="cbf70031-bib-0016" ref-type="bibr">16</xref>], probiotics/immunobiotics [<xref rid="cbf70031-bib-0017" ref-type="bibr">17</xref>], drugs [<xref rid="cbf70031-bib-0018" ref-type="bibr">18</xref>], and natural herbal compounds [<xref rid="cbf70031-bib-0018" ref-type="bibr">18</xref>, <xref rid="cbf70031-bib-0019" ref-type="bibr">19</xref>]. Some strategies have reduced diarrhea fluid loss and duration, but none is accepted as a consistent treatment for rotavirus diarrhea.</p><sec id="cbf70031-sec-0040"><label>3.1</label><title>Passive Immunization</title><p>Passive immunization involves the administration of already mature immunoglobulins (antibodies, Igs) to overcome infectious diseases. This type of immunity may be natural, where maternal antibodies are transferred to the offspring, inducing protection before their self&#8208;immunity is built up [<xref rid="cbf70031-bib-0020" ref-type="bibr">20</xref>]. Passive immunity can also be induced by immunization of cows against HRV, providing colostrums or mature milk with pathogen&#8208;specific antibodies to prevent diarrhea and reduce rotavirus shedding [<xref rid="cbf70031-bib-0021" ref-type="bibr">21</xref>]. The bovine milk with rotavirus&#8208;specific immunoglobulins has shown protective effects in mice [<xref rid="cbf70031-bib-0022" ref-type="bibr">22</xref>], cows [<xref rid="cbf70031-bib-0023" ref-type="bibr">23</xref>], and piglets [<xref rid="cbf70031-bib-0024" ref-type="bibr">24</xref>]. Similar passive defense of suckling mice and cows against HRV infection has also been achieved with oral immunoglobulin from the egg yolk (IgY) of hens immunized with rotavirus [<xref rid="cbf70031-bib-0025" ref-type="bibr">25</xref>]. Calves are protected from RVA infection on administration of anti&#8208;bovine rotavirus IgY obtained in a noninvasive way (extracted and purified) from egg yolk of hens immunized with the two distinct RVAs genotypes G6P [<xref rid="cbf70031-bib-0005" ref-type="bibr">5</xref>] and G10P [<xref rid="cbf70031-bib-0002" ref-type="bibr">2</xref>, <xref rid="cbf70031-bib-0011" ref-type="bibr">11</xref>]. Strong cross&#8208;reactivity was seen between the anti&#8208;bovine IgYs and bovine RVA with the same G and P genotypes. IgY, being with high sialic acid, has increased half&#8208;life and improved efficacy against infections [<xref rid="cbf70031-bib-0020" ref-type="bibr">20</xref>]. Recently, incorporating oral bovine immunoglobulin in infant nutrition and dairy products may be a brilliant approach to maintaining immune function in weak groups such as infants, children, elderly, and immune&#8208;compromised patients [<xref rid="cbf70031-bib-0026" ref-type="bibr">26</xref>]. Passive immunization using animal colostrum or IgYAbs has raised concerns about adventitious viruses and allergic reactions.</p></sec><sec id="cbf70031-sec-0050"><label>3.2</label><title>Single&#8208;Domain Antibodies (sdAbs)</title><p>Conventional/mAbs have high antigen specificity and affinity and are successfully used to diagnose and treat several diseases. However, their large size (150&#8201;kDa prevents them from penetrating tissues and making some epitopes inaccessible) and high production costs limit their therapeutic efficiency [<xref rid="cbf70031-bib-0027" ref-type="bibr">27</xref>]. In addition, camelids (camels and Ilamas) serum contains distinct antibodies that do not have light chains and are called &#8220;heavy&#8208;chain only&#8221; or sdAbs [<xref rid="cbf70031-bib-0028" ref-type="bibr">28</xref>]. The single variable region of these heavy chain antibodies called VHH or nanobodies is the naturally occurring antigen binding region. sdAbs are smaller in size (~15&#8201;kDa, can easily penetrate dense tissues), possess specificity for epitopes, stable at high temperatures, and extreme pH (conditions such as of the gastrointestinal tract), low immunogenicity, attractive pharmacokinetics and pharmacodynamic properties, and relatively low&#8208;production costs [<xref rid="cbf70031-bib-0029" ref-type="bibr">29</xref>]. Since camelid's VHH antibody fragments are encoded by only a single gene (<italic toggle="yes">vhh</italic>) comprising a single polypeptide with no glycosylation, it allows their production in prokaryotic expression systems (bacteria), thus saving time and money. They are also proficiently produced in large amounts of yeast, mammalian, or plant cells with realistic costs [<xref rid="cbf70031-bib-0030" ref-type="bibr">30</xref>]. Ilamas immunized with rhesus&#8208;monkey group A rotavirus (RVA) strain produce an anti&#8208;rotavirus VHH (termed anti&#8208;rotavirus protein, ARP1), which has been expressed in rice seeds (termed MucoRice&#8208;ARP1) at high levels by simultaneously suppressing the major rice endogenous storage proteins. ARP1 produced in rice seeds can be consumed directly with minimum processing or purification and stored at room temperature for a long time without losing antiviral activity. This is helpful for remote areas where cold chains are not easy to maintain. MucoRice&#8208;ARP1 neutralizes 11 strains even after long&#8208;term storage (&gt;&#8201;1&#8201;y) and prevents RVA&#8208;induced diarrhea in neonatal mouse models after heat treatment at 94&#176;C for 30&#8201;min [<xref rid="cbf70031-bib-0026" ref-type="bibr">26</xref>, <xref rid="cbf70031-bib-0031" ref-type="bibr">31</xref>]. Probiotic lactobacilli (<italic toggle="yes">Lactobacillus paracasei</italic>) expressing anti&#8208;rotavirus VHH have been developed to deliver therapeutic agents for treating gastroenteritis [<xref rid="cbf70031-bib-0032" ref-type="bibr">32</xref>, <xref rid="cbf70031-bib-0033" ref-type="bibr">33</xref>]. Recently, the first clinical trial of oral ARP1 therapy in infants with RVA&#8208;associated diarrhea showed a substantial decrease in stool frequency with no side effects [<xref rid="cbf70031-bib-0034" ref-type="bibr">34</xref>]. One more VHH, 3B2, specific to the inner capsid protein VP6, has shown a broader neutralizing capacity against RVA strains at low doses and protected RVA&#8208;induced diarrhea in neonatal mice and gnotobiotic piglets [<xref rid="cbf70031-bib-0035" ref-type="bibr">35</xref>]. In a neonatal model, additional postinfection therapeutic therapy with 3B2 or 2KD1 significantly decreased the duration of RVA&#8208;induced diarrhea [<xref rid="cbf70031-bib-0036" ref-type="bibr">36</xref>]. The two significant difficulties, like the short half&#8208;life of sdAbs in circulation and their potential immunogenicity, must be resolved before allowing their use in vivo. Several strategies, that is, linking sdAbs with other molecules or pro&#8208;drugs and combining sdAbs that bind various epitopes or have diverse modes of action, allow the development of multivalent compounds with high affinity or efficacy [<xref rid="cbf70031-bib-0037" ref-type="bibr">37</xref>].</p></sec><sec id="cbf70031-sec-0060"><label>3.3</label><title>Immunobiotics</title><p>Immunobiotics administer live microbes in adequate amounts to modulate the host mucosal and systematic immune systems. The immuno&#8208;regulatory probiotic microorganisms (immunobiotic) can protect humans and animals against intestinal rotavirus infections. The immunobiotic strains beneficially alter toll&#8208;like receptor 3&#8208;initiated immune responses in bovine intestinal epithelial cells to reduce the disruption of intestinal homeostasis brought by intraepithelial lymphocytes and increase the resistance to viral infections [<xref rid="cbf70031-bib-0038" ref-type="bibr">38</xref>]. Lactic acid bacteria can protect against viral pathogens by modulating antiviral immune responses in humans and livestock animals [<xref rid="cbf70031-bib-0039" ref-type="bibr">39</xref>]. The segmented filamentous bacteria promote the protection of mice against RV infection and associated diarrhea in an immune cell&#8208;independent way, presumably by altering the host's gene expression, accelerating the turnover of epithelial cells, or directly neutralizing RV [<xref rid="cbf70031-bib-0040" ref-type="bibr">40</xref>]. Studies on gnotobiotic pig and neonatal rat models and human intestinal organoids/enteroids have shown that commensal gut microbiota and probiotics limit the severity of RV infection either by reducing mucin secretion or inducing cytokine interferon lambda (IFN&#8208;&#955;) and IFN&#8208;&#945;/&#946; or activating cytokine interleukin 22 (IL&#8208;22) and IL&#8208;18 signaling [<xref rid="cbf70031-bib-0041" ref-type="bibr">41</xref>]. Further, more studies are required to understand the mechanisms of gut microbiota interactions with RV infection.</p></sec><sec id="cbf70031-sec-0070"><label>3.4</label><title>Vaccine Development</title><p>Vaccination is the most active measure to control rotavirus infection. The global HRV vaccine market is expected to grow from its estimated valuation of USD 7.20 billion in 2022 to USD 10.36 billion by 2030 (Data Bridge Market Research, Global HRV vaccine market &#8211; Industry trends and forecast to 2030, retrieved on November 26, 2024, from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.databridgemarketresearch.com/reports/global-human-rotavirus-vaccine-market" ext-link-type="uri">www.databridgemarketresearch.com/reports/global-human-rotavirus-vaccine-market</ext-link>). Several types of rotavirus vaccines currently approved and under development are presented in Figure&#160;<xref rid="cbf70031-fig-0001" ref-type="fig">1</xref>.</p><fig position="float" fig-type="Figure" id="cbf70031-fig-0001" orientation="portrait"><label>Figure 1</label><caption><p>Rotavirus vaccines approved and under development.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CBF-42-e70031-g001.jpg"/></fig><sec id="cbf70031-sec-0080"><label>3.4.1</label><title>Current Licensed Live Oral&#8208;Attenuated Rotavirus Vaccines</title><p>Rotavirus causes infection at the mucosal surfaces of the host intestine, and systemic immunity is usually ineffective in providing adequate protection against them. Mucosal immunity induced by oral/nasal administration of vaccines (characterized by the local synthesis of secretory IgA and systemic immunity) provides efficient protection against these pathogens [<xref rid="cbf70031-bib-0042" ref-type="bibr">42</xref>]. The first licensed rotavirus vaccine, Rotashield, a tetravalent rhesus monkey&#8208;human reassortment vaccine, was released in the USA in 1998. However, it was withdrawn in 1999 due to an increased risk of intussusceptions (a rare bowel obstruction). Subsequently, four oral, live&#8208;attenuated rotavirus vaccines have been developed and licensed for worldwide use against all broad&#8208;range forms of rotavirus infections (Table&#160;<xref rid="cbf70031-suppl-0001" ref-type="supplementary-material">S4</xref>). These are a monovalent vaccine, Rotarix (RV1, GlaxoSmithKline Biologics, Belgium) and a pentavalent vaccine, RotaTeq (RV5, Merck &amp; Co. Inc., USA) prequalified by the WHO in 2006; Rotavac (Bharat Biotech, Hyderabad, India) and Rotasiil (Serum Institute of India, Pune, India) prequalified in 2018 [<xref rid="cbf70031-bib-0043" ref-type="bibr">43</xref>, <xref rid="cbf70031-bib-0044" ref-type="bibr">44</xref>]. These vaccines have tremendously succeeded in preventing and reducing the prevalence of rotavirus diarrhea and hospitalization in children. However, vaccine efficiency differs by region and country. The efficacy of RV1 and RV5 vaccines is higher in developed than middle&#8208; to low&#8208;income countries. The efficacy of recently prequalified vaccines, Rotavac and Rotasiil, outside of India would be considered only when introduced globally. The implementation of the licensed replicating live attenuated vaccines suffers from difficulties in developing countries due to (i) their high price, (ii) the low efficacies in sub&#8208;Saharan Africa and Asia which account for 90% of all Rotavirus infections worldwide [<xref rid="cbf70031-bib-0045" ref-type="bibr">45</xref>], (iii) the risk of reversion to virulence, leading to vaccine&#8208;induced disease, (iv) capability of genome reassortment either with circulating wild strain or attenuated polyvalent vaccines components may result in the emergence of virulent strains resistant to vaccine, (v) Rotavirus symptomatic infection can even occur in vaccinated children in Spain [<xref rid="cbf70031-bib-0046" ref-type="bibr">46</xref>], (vi) Rotavirus vaccines including those from India are associated with a considerable risk of intussusceptions [<xref rid="cbf70031-bib-0045" ref-type="bibr">45</xref>], and environmental enteric dysfunction in 80% of infants aged 12 weeks [<xref rid="cbf70031-bib-0047" ref-type="bibr">47</xref>], (vii) contaminations of globally licensed rota&#8208;vaccines with porcine circoviruses, and (viii) all vaccines except Rotasiil require a cold chain to maintain efficacy, long life span, and transportation. Moreover, the total capacity for rotavirus vaccine production is far less than the global demand [<xref rid="cbf70031-bib-0048" ref-type="bibr">48</xref>], which requires strenuous efforts to develop new non&#8208;replicating oral vaccines that are safer, inexpensive, and efficient against rotavirus infection without intussusceptions.</p></sec><sec id="cbf70031-sec-0090"><label>3.4.2</label><title>Locally Licensed New Live Oral Attenuated Rotavirus Vaccines</title><p>Additional live attenuated vaccines licensed for domestic use have been developed to overcome the limitations of live attenuated oral vaccines and to ensure vaccine diversity and adequate global vaccine supply at low cost. The nationally licensed (ROTAVIN&#8208;M1, POLYVAC, Vietnam; Lanzhou Lamb Rotavirus, Lanzhou Institute of Biological Products, China and RV3&#8208;BB, PT Biofarma, Indonesia) vaccines have been developed in developing countries (Table&#160;<xref rid="cbf70031-suppl-0001" ref-type="supplementary-material">S5</xref>). The manufacturing process details of currently available oral rotavirus vaccines (Rotateq, Rotarix, Rotavac, and Rotasiil) have not been published [<xref rid="cbf70031-bib-0049" ref-type="bibr">49</xref>]. However, a low&#8208;cost (maximum of 3&#8211;5 USD per entire vaccination course of three doses) commercial production of liquid RV3&#8208;BB rotavirus vaccine formulations stable at 2&#176;C&#8211;8&#176;C (refrigerator temperature) for 2 years has been produced from the naturally attenuated RV3 strain of rotavirus. For neonatal use, liquid RV3&#8208;BB vaccines are administrated orally in lower volumes (0.50&#8211;1.0&#8201;mL) to prevent the virus from becoming inactivated in the stomach's acidic environment [<xref rid="cbf70031-bib-0050" ref-type="bibr">50</xref>]. RV3&#8208;BB neonatal (G3P [<xref rid="cbf70031-bib-0006" ref-type="bibr">6</xref>]) vaccine is safe and immunogenic in neonates and infants in Indonesia. It can potentially protect infants in other high child mortality countries of Africa and Asia [<xref rid="cbf70031-bib-0051" ref-type="bibr">51</xref>].</p><p>The Phase I clinical trial of live attenuated hexavalent bovine&#8208;human reassortment rotavirus (G1, G2, G3, G4, G8, and G9) developed by the Wuhan Institute of Biological Products, China, is safe in all adults, toddlers, and infants and protect children against rotavirus [<xref rid="cbf70031-bib-0052" ref-type="bibr">52</xref>].</p></sec><sec id="cbf70031-sec-0100"><label>3.4.3</label><title>Non&#8208;Replicating Injectable Rotavirus Vaccines That Avoid the Oral Route</title><p>Non&#8208;replicating rotavirus vaccines use killed or inactivated protein antigens or their parts (subunits) injected directly into the bloodstream, bypassing the gut and reducing the risk of intussusception. They offer superior efficacy in low&#8208;income countries by avoiding factors hindering immune responses, such as microbiota composition and malnutrition [<xref rid="cbf70031-bib-0053" ref-type="bibr">53</xref>]. These include subunit vaccines, VLPs, and nanoparticles. Unlike live oral vaccines, they do not replicate in the intestine.</p><sec id="cbf70031-sec-0110"><label>3.4.3.1</label><title>Subunit Vaccines</title><p>Subunit vaccines comprise purified whole proteins or their parts (epitopes) as antigens, which are prevalent due to their safety and high&#8208;volume production compared to whole&#8208;pathogen vaccines. However, they are less immunogenic than whole&#8208;pathogen vaccines, requiring adjuvants and repeated vaccination doses to improve their immunogenicity [<xref rid="cbf70031-bib-0054" ref-type="bibr">54</xref>]. Their immunogenicity and stability have also been increased by approaches like VLPs and nanoparticle vaccines [<xref rid="cbf70031-bib-0055" ref-type="bibr">55</xref>]. VP6 is the major, most immunogenic, and highly conserved protein of the intermediate layer of the rotavirus that contains determinants for viral group and subgroup. VP6 vaccine induces heterologous cross&#8208;protective rotavirus immunity in mice, although induced antibodies against VP6 are not neutralizing. VP6 protein fused with maltose binding protein (MBP: VP6) on administration via several methods, such as intranasally, orally, or intrarectally, to mice, has provided both immunogenicity and protection [<xref rid="cbf70031-bib-0056" ref-type="bibr">56</xref>]. The vaccinated mice have shown 100% protection against challenges with rotavirus on coadministration with adjuvant. Oral and intrarectal single dose of MBP: VP6 has protected all mice strains for at least 1 year. The outer protein layer of VP4 and VP7 are targets of neutralizing and protective antibodies (Abs). VP4, a non&#8208;glycosylated protein, is cleaved in the presence of trypsin into a stalk VP5* and globular head VP8* proteins. The mAbs targeted towards VP8, but not VP5, are competent to neutralize virus infectivity by preventing viral binding. VP7 is a major neutralizing antigen that induces neutralizing Abs.</p></sec><sec id="cbf70031-sec-0120"><label>3.4.3.2</label><title>Truncated VP8* Subunit Vaccine</title><p>A truncated rotavirus VP8* subunit protein induces highly effective neutralizing antibodies against RV and controls diarrhea. It has low immunogenicity owing to its small size and low valence. VP8* has been used in several vaccine platforms, including recombinant fusion proteins (each VP8* truncation joined at the N&#8208;terminus with the P2 epitope of tetanus toxin [<xref rid="cbf70031-bib-0057" ref-type="bibr">57</xref>]) and nanoparticles (VP8* inserted in the structural loops of the norovirus S or P particle) to make it more immunogenic. The National Institute of Health (NIH) and the Program for Appropriate Technology in Health (PATH) have developed a trivalent P2&#8208;VP8 non&#8208;replicating rotavirus vaccine that is made of by fusing three truncated rotavirus VP8 subunit proteins from the most common rotavirus serotypes P[4], P[6], and P[8] with P2&#8208;epitope of tetanus toxin resulting in P2&#8208;VP8&#8208;P[4], P2&#8208;VP8&#8208;P[6], and P2&#8208;VP8&#8208;P[8]. These three recombinants truncated VP8 serotypes are manufactured by expressing them in <italic toggle="yes">Escherichia coli</italic> and recovered by multiple centrifugation steps, cell lysis, and chromatography, followed by their blending and formulation with adjuvant [<xref rid="cbf70031-bib-0058" ref-type="bibr">58</xref>]. Advance trials of the parenteral P2&#8208;VP8&#8208;P[8] and trivalent P2&#8208;VP8&#8208;P[4], [6], [8] subunit vaccines are tolerable and immunogenic in infants and all South African participants (adults, toddlers, and infants) at all doses [<xref rid="cbf70031-bib-0059" ref-type="bibr">59</xref>], respectively. The promising safety and immunogenicity of P2&#8208;VP8&#8208;P[4], [6], [8] have advanced the vaccine at phase 3 trials for efficacy testing [<xref rid="cbf70031-bib-0060" ref-type="bibr">60</xref>] and vaccine potency (physiochemical stability of each protein antigen) and degradation [<xref rid="cbf70031-bib-0061" ref-type="bibr">61</xref>]. Molecular engineering of trivalent non&#8208;replicating subunit vaccine using advanced genomic methods has improved its production (by reducing steps compared to the standard procedure using microbial expression recovery), reduced product&#8208;related modifications (caused by N&#8208;terminal truncation, hyper&#8208;mannosylation, and aggregation), increased titers by concomitantly manufacturing multiple serotypes, and promoted secretion by a yeast (<italic toggle="yes">Komagataella phaffii</italic>) host [<xref rid="cbf70031-bib-0062" ref-type="bibr">62</xref>]. Thus, molecular engineering of trivalent vaccines has reduced the vaccine production cost by minimizing the necessary facility, time, and space. Moreover, the crystallization of the non&#8208;replicating rotavirus vaccine, P2&#8208;VP8, has been designed to reduce purification costs, offer new product storage stability, improve operational flexibility, and reduce required facilities [<xref rid="cbf70031-bib-0063" ref-type="bibr">63</xref>]. A two&#8208;step workflow has been designed for screening variants of recombinant protein vaccine antigens [P8] and [P4] under various vaccine formulations to identify a low&#8208;cost, aluminum adjuvanted, multidose vaccine targeted for use in low&#8208; and medium&#8208;income countries [<xref rid="cbf70031-bib-0064" ref-type="bibr">64</xref>]. Further, a conjugate bivalent vaccine (Vi&#8208;&#916;VP8*) developed by covalently conjugating a truncated version of the rotavirus &#916;VP8* to the <italic toggle="yes">Salmonella typhi</italic> virulence capsular polysaccharide (Vi) has not only significantly enhanced VP8*'s immunogenicity but also induced immune responses against both antigens in immunized mice [<xref rid="cbf70031-bib-0065" ref-type="bibr">65</xref>].</p></sec><sec id="cbf70031-sec-0130"><label>3.4.3.3</label><title>VLPs</title><p>VLPs are non&#8208;replicating rotavirus vaccines produced by co&#8208;expression of viral structural proteins (VP2, VP4, VP6, and VP7) in prokaryotic or eukaryotic organisms to form empty single&#8208;layered particles (VP2), double&#8208;layered particles (VP2 and VP6) and triple layered particles (VP2, VP6, and VP7 [<xref rid="cbf70031-bib-0066" ref-type="bibr">66</xref>] or VP2, VP6, VP7, and VP4 [<xref rid="cbf70031-bib-0067" ref-type="bibr">67</xref>]). Therefore, VLPs do not contain virus genetic material and are safe (noninfectious). Rotavirus&#8208;like particles (RLPs) have been produced in plants and mammalian cells, but their production has been the most successful in baculovirus&#8208;infected insect cells. These VLPs have demonstrated immunogenicity in various animal models and have provided protection of various degrees following infection with the virus [<xref rid="cbf70031-bib-0068" ref-type="bibr">68</xref>]. However, plant&#8208;based RLPs made up of viral proteins VP2, VP6, and VP7 in the first human clinical trial were found to be well tolerated. They induced a homotypic immune response in infants [<xref rid="cbf70031-bib-0069" ref-type="bibr">69</xref>]. However, their protection efficacy has varied with their protein composition, administration route, adjuvant type, and animal species.</p></sec><sec id="cbf70031-sec-0140"><label>3.4.3.4</label><title>Nanoparticles (Norovirus P or S Particle With Inserted &#916;VP8*)</title><p>The norovirus (NoV) capsid consists of a critical structural protein (VP1) with shell (S) and protruding (P) domains at the N&#8208; and C&#8208;terminals, respectively. These domains are structurally and functionally independent. P domain is composed of 24 mer&#8208;P particles in an octahedral symmetry. P particles self&#8208;assemble on the expression of the P protein in <italic toggle="yes">E. coli</italic>. P particles are highly immunogenic and stable. Each P domain has three surface loops for inserting foreign antigens to produce a new chimeric P particle for immune enhancement, making it a valuable platform for novel vaccine development. The non&#8208;replicating parenterally administered P24&#8208;VP8* nanoparticle vaccine, which contains 24 surface&#8208;displayed HRV VP8*s and a 24 valent core of NoV P particle, has been developed as an exciting dual vaccine towards rotavirus and NoV and produces a significantly higher VP8* specific antibody response than free VP8* particles [<xref rid="cbf70031-bib-0070" ref-type="bibr">70</xref>]. P24&#8208;VP8* nanoparticle vaccine has protected immunized mice and gnotobiotic pigs from rotavirus infection and diarrhea [<xref rid="cbf70031-bib-0071" ref-type="bibr">71</xref>].</p><p>In the <italic toggle="yes">E. coli</italic> expression platform, Xia et al. [<xref rid="cbf70031-bib-0072" ref-type="bibr">72</xref>] produced self&#8208;assembled S60 nanoparticles (with 60 shell domains, each with a free C&#8208;terminus), and these S particles are used to show foreign antigens to increase immunogenicity. The development of SR69A&#8208;VP8* and S60&#8208;VP8* nanoparticles in <italic toggle="yes">E. coli</italic> has been aided by the introduction of mutations R69A (SR69A) and triple cysteine mutations (V57C/Q58C/S136C) in the norovirus S domain. The chimeric particle, S60&#8208;VP8*, displays 60 rotavirus&#8208;neutralizing VP8* antigens fused to the C&#8208;terminus of the S protein, and mice immunized with S60&#8208;VP8* particles offer protection against homologous murine rotavirus challenge by reducing viral shedding compared to negative control mice and control rotavirus disease [<xref rid="cbf70031-bib-0072" ref-type="bibr">72</xref>]. Further, the vaccine self&#8208;assembled to SR69A&#8208;NSP4&#8208;VP8* nanoparticles once the rotavirus antigen NSP4 (RV enterotoxin) was added to previously synthesized SR69A&#8208;VP8*/S60&#8208;VP8* nanoparticles, but this did not further boost the immune response and protection from them. The SR69A&#8208;VP8*/S60&#8208;VP8* nanoparticles respond better to alum adjuvant than CpG adjuvant [<xref rid="cbf70031-bib-0073" ref-type="bibr">73</xref>]. The nanoparticles developed from norovirus S and P capsid proteins can efficiently transfer RV antigens to the immune system.</p></sec></sec></sec><sec id="cbf70031-sec-0150"><label>3.5</label><title>Nucleic Acid Vaccines: DNA and mRNA Vaccines</title><p>Nucleic acid vaccines are either DNA or mRNA vaccines. A DNA vaccine is a subunit vaccine developed by expressing cDNA encoding for a specific rotavirus protein antigen, VP4, VP6, and VP7, driven by a eukaryotic promoter in cells of the inoculated host. These vaccinations are given intravenously, intramuscularly, intradermally, or by injecting DNA&#8208;coated particles into the epidermis using a gene gun [<xref rid="cbf70031-bib-0074" ref-type="bibr">74</xref>]. They effectively evoke both antibody and cytotoxic T cell (CTL) responses and could induce positive immunity against rotavirus challenge. DNA vaccines are steady and do not require constant cold storage. Rotavirus VP6 DNA vaccine coupled with poly (lactide&#8208;coglycolide) microparticles are administered by oral route and concomitantly induced mucosal immune responses [<xref rid="cbf70031-bib-0075" ref-type="bibr">75</xref>]. Similarly, the oral and intranasal delivery of the VP6 DNA vaccine resulted in adequate immunization and subsequent defense against rotavirus exposure [<xref rid="cbf70031-bib-0076" ref-type="bibr">76</xref>]. All the rotavirus DNA vaccines have been tested in mice as an animal model. Their significant concerns about safety and clinical effectiveness remain to be determined. The two potential risks associated with DNA vaccines are the incorporation of vaccine DNA into the genome of the host cell or the production of vaccine DNA&#8208;specific antibodies. However, their high stability, durability of response (enhanced cell&#8208;mediated immune responses for long&#8208;lasting immunity), and ease of manufacture (cost&#8208;effective) could make them valuable alternatives to mRNA, adeno, viral vector, and recombinant protein vaccine technologies.</p><p>mRNA vaccines consist of antigen&#8208;encoding RNA encapsulated in noninflammatory lipid nanoparticles. These vaccines can elicit more potent immune responses than the DNA vaccines against infectious pathogens. Therefore, they are required in lower doses to stimulate immune responses but require low temperatures for storage. The Bill and Melinda Gates Foundation has partnered with CureVac (Tubingen, Germany) to fund the development of a rotavirus VP8* mRNA vaccine, which is now in the preclinical stage. This vaccine is based on mRNA&#8208;based technology [<xref rid="cbf70031-bib-0077" ref-type="bibr">77</xref>]. mRNA has been produced by in vitro transcription using the cell&#8208;free system, avoiding bacterial contamination and chromosomal integration. Further, mRNA is feasible for any protein antigen and cost&#8208;effective at large scales.</p></sec><sec id="cbf70031-sec-0160"><label>3.6</label><title>In&#8208;Silico Multiepitope Vaccine via Reverse Vaccinology (RV)</title><p>RV is a valuable tool that uses a pathogen's proteome and genome data for the in silico multiepitope vaccine design by computational and immunoinformatics approaches [<xref rid="cbf70031-bib-0078" ref-type="bibr">78</xref>]. Unlike conventional vaccines, RV eliminates the need for culturing and identifying the pathogen to produce a more stable vaccine at a faster rate, lower cost, and effective for long duration against all circulating rotavirus genotypes with decreased side effects. In silico multiepitope vaccines have been developed for various pathogens, including rotavirus [<xref rid="cbf70031-bib-0079" ref-type="bibr">79</xref>, <xref rid="cbf70031-bib-0080" ref-type="bibr">80</xref>]. In&#8208;silico vaccine design has used either the entire rotavirus proteome [<xref rid="cbf70031-bib-0081" ref-type="bibr">81</xref>] or the majority of the antigenic proteins (VP7, VP6, VP4, and VP8*) [<xref rid="cbf70031-bib-0079" ref-type="bibr">79</xref>, <xref rid="cbf70031-bib-0080" ref-type="bibr">80</xref>, <xref rid="cbf70031-bib-0082" ref-type="bibr">82</xref>] or conserved regions of the fused peptide of VP4 and VP6 [<xref rid="cbf70031-bib-0083" ref-type="bibr">83</xref>] for epitope screening. Overall, the methodology used in all these cases was similar; only one case was validated with experimental mice [<xref rid="cbf70031-bib-0082" ref-type="bibr">82</xref>]. The procedure for multiepitope vaccine synthesis involves the selection of highly immunogenic and antigenic structural or nonstructural proteins of rotavirus for the in&#8208;silico prediction of the most effective, nonallergenic, and nontoxic CTL (cytotoxic T&#8208;lymphocyte), HTL (helper T lymphocyte), and LBL (linear B lymphocyte) epitopes that are joined with suitable linkers and adjuvants. Various validation studies, including molecular docking, molecular dynamics simulation, and immunological simulation, are to be conducted to confirm the induction of humoral and cellular immune responses to defense against disease. Additional in vitro and in vivo studies are required to validate the computational findings.</p></sec></sec><sec id="cbf70031-sec-0170"><label>4</label><title>Bio&#8208;Production Systems for Recombinant DNA&#8208;Based Rotavirus Vaccines</title><p>Recombinant DNA technology has facilitated the production of individual full&#8208;length viral antigens or parts of viral antigens or VLPs composed of rotavirus proteins at high levels in heterologous expression systems for their use as proficient vaccines to combat a wide range of viral pathogens.</p><sec id="cbf70031-sec-0180"><label>4.1</label><title>Prokaryotic Systems</title><p>Three bacterial species, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Bacillus substilis</italic>, and <italic toggle="yes">Lactococcus lactis</italic>, generally recognized as safe species with adjuvant properties, have been promising candidates for oral vaccination. McCrae and McCorquodale [<xref rid="cbf70031-bib-0084" ref-type="bibr">84</xref>] could not express a full&#8208;length bovine rotavirus VP7 antigen in <italic toggle="yes">E. coli</italic>, probably due to the instability of antigen protein in <italic toggle="yes">E. coli</italic>. However, they have expressed VP7 antigen as a fusion protein with a C&#8208;terminal extension of &#946;Gal (&#946;Gal&#8208;VP7) under the control of the bacteriophage &#955; pR promoter in 5%&#8211;15% higher amounts of the total bacterial cell protein after 90&#8201;min of induction. Immunization of rabbits and mice with this fusion protein showed neutralization of viral infectivity [<xref rid="cbf70031-bib-0084" ref-type="bibr">84</xref>]. A nonstructural protein (NSP3) gene isolated from the Indian isolate of the G2 genotype of HRV has been expressed in <italic toggle="yes">E. coli</italic> in large amounts and purified to homogeneity [<xref rid="cbf70031-bib-0085" ref-type="bibr">85</xref>].</p><p>
<italic toggle="yes">L. lactis</italic>, a lactic acid bacterium found in both animals and human intestines, develops rapidly and serves as a vehicle for administering live oral antigens to develop live mucosal vaccine. Various expression systems, including the most extensively used, the nisin&#8208;controlled gene expression, have been developed for accumulating protein antigens in the cytoplasm, anchoring them in the cell wall, or secreting them into the extracellular space. Several rotavirus proteins, for example, NSP4, VP7, VP8, and VP6 have been expressed in <italic toggle="yes">L. lactis</italic> [<xref rid="cbf70031-bib-0086" ref-type="bibr">86</xref>, <xref rid="cbf70031-bib-0087" ref-type="bibr">87</xref>]. The recombinant entire NSP4 has been produced intra&#8208; or extracellularly using the nisin&#8208;controlled expression system [<xref rid="cbf70031-bib-0086" ref-type="bibr">86</xref>]. Though the secretion efficiency of rNSP4 was low, the highest production levels were obtained on the fusion of rNSP4 with lactococcal signal peptide. The recombinant rotavirus proteins produced in <italic toggle="yes">L. lactis</italic> have shown antigenic and immunogenic properties. Another species of lactic acid bacteria, <italic toggle="yes">L. plantarum</italic>, has also been used to produce a part of rotavirus VP7 (250 amino acids) [<xref rid="cbf70031-bib-0088" ref-type="bibr">88</xref>]. <italic toggle="yes">L. lactis</italic> offers the prospect of producing other rota proteins that are difficult to produce in <italic toggle="yes">E. coli</italic>. Cell wall&#8208;derived particles (CWDP), a new generation rotavirus vaccine made from a recombinant <italic toggle="yes">L. lactis</italic> that expresses a cell wall&#8208;anchored version of the rotavirus VP6 protein, have recently been shown to induce systemic humoral immune responses in mice following mucosal immunization (intranasal) without adjuvant [<xref rid="cbf70031-bib-0089" ref-type="bibr">89</xref>]. More research is needed to determine whether they may be used as a substitute for live <italic toggle="yes">L. lactis</italic> for mucosal antigen delivery.</p><p>A recombinant <italic toggle="yes">Bacillus subtilis</italic> strain has been constructed that displays the heterologous VP8 antigen protein of porcine rotavirus on the spore surface using the spore&#8208;coat protein Cot B as a carrier. The fusion protein, Cot B&#8208;VP8, maintains its immunogenicity on the spores, which, on oral administration, delivers VP8 to the intestinal mucosa and induces both mucosal (IgA) and systemic (IgG) immune responses. <italic toggle="yes">B. subtilis</italic> spores are used as an antigen delivery vehicle in an alternative rotavirus live mucosal subunit vaccine [<xref rid="cbf70031-bib-0090" ref-type="bibr">90</xref>]. VP8* of rotavirus genotype G9P[8] has been expressed and displayed on the surface of <italic toggle="yes">E. coli</italic> BL21 (DE3) cells as confirmed by Western blot and Enzyme&#8208;Linked Immunosorbent Assays (ELISA) [<xref rid="cbf70031-bib-0073" ref-type="bibr">73</xref>]. The developed VP8* cell surface display system can identify and isolate viral receptors in vaccine development.</p></sec><sec id="cbf70031-sec-0190"><label>4.2</label><title>Yeasts</title><p>Yeasts like <italic toggle="yes">Saccharomyces cerevisiae</italic> and <italic toggle="yes">Pichia pastoris</italic> are eukaryotic single&#8208;celled and well&#8208;studied organisms with rapid growth and many genetic and genome editing toolboxes. Yeast cells have been frequently used to produce recombinant proteins and VLPs. Three rotavirus structure proteins, VP2, VP6, and VP7 genes have been expressed in the same cell intracellularly in <italic toggle="yes">S. cerevisiae</italic> and produced triple&#8208;layered rota&#8208;like particles (RLP) as confirmed by immunoblotting and transmission electron microscopy [<xref rid="cbf70031-bib-0091" ref-type="bibr">91</xref>]. Subsequently, the raw yeast extracts containing RLPs generated by cell rupture and centrifugation have been proven efficient in producing a defense against infection in adult mice [<xref rid="cbf70031-bib-0092" ref-type="bibr">92</xref>]. The use of RLPs as a vaccine has several advantages. These are (i) RLPs are polyvalent vaccines with several genotypes; (ii) the downstream processing avoids expensive purification steps; and (iii) some yeast species showed adjuvant effects. Production of RLP with complex architecture in yeasts could lead to novel vaccine candidates with reduced controlling agency regulations [<xref rid="cbf70031-bib-0093" ref-type="bibr">93</xref>]. The success of antigen production may be valuable in a recombinant veterinary vaccine formulation. However, it can be generalized for human use when the costs associated with downstream processes become viable. However, the production and purification of RLPs are not cost&#8208;effective for farm animals.</p><p>Rotavirus VP6 protein gene with optimized codons has been expressed intracellularly in two methylotrophic yeasts, <italic toggle="yes">P. pastoris</italic> and <italic toggle="yes">Hansenula polymorpha</italic>, to produce VP6 [<xref rid="cbf70031-bib-0094" ref-type="bibr">94</xref>]. These yeasts are ideal expression platforms because of their following characteristics: (i) high&#8208;stress tolerance, (ii) ability to utilize various carbon sources, (iii) availability of strong promoters and other genetic tools, (iv) high cell density in the fermenter, (v) low secretion of endogenous protein into the medium, (vi) less hyper&#8208;mannosylation. <italic toggle="yes">H. polymorpha</italic> is the more effective in producing VP6 protein than <italic toggle="yes">P. pastoris</italic> [<xref rid="cbf70031-bib-0094" ref-type="bibr">94</xref>].</p></sec><sec id="cbf70031-sec-0200"><label>4.3</label><title>Insect Cells and Larvae</title><p>One of insects' most prevalent eukaryotic expression systems is the baculovirus, which allows for the expression of foreign genes in insect cells under the powerful baculovirus polyhedrin gene promoter. This system has been used successfully to produce rotavirus proteins like VP7 in high amounts while maintaining its biological activity of neutralizing rotavirus infectivity in mammalian cells [<xref rid="cbf70031-bib-0095" ref-type="bibr">95</xref>]. The role of the rotavirus structural proteins in the generation of CD8+ T cells that mediate the clearing of chronic rotavirus infection in severe combined immune&#8208;deficient mice has identified following immunization of mice with SF9 cells infected with recombinant baculovirus expressing any three of the significant structural rotavirus proteins VP4, VP6, VP7 and a polymerase (VP1), but not with VP2, NS53, NS35, NS28, or wild&#8208;type baculovirus [<xref rid="cbf70031-bib-0096" ref-type="bibr">96</xref>].</p><p>Production of each structural protein of rotavirus in proper amounts and combinations is imperative for the efficient assembly of VLP. Insect cells, Sf9, and larvae of <italic toggle="yes">Spodoptera frugiperda</italic> on infection with recombinant baculovirus bearing VP2 and VP6 genes from simian rotavirus SA11 have produced/co&#8208;expressed double layered virus particles (VLP2/6) that are released into the medium or hemolymph [<xref rid="cbf70031-bib-0097" ref-type="bibr">97</xref>]. Unlike cell cultures, insect larvae produced high levels of VLPs at significantly low cost because they do not require sterile conditions or growth media during production. Triple&#8208;layered particles consisting of three rotavirus proteins, VP2, VP6, and VP7, have been produced in high concentrations in insect cell&#8208;baculovirus expression systems by single infection with three cistronic baculovirus vectors than co&#8208;infection with three monocistronic baculovirus vectors [<xref rid="cbf70031-bib-0098" ref-type="bibr">98</xref>]. These results confirm the relevance of more rational vector design for improved efficiency in VLP production, but more information on baculovirus DNA duplication, mRNA stability, protein synthesis, stoichiometry, and thermodynamics of assembly kinetics is needed for enhanced efficacy in VLP production [<xref rid="cbf70031-bib-0099" ref-type="bibr">99</xref>]. Recently, a highly efficient baculovirus&#8208;silkworm multigene expression system named <italic toggle="yes">Bombyx mori</italic> MultiBac has been used to simultaneously express three rotaviruses structural and three fluorescent genes in silkworm larvae, resulting in the formation of VLPs of rotavirus and the color change of larvae. The VLPs yielding 12.7&#8201;&#181;g per larva have been purified from hemolymph by ultra&#8208;centrifugation; this Bm MultiBac expression system provides an appropriate, cost&#8208;effective platform to produce VLPs [<xref rid="cbf70031-bib-0100" ref-type="bibr">100</xref>].</p></sec><sec id="cbf70031-sec-0210"><label>4.4</label><title>Mammalian Cells/Animals</title><p>Mammalian cells coinfected with recombinant vaccinia viruses carrying VP2 and VP6 genes have co&#8208;expressed rotavirus structural proteins, VP2 and VP6, at 25%&#8211;30% and 4%&#8211;55% levels, respectively, resulting in the formation of intracellular double&#8208;layered rotavirus particles [<xref rid="cbf70031-bib-0101" ref-type="bibr">101</xref>]. Transgenic animals produce human proteins in the mammary gland, secreted in milk and eventually extracted from there. Transgenic rabbits whose milk was used to secrete recombinant proteins VP2 and VP6 at a concentration of less than 1&#8201;mg/ml also serve as a source of rotavirus antigens. The viral proteins elicited an immune response. In mice infected with the mouse strain of the virus, rectal administration of partially pure milk proteins VP2 and VP6, along with an adjuvant, virtually entirely prevented diarrhea [<xref rid="cbf70031-bib-0102" ref-type="bibr">102</xref>]. A milk&#8208;based rotavirus subunit vaccine has been developed by introducing the <italic toggle="yes">VP6</italic> gene into rabbit &#946; casein (<italic toggle="yes">CSN2</italic>) locus using CRISPR/Cas technology into transgenic rabbits [<xref rid="cbf70031-bib-0103" ref-type="bibr">103</xref>]. However, the immunogenicity and protection capacity of the milk&#8208;based VP6 subunit vaccines have not been demonstrated. In another study, recombinant VP6&#8208;ferritin nanoparticles self&#8208;assembled in <italic toggle="yes">E. coli</italic> on oral administration have induced a higher immune response than rVP6 in mice. Moreover, these nanoparticles on transgenic production in mammary glands have protected breastfed pup mice against rotavirus infection [<xref rid="cbf70031-bib-0103" ref-type="bibr">103</xref>]. Some other mammalian species (e.g., goat, sheep, cow, etc.) can also be used to produce RV subunit vaccines in their milk, the leading healthy food taken orally without purification by infants and young children.</p></sec><sec id="cbf70031-sec-0220"><label>4.5</label><title>Transgenic Plants</title><p>Plants have gained acceptance as a feasible and flexible host for expressing several recombinant therapeutic proteins like viral antigens, antibodies, cytokines, hormones, enzymes, growth factors, and other functional proteins [<xref rid="cbf70031-bib-0104" ref-type="bibr">104</xref>, <xref rid="cbf70031-bib-0105" ref-type="bibr">105</xref>, <xref rid="cbf70031-bib-0106" ref-type="bibr">106</xref>]. Viral full&#8208;length immune&#8208;relevant antigens or their fragments (epitopes) produced in plants are propitious vaccines with several advantages [<xref rid="cbf70031-bib-0107" ref-type="bibr">107</xref>]. These are (i) The plants carry out posttranslational modifications (PTMs), for example, phosphorylation, glycosylation, and so forth, which are required for the stability and biological activity of vaccines, (ii) Viral antigens expressing plants or their parts in lyophilized form can be stable at ambient temperature for many years without the loss of recombinant vaccine efficacy as determined by using diagnostics and cell&#8208;based systems and other studies carried out in animals, (iii) The vaccine antigens expressed in edible plants or plant parts like leaves, storage roots, fruits, and seeds of the diverse plant species are called &#8220;edible vaccines&#8221; which, on direct administration, orally induced mucosal and systemic immune responses without pain and risk of injections and medical professional, (iv) It is challenging to control antigen dose in fresh edible parts of the plants. The antigen dose can be predetermined by freeze&#8208;drying the plant materials. (v) The vaccine produced in plant cells is bio&#8208;encapsulated within the plant cell wall. It is protected from the stomach's harsh environment until and unless digested by gut microbes to release the antigens and improve their bioavailability.</p><p>Different plant expression strategies used are: (i) stable expression (via nuclear transformation, transgenic plants or chloroplast transformation, transplastomic plants) or transient expression (agro&#8208;infiltration of the non&#8208;transgenic plant); (ii) use of constitutive or tissue&#8208;specific or inducible expression; and (iii) targeting proteins to suitable cell compartments for their accumulation or PTM and to facilitate downstream processing have been explored [<xref rid="cbf70031-bib-0108" ref-type="bibr">108</xref>].</p><sec id="cbf70031-sec-0230"><label>4.5.1</label><title>Nucleus&#8208;Transformed (Transgenic) Plants</title><p>Viral capsid structural (VP4, VP6, and VP7) or nonstructural protein genes, either alone or in combinations, are introduced into diverse plant species using mainly the <italic toggle="yes">Agrobacterium</italic>&#8208;mediated gene transfer method (Table&#160;<xref rid="cbf70031-tbl-0001" ref-type="table">1</xref>). The antigen genes integrate randomly into the plant nuclear genome, express to produce recombinant antigen protein(s), and are inherited by the next generation. The recombinant plant&#8208;produced antigen protein on oral and nasal administrations retained their immunogenicity. It induced mucosal and systemic immune responses in animals and human trials to protect from severe rotavirus&#8208;induced diarrhea. In many cases, Cholera Toxin B (CTB)/heat liable enterotoxin B (LTB) provides adjuvant activity to the antigen co&#8208;administered orally.</p><table-wrap position="float" id="cbf70031-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Vaccine antigens against rotavirus expressed in plants.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="center" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">S. No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Antigen</th><th align="center" valign="bottom" rowspan="1" colspan="1">Expression system/method of introduction</th><th align="center" valign="bottom" rowspan="1" colspan="1">Plant species</th><th align="center" valign="bottom" rowspan="1" colspan="1">Expression level/molecular analysis</th><th align="center" valign="bottom" rowspan="1" colspan="1">Immunogenicity of recombinant protein</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">VP6</td><td align="center" valign="top" rowspan="1" colspan="1">Potato X virus&#8208;derived vector</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Nicotiana benthamiana</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">50&#8201;&#181;g/g of fresh leaf tissue, VP6 formed trimers, assembled around VP2 core, VP6 assembled into VLPs</td><td align="center" valign="top" rowspan="1" colspan="1">Not examined</td><td align="center" valign="top" rowspan="1" colspan="1">O&#697;Brien et al. [<xref rid="cbf70031-bib-0109" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Bovine VP6</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic, <italic toggle="yes">Agrobacterium tumefaciens</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Solanum tuberosum</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.1% TSP (30&#8201;&#181;g/g fresh leaves)</td><td align="center" valign="top" rowspan="1" colspan="1">Mice developed Anti&#8208;VP6 antibodies, protective immunity not determined</td><td align="center" valign="top" rowspan="1" colspan="1">Matsumura et al. [<xref rid="cbf70031-bib-0110" ref-type="bibr">110</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">VP6 (Murine rotavirus gene)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">A. tumefaciens</italic> LBA4404 (pBI121)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">S. tuberosum</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.01% TSP</td><td align="center" valign="top" rowspan="1" colspan="1">Oral immunization of mice generated anti&#8208;VP6 serum IgG and intestinal IgA antibodies</td><td align="center" valign="top" rowspan="1" colspan="1">Yu and Langridge [<xref rid="cbf70031-bib-0111" ref-type="bibr">111</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">VP7 (human rotavirus gene)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">A. tumefaciens</italic> LBA4404 (pBI121)</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic potato</td><td align="center" valign="top" rowspan="1" colspan="1">3.84&#8201;&#181;g/mg of total soluble protein</td><td align="center" valign="top" rowspan="1" colspan="1">Mice elicited serum IgG and mucosal IgA specific for VP7</td><td align="center" valign="top" rowspan="1" colspan="1">Wu et al. [<xref rid="cbf70031-bib-0112" ref-type="bibr">112</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Immune&#8208;relevant peptide, eBRV4, of the VP4 protein of bovine rotavirus</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">A. tumefaciens</italic> LBA4404 (pBI121)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Medicago sativa</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.9&#8201;mg/g of TPS</td><td align="center" valign="top" rowspan="1" colspan="1">Epitope eBRV4 on administration in mice induces an anti&#8208;rotavirus antibody response and protects pups</td><td align="center" valign="top" rowspan="1" colspan="1">Wigdorovitz et al. [<xref rid="cbf70031-bib-0113" ref-type="bibr">113</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">Bovine rotavirus VP8</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic, tobacco mosaic virus vector</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Recombinant VP8 protein 5&#8201;&#956;g/g per gram of fresh leaf, Western blot analysis</td><td align="center" valign="top" rowspan="1" colspan="1">VP8 retained native antigenic properties and the ability to induce passive protection in a murine model</td><td align="center" valign="top" rowspan="1" colspan="1">Perez Filgueira et al. [<xref rid="cbf70031-bib-0114" ref-type="bibr">114</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">VP6 (human group A rotavirus)</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic, <italic toggle="yes">A. tumefaciens</italic> LBA4404 (pBI121)</td><td align="center" valign="top" rowspan="1" colspan="1">Alfalfa</td><td align="center" valign="top" rowspan="1" colspan="1">0.28% of the TSP, Southern blot, RT&#8208;PCR, ELISA, Western blot</td><td align="center" valign="top" rowspan="1" colspan="1">Immunized mice developed high titers of anti&#8208;VP6 serum IgG and mucosal IgA, Protect pups after challenge with rotavirus</td><td align="center" valign="top" rowspan="1" colspan="1">Dong et al. [<xref rid="cbf70031-bib-0115" ref-type="bibr">115</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8.</td><td align="center" valign="top" rowspan="1" colspan="1">Simian rotavirus VP7 linked to N&#8208;terminus of Ricin toxin B subunit</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">A. tumefaciens</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">S. tuberosum</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.03% of TSP, Immunoblot</td><td align="center" valign="top" rowspan="1" colspan="1">Not determined</td><td align="center" valign="top" rowspan="1" colspan="1">Choi et al. [<xref rid="cbf70031-bib-0116" ref-type="bibr">116</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">VP2 and VP6 (vp6 from mouse EW rotavirus strain &#8230; and vp2 synthetic gene based on vp2 gene of native simian rotavirus)</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic, <italic toggle="yes">A. tumefaciens</italic> pCAMBIA 2300</td><td align="center" valign="top" rowspan="1" colspan="1">Tomato (<italic toggle="yes">Lycopersicon esculentum</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">Western blot, ELISA, VLP<sub>S</sub> by electron&#8208;microscopy</td><td align="center" valign="top" rowspan="1" colspan="1">A small proportion of VP2/VP6 assembled into VLPs, immunized mice showed anti&#8208;rotavirus antibodies in serum</td><td align="center" valign="top" rowspan="1" colspan="1">Salda&#241;a et al. [<xref rid="cbf70031-bib-0117" ref-type="bibr">117</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">Human rotavirus VP7 expressed for 50 generations</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic, <italic toggle="yes">A. tumefaciens</italic> LBA4404 (pBI121)</td><td align="center" valign="top" rowspan="1" colspan="1">Potato</td><td align="center" valign="top" rowspan="1" colspan="1">40&#8201;&#956;g/g in tubers</td><td align="center" valign="top" rowspan="1" colspan="1">Immunized mice showed a naive T&#8208;cell bias to Th1&#8208; and Th3&#8208;type routes</td><td align="center" valign="top" rowspan="1" colspan="1">Li et al. [<xref rid="cbf70031-bib-0118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">Codon&#8208;optimized human rotavirus VP6</td><td align="center" valign="top" rowspan="1" colspan="1">Transient (<italic toggle="yes">Beet black scorch virus</italic>&#8208;based plant protein expression system)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Chenopodium amaranticolor</italic> leaves</td><td align="center" valign="top" rowspan="1" colspan="1">0.25% TSP (1.54&#8201;&#181;g/g fresh leaves)</td><td align="center" valign="top" rowspan="1" colspan="1">Orally immunized mice produced anti&#8208;VP6 specific IgG and serum IgG, 60% mice protection after virus challenge</td><td align="center" valign="top" rowspan="1" colspan="1">Zhou et al. [<xref rid="cbf70031-bib-0119" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">VP<sub>2</sub>, VP6, VP7</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic, <italic toggle="yes">A. tumefaciens</italic> LBA4404 (pBI121)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">VP6 1.5% of the TSP, plant&#8208;derived VP2, VP6, and VP7 proteins self&#8208;assembled into 2/6 or 2/6/7 RV VLPs.</td><td align="center" valign="top" rowspan="1" colspan="1">VP 2/6/7 induced higher serum IgG and fecal IgA titers in mice compared with VP 2/6</td><td align="center" valign="top" rowspan="1" colspan="1">Yang et al. [<xref rid="cbf70031-bib-0120" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">Single or dimeric human rotavirus VP7 and a truncated VP4 antigen fused with <italic toggle="yes">Salmonella typhimurium</italic>'s flagellin fljB subunit</td><td align="center" valign="top" rowspan="1" colspan="1">Transient expression via agro&#8208;infiltration</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.85&#8211;31.97&#8201;&#181;g of recombinant protein per gram of fresh leaf tissue</td><td align="center" valign="top" rowspan="1" colspan="1">Mice immunization with proteins from transformed leaves with constructs bearing the fljB moiety elicited an fljB&#8208;specific&#8208;humoral response</td><td align="center" valign="top" rowspan="1" colspan="1">Bergeron&#8208;Sandoval et al. [<xref rid="cbf70031-bib-0121" ref-type="bibr">121</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">VP8</td><td align="center" valign="top" rowspan="1" colspan="1">Transplastomic (Particle bombardment pBSW&#8208;utr/vp8)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">600&#8201;&#181;g/g of fresh tissue, Southern blot, ELISA, and Virus neutralization test</td><td align="center" valign="top" rowspan="1" colspan="1">Immunized mice showed high titers of IgG antibodies specific to VP8, 80%&#8211;100% protection after challenge with rotavirus</td><td align="center" valign="top" rowspan="1" colspan="1">Lentz et al. [<xref rid="cbf70031-bib-0122" ref-type="bibr">122</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">Muco&#8208;ARP1 (heavy chain antibody fragment)</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic</td><td align="center" valign="top" rowspan="1" colspan="1">Rice</td><td align="center" valign="top" rowspan="1" colspan="1">11.9% of TSP</td><td align="center" valign="top" rowspan="1" colspan="1">Administration reduces symptoms and provides complete protection against rotavirus</td><td align="center" valign="top" rowspan="1" colspan="1">Tokuhar et al. [<xref rid="cbf70031-bib-0031" ref-type="bibr">31</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">N&#8208;terminally fusing Lumazine Synthase from <italic toggle="yes">Brucella</italic> spp. (BLS) toVP8 domain bovine rotavirus</td><td align="center" valign="top" rowspan="1" colspan="1">Transplastomic, particle bombardment</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Nicotiana tabacum</italic> cv. Petit Havana</td><td align="center" valign="top" rowspan="1" colspan="1">BLSVP8d expressed 40% of TSP (4.85&#8201;mg/g fresh tissue)</td><td align="center" valign="top" rowspan="1" colspan="1">Soluble protein extracts from fresh and lyophilized leaves induced specific neutralizing IgY antibodies in a laying hen model</td><td align="center" valign="top" rowspan="1" colspan="1">Alfano et al. [<xref rid="cbf70031-bib-0123" ref-type="bibr">123</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">VP2 and VP6 human rotavirus G9P</td><td align="center" valign="top" rowspan="1" colspan="1">Transient agroinfiltration&#8208;mediated expression</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">VP2 and VP6 assembled into VLPs</td><td align="center" valign="top" rowspan="1" colspan="1">The immunogenic potential of the VLPS has not been studied</td><td align="center" valign="top" rowspan="1" colspan="1">P&#234;ra et al. [<xref rid="cbf70031-bib-0124" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">VP6&#8208;LTB fused NSP4</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic, particle bombardment pSB130</td><td align="center" valign="top" rowspan="1" colspan="1">Maize</td><td align="center" valign="top" rowspan="1" colspan="1">0.35% and 0.20% TSP</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic seeds stimulate systemic and mucosal responses with high titers serum and mucosal IgG antibodies.</td><td align="center" valign="top" rowspan="1" colspan="1">Feng et al. [<xref rid="cbf70031-bib-0125" ref-type="bibr">125</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">Rotavirus VP7&#8208;CTB fusion</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Arabidopsis thaliana</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.39% of the TSP in the transgenic seeds (52.65&#8201;&#956;g/g)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Li et al. [<xref rid="cbf70031-bib-0126" ref-type="bibr">126</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">Single chain variable fragment (scFV) antibody fusion with rotavirus VP6 protein via OLLAS teg</td><td align="center" valign="top" rowspan="1" colspan="1">Transient expression in cytoplasm and apoplast</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>, <italic toggle="yes">Nicotiana sylvestris</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Presence of recombinant protein confirmed by immune&#8208;detection in both cytoplasm and apoplast in both the <italic toggle="yes">Nicotiana</italic> species</td><td align="center" valign="top" rowspan="1" colspan="1">The antigen is directed to the dendritic cells to generate a faster and more powerful immune response</td><td align="center" valign="top" rowspan="1" colspan="1">Castillo&#8209;Esparza and Gomez&#8209;Lim [<xref rid="cbf70031-bib-0127" ref-type="bibr">127</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">Human three&#8208;layer VLP containing VP2, VP4, VP6 and VP7</td><td align="center" valign="top" rowspan="1" colspan="1">Baculovirus expression</td><td align="center" valign="top" rowspan="1" colspan="1">VLP production in the insect cells</td><td align="center" valign="top" rowspan="1" colspan="1">Rotavirus A proteins in VLP confirmed by the ELISA, SDS&#8208;PAGE, and western blot analysis</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Cherepushkin et al. [<xref rid="cbf70031-bib-0067" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">Rotavirus&#8208;like particles composed of VP6, VP7, and VP2 derived from human rotavirus strain</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Transient expression,</p>
<p>
<italic toggle="yes">A. tumefaciens</italic>
</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Ro&#8208;VLP (87&#8201;nm in size) with 90% purity and made up of triple&#8208;layered particles composed of 11% VP7, 49% VP6, and 39% VP2</td><td align="center" valign="top" rowspan="1" colspan="1">Intramuscular administration of RV&#8208;VLP without adjuvant elicited an antibody&#8208;neutralizing response in rats and showed no toxicity</td><td align="center" valign="top" rowspan="1" colspan="1">Kurokawa et al. [<xref rid="cbf70031-bib-0066" ref-type="bibr">66</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">&#8208;do&#8208;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8208;do&#8208;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8208;do&#8208;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8208;do&#8208;</td><td align="center" valign="top" rowspan="1" colspan="1">RV&#8208;VLP vaccine induced homotypic immune response in infants and tolerated well in all age groups tested</td><td align="center" valign="top" rowspan="1" colspan="1">Kurokawa et al. [<xref rid="cbf70031-bib-0069" ref-type="bibr">69</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">VP6</td><td align="center" valign="top" rowspan="1" colspan="1">Transgenic, <italic toggle="yes">A. tumefaciens</italic>&#8208;mediated</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">Trifolium alexandrinum</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">VP6 protein produced in transgenic plants at 0.03% TSP</td><td align="center" valign="top" rowspan="1" colspan="1">Oral feeding induced higher titers of anti&#8208;VP6 serum IgG antibodies in rabbit</td><td align="center" valign="top" rowspan="1" colspan="1">Malik et al. [<xref rid="cbf70031-bib-0128" ref-type="bibr">128</xref>]</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>VP6, the intermediate capsid protein of the triple&#8208;layered rotavirus, constitutes 51% of the entire virion mass. Because of its excellent immunogenicity and conservation, it provides an effective alternative to the current live attenuated oral rotavirus vaccines [<xref rid="cbf70031-bib-0128" ref-type="bibr">128</xref>]. Depending on the ionic strength, divalent ion concentration, and pH, it can self&#8208;assemble into highly immunogenic nanostructures, nanospheres, and nanotubes. These nanostructures exhibit immunostimulatory properties and promote immunogenicity of the co&#8208;administered antigens. VP6 has an adjuvant effect and can act as an adjuvant&#8208;free vaccine [<xref rid="cbf70031-bib-0129" ref-type="bibr">129</xref>]. Rotavirus VP6 protein has been expressed at low levels of 0.006% and 0.002% of TSP in transgenic potato leaves and tubers, respectively [<xref rid="cbf70031-bib-0110" ref-type="bibr">110</xref>]. However, codon&#8208;optimization of the VP6 gene in transgenic alfalfa has expressed a relatively high level of 0.28% of TSP [<xref rid="cbf70031-bib-0115" ref-type="bibr">115</xref>]. Oral immunization with transgenic alfalfa has induced specific mucosal IgA and serum IgG antibodies in mice. Further, VP6 produced in transgenic potatoes, <italic toggle="yes">Chenopodium amaranticolor</italic>, or alfalfa stimulates a passive immune response and protects suckling mice from rotavirus infection [<xref rid="cbf70031-bib-0111" ref-type="bibr">111</xref>, <xref rid="cbf70031-bib-0115" ref-type="bibr">115</xref>, <xref rid="cbf70031-bib-0119" ref-type="bibr">119</xref>]. Transient expression of two rotavirus structural proteins, VP2 and VP6, in <italic toggle="yes">N. benthamiana</italic>, has assembled into VLPs that act as a subunit vaccine for the G9 (P) 6 rotavirus strain [<xref rid="cbf70031-bib-0124" ref-type="bibr">124</xref>]. These proteins have also been expressed in the fruits from transgenic tomato plants and developed into VLPs with protective immune response [<xref rid="cbf70031-bib-0117" ref-type="bibr">117</xref>]. Codon&#8208;optimized VP6 and NSP4 rotavirus subunits fused with the nontoxic adjuvant subunit B of <italic toggle="yes">E. coli</italic> heat&#8208;labile enterotoxin (LTB) have been expressed in maize seeds at 0.35% and 0.20% of TPS, respectively. Oral feeding of maize seeds to female BALB/c mice has induced mucosal and systemic responses in mice even after storage for a month [<xref rid="cbf70031-bib-0125" ref-type="bibr">125</xref>]. This work paves the groundwork for creating a bivalent VP6&#8208;NSP4 rotavirus vaccine.</p><p>VP7 is the outer capsid glycoprotein (38&#8201;kDa) and 30% of the total virion mass. It is responsible for defining viral serotypes. It has three antigenic sites: A (aa 87&#8211;99), B (aa 145&#8211;150), and C (aa 211&#8211;223) that can induce neutralizing antibodies; therefore, they can be used as targets for subunit vaccine development. A full&#8208;length VP7 antigen gene from HRV group A has been expressed in potatoes at the soluble protein level of 3.84&#8201;&#181;g/mg, and immunization of mice with transformed potatoes has stimulated the mucosal system of the body to secrete IgA to neutralize rotavirus [<xref rid="cbf70031-bib-0112" ref-type="bibr">112</xref>]. Expression of a full&#8208;length VP7 gene in transgenic potato tubers at 40&#8201;&#181;g/g TSP is stably inherited and expressed over 50 generations and induced cell immunity on oral vaccination of BALB/c mice [<xref rid="cbf70031-bib-0118" ref-type="bibr">118</xref>]. The VP7 protein gene of simian rotavirus SA11 fused to the N&#8208;terminus of the ricin toxin B subunit (RTB) has expressed in transgenic potato tubers at 0.03% of TSP [<xref rid="cbf70031-bib-0116" ref-type="bibr">116</xref>]. RTB is a monomeric molecule with broad receptor binding specificity that binds to the receptors on the epidermal cell membrane to deliver antigens into gut epidermal cells. The potential of VP7::RTB fusion protein to induce humoral and cellular immune responses against rotavirus challenge is yet to be worked out.</p><p>HRV VP7 protein and HRVVP7&#8208;CBT fusion protein have been expressed in transgenic <italic toggle="yes">Arabidopsis thaliana</italic> seeds at a level of 0.06%&#8211;0.31% of TSP and 0.03%&#8211;0.39% of TSP, respectively [<xref rid="cbf70031-bib-0126" ref-type="bibr">126</xref>]. Immunization of mice with the transgenic seed extract has elicited an efficient immune response to protect neonatal mice born to immunized dams against rotavirus infection [<xref rid="cbf70031-bib-0126" ref-type="bibr">126</xref>]. The fusion protein VP7&#8208;CBT exerts a better mucosal adjuvant effect than VP7. However, the low expression of the recombinant antigen proteins, position effect, gene silencing, the complexity in controlling antigen dosage, and concerns over the public acceptance of transgenic material are to be resolved for the commercial development of plant&#8208;based recombinant vaccines.</p></sec><sec id="cbf70031-sec-0240"><label>4.5.2</label><title>Chloroplast&#8208;Transformed (Transplastomic) Plants</title><p>Transplastomic plants (generated via chloroplast transformation) have several attractive advantages over transgenic plants (generated via nuclear transformation) for the production of commercial vaccines. These are high transgene(s) expression levels due to the high copy number of chloroplasts; the precise integration of transgenes due to the homologous recombination, the absence of position effect and gene silencing, low risk of horizontal gene transfer due to the maternal inheritance of chloroplasts, absence of human pathogens and toxins, oral delivery with lyophilized powder of transplastomic leaves in capsules, and long&#8208;term storage stability of the recombinant vaccine even at room temperature thus eliminates the need for cold&#8208;chain and facilitates transportation. Transplastomic tobacco plants with an efficient accumulation of bovine rotavirus VP8 protein (~600&#8201;&#181;g per g of fresh leaf weight), mainly as insoluble aggregates and devoid of nicotine, were created [<xref rid="cbf70031-bib-0122" ref-type="bibr">122</xref>], contrary to bovine rotavirus VP6 in transplastomic plants was unstable in older leaves and primarily present in younger leaves [<xref rid="cbf70031-bib-0130" ref-type="bibr">130</xref>]. Immunization of mice with VP8 has protected mice against the bovine rotavirus challenge. Additionally, young mice from immunized dams have demonstrated resistance to an oral challenge with virulent rotavirus. <italic toggle="yes">Brucella</italic> species (BLS) are protein carriers for antigen transport and immunomodulators. BLS exhibits immunogenic properties on expression as a fusion protein, not co&#8208;expression with the antigen [<xref rid="cbf70031-bib-0131" ref-type="bibr">131</xref>]. Bovine rotavirus protein, VP8 gene fused N&#8208;terminally to BLS on expression in transplastomic <italic toggle="yes">Nicotiana tabacum</italic> plants has produced fusion protein, BLSVP8, at 40% of TSP. Even after a month of room temperature storage, the fresh or lyophilized transplastomic leaves have produced specific neutralizing IgY antibodies in a laying hen model [<xref rid="cbf70031-bib-0123" ref-type="bibr">123</xref>]. The lyophilization of transplastomic leaves expressing a stable recombinant fusion of a highly immunogenic BLS to an antigen reduces the cost by simplifying downstream processing. The chloroplast transformation technology has been restricted to only a few plant species.</p></sec><sec id="cbf70031-sec-0250"><label>4.5.3</label><title>Transient Expression in Plants</title><p>Transient expression involves expressing viral antigen genes in plants without their integration into the plant genome. The viral antigen genes are introduced into the plants via Agroinfiltration or viral vectors, produce antigen proteins at high levels within days, and can be scalable to commercial levels. It has emerged as a preferred expression system for plant&#8208;made recombinant proteins (Table&#160;<xref rid="cbf70031-tbl-0001" ref-type="table">1</xref>). The bovine rotavirus antigen VP8 portion of the VP4 protein was transiently expressed in <italic toggle="yes">N. benthamiana</italic> using a modified vector of RNA plant virus, Tobacco Mosaic Virus (TMV) vector TMV&#8208;30B. This vector contains seven histidine amino acids at the C&#8208;terminus of the viral antigen. The plant&#8208;based VP8 retains native antigenic properties and provides passive protection in the murine model [<xref rid="cbf70031-bib-0114" ref-type="bibr">114</xref>]. Transient expression of a single chain variable fragment antibody coupled with VP6 protein by an OLLAS tag has been detected immunologically in two cell compartments (cytoplasm and apoplast) of two <italic toggle="yes">Nicotiana</italic> species (<italic toggle="yes">N. benthamiana</italic> and <italic toggle="yes">Nicotiana sylvestris</italic>) to direct the antigen to the dendritic cells for a quick and effective immune reaction [<xref rid="cbf70031-bib-0127" ref-type="bibr">127</xref>].</p></sec></sec></sec><sec id="cbf70031-sec-0260"><label>5</label><title>Plants Viruses to Boost Rotavirus Vaccines</title><p>Plant viruses and their VLPs have shown properties of new adjuvants with no harm to animals and humans and are obtained economically [<xref rid="cbf70031-bib-0132" ref-type="bibr">132</xref>]. A plant virus, <italic toggle="yes">Alternanthera Mosaic Virus</italic> (AltMV), coat proteins (CP) in the absence of RNA can produce fibrous VLPs in the laboratory [<xref rid="cbf70031-bib-0133" ref-type="bibr">133</xref>]. These VLPs display adjuvant characteristics, resemble AltMV virions, and are stable in physiological conditions [<xref rid="cbf70031-bib-0133" ref-type="bibr">133</xref>]. AltMV CP at the C terminus was combined with an RV14 epitope of rotavirus A protein VP6 to create filamentous AltMV VLPs recognized by commercially available rotavirus antibodies [<xref rid="cbf70031-bib-0134" ref-type="bibr">134</xref>]. The developed recombinant vaccine (a chimeric protein in the native AltMV coat protein fused with an epitope of rotavirus VP6) does not require additional adjutants. It is a safe candidate against rotavirus infection. Combining other rotavirus antigens of the most widely circulating strains would develop a universal rotavirus A vaccine.</p><p>PTMs significantly influence the immunogenicity of vaccines by altering protein structure, stability, and interaction with the immune system. Among the various PTMs, glycosylation plays a crucial role in determining the antigenicity of vaccines. Mammalian cell systems, such as Chinese hamster ovary cells, produce glycosylation patterns similar to human glycans, which reduce immunogenicity and enhance stability [<xref rid="cbf70031-bib-0135" ref-type="bibr">135</xref>]. In contrast, plant&#8208;based systems may introduce plant&#8208;specific glycans, such as &#946;1,2&#8208;xylose and &#945;1,3&#8208;fucose, which can provoke adverse immune responses due to their absence in humans [<xref rid="cbf70031-bib-0136" ref-type="bibr">136</xref>]. Similarly, insect cell systems, widely used for producing influenza vaccines, generate truncated glycans, which can impact vaccine efficacy and immune recognition [<xref rid="cbf70031-bib-0137" ref-type="bibr">137</xref>]. These variations underscore the importance of tailoring PTMs to optimize vaccine immunogenicity across different production systems.</p><p>Production systems also influence other PTMs, such as phosphorylation and disulfide bond formation, which affect antigen folding and stability. Phosphorylation is crucial for maintaining the functional conformation of certain antigens, while disulfide bonds ensure structural integrity, particularly in complex proteins like viral glycoproteins [<xref rid="cbf70031-bib-0138" ref-type="bibr">138</xref>]. However, bacterial systems, which are cost&#8208;effective and scalable, lack the glycosylation machinery and often require additional steps to mimic human PTMs. Advances in host cell engineering, such as glycoengineered yeast and plant systems, have shown promise in producing human&#8208;like PTMs, reducing the risk of immunogenic side effects [<xref rid="cbf70031-bib-0139" ref-type="bibr">139</xref>]. The interplay between PTMs and production platforms highlights the need to evaluate their immunological implications carefully to ensure vaccine safety and efficacy.</p></sec><sec id="cbf70031-sec-0270"><label>6</label><title>CRISPR/Cas Editing for the Development of Recombinant Viral Vaccine</title><p>CRISPR/Cas is a DNA or RNA genome editing tool that has a role in early diagnosis (by CRISPR/Cas&#8208;based sensors for virus detection) and effectively preventing viral infections. It has also been successfully used to study gene functions, generate virus mutants, and activate and deactivate virus replication. It has emerged as an antiviral therapy that targets either RV entry or replication by knocking out different host factors involved in viral entry or replication but is not required for the host [<xref rid="cbf70031-bib-0140" ref-type="bibr">140</xref>]. The CRISPR&#8208;Csy4, a single strand RNA specific nuclease, fused with a major viroplasms' protein, NSP5, to localize Csy4 into the viroplasm (a site of RV genome replication) where it specifically targets and cleaves RV (+) ssRNA replication intermediates, producing defined and discrete deletions in edited viral genome dsRNA segment with the Csy4 target sequence. This allows modification of transcripts produced during the secondary transcription that mainly contributes to the production of rotavirus proteins in infected cells, as confirmed by encoding fluorescent or other tagged reporters [<xref rid="cbf70031-bib-0141" ref-type="bibr">141</xref>]. Csy4 activity generates a deletion of 21&#8211;45&#8201;nt in the RV genome with up to 95% efficiency in one round of replication. There is no known repair mechanism for a cleaved RV genome nor a sequence&#8208;specific programmable CRISPR nuclease targeting dsRNA. The following two examples elucidate the role of CRISPR/Cas in developing rotavirus vaccines.</p><p>CRISPR/Cas has been used to integrate VP6 in rabbit &#946; casein (<italic toggle="yes">CSN2</italic>) locus in transgenic rabbits to produce a milk&#8208;based rotavirus subunit vaccine against rotavirus infection [<xref rid="cbf70031-bib-0142" ref-type="bibr">142</xref>]. Vero cell lines, also known as African green monkey kidney cells, are genetically stable continuous cell lines that can safely produce viral vaccines for human use under underspecified regulatory guidelines. Short interfering RNA has been used to identify Vero cell host genes that, on knockdown, increased rotavirus replication and rotavirus vaccine antigen expression. These antiviral host genes were selectively removed using CRISPR/Cas. Gene editing has improved rotavirus vaccine substrates, suggesting a potential path for improvement in rotavirus vaccine manufacturing [<xref rid="cbf70031-bib-0143" ref-type="bibr">143</xref>]. A Vero cell substrate with improved RV replication or antigen expression would reduce the efforts, time, and money required to produce enough vaccine viruses. Further, using several guide RNAs to target conserved regions of the viral genome in combination with high&#8208;fidelity Cas would efficiently prevent viral infections. The safety and specificity of CRISPR/Cas would be achieved through the delivery of ribonucleoproteins with suitable carriers.</p></sec><sec id="cbf70031-sec-0280"><label>7</label><title>Rotaviruses RG to Develop New Vaccines or Antivirals</title><sec id="cbf70031-sec-0290"><label>7.1</label><title>Rotaviruses RG</title><p>RG helps in assigning phenotypic changes to genotypic mutations. This approach rescues live (infectious) rotavirus from a mutated genome (addition or deletion in individual viral genes at cDNA level). It generates recombinant rotaviruses that serve as expression platforms for heterologous proteins. It is a potent tool for understanding the molecular mechanisms of virus&#8211;host interactions, pathogenesis, and viral replication and to generate rational RV vaccines, antivirals, and viral vectors. RG systems for RNA viruses have proved more sophisticated because RNA viruses require in vitro reverse transcription of the genomic RNA into cDNA, in vitro mutation of cDNA, and the development of infectious viruses from mutant cDNAs [<xref rid="cbf70031-bib-0144" ref-type="bibr">144</xref>].</p></sec><sec id="cbf70031-sec-0300"><label>7.2</label><title>RG Systems for RV Vaccine Production</title><p>Present&#8208;day rotavirus vaccines have been developed from wild&#8208;type RV strains using conventional methods, such as repeated passages of human RV isolate in culture or reassortment between animal and human RV strains. These procedures involve extensive genotyping and screening to find vaccine candidates. RG has enabled it to generate mutants, perform simultaneous alterations in various genome segments, combine favored genome segments, and reassort diverse RV strains. Exploiting RV genes governing viral growth potential, antigenicity, and pathogenicity is also potent. RG has been applied to obtain recombinant RV vaccine cultures of appropriate serotypes that exhibit high duplication activity in cell culture and loss of virulence (for live vaccine). It is a rapid (reduces the time for the emergence of spontaneous mutations during repeated cultures) and repeatable method to enable gene&#8208;targeted reassortment and generate a large variety of VP4 and VP7 reassortment viruses between human and animal RV strains [<xref rid="cbf70031-bib-0145" ref-type="bibr">145</xref>]. VP4&#8208; or VP7&#8208;substituted chimeric virus has been used to characterize RV outer capsid proteins for antigenic potential as an improved seed virus for vaccine production. Once vaccine seed virus strains have been created, VP4 and VP7 genes cloned from RV strains in the target location can be inserted to create vaccine viruses unique to a region or nation [<xref rid="cbf70031-bib-0146" ref-type="bibr">146</xref>].
<list list-type="bullet"><list-item><p>If genes necessary for RV virulence are identified, finding attenuated vaccine candidates through gene alterations is encouraging. The NSP1 gene has been found to determine rotavirus virulence. NSP1 mutants that cannot disrupt the innate immune response of the host cell may be used as attenuated vaccination candidates.</p></list-item><list-item><p>RVAs have been used as vectors for the expression of heterologous immunogenic portions of SAR&#8208;CoV&#8208;2 proteins or proteins of other viral pathogens (at the C&#8208;terminus of NSP3) to generate oral live&#8208;attenuated combined vaccines against both SARS&#8208;CoV&#8208;2 and rotavirus [<xref rid="cbf70031-bib-0147" ref-type="bibr">147</xref>]. Three nonstructural rotavirus proteins, NSP1, NSP3, and NSP5, can tolerate heterologous gene (like reporter gene, GFP) insertion at C&#8208;termini. Rotavirus expressing GFP has been used to develop a high&#8208;throughput neutralization assay that rapidly evaluates pre&#8208;existing immunity in several animals, including humans [<xref rid="cbf70031-bib-0148" ref-type="bibr">148</xref>]. However, the general genome packaging capacity of RV remains to be determined.</p></list-item><list-item><p>The RV vaccine is now being produced using Vero cells that are approved for use in human vaccines. However, due to their poor transfection efficiency, there are better cells for recombining RVs. To create affordable RV vaccines with greater efficacy and safety to protect animals and humans against rotavirus infections, the RG method, which rescues recombinant viruses in Vero cells, will be necessary.</p></list-item></list>
</p></sec></sec><sec id="cbf70031-sec-0310"><label>8</label><title>Development of Novel Antivirals Against Rotavirus</title><p>Since no specific and compelling FDA&#8208;approved medications are available, developing effective antiviral therapies is urgently needed to combat rotavirus. The studies on host&#8211;virus interactions will facilitate a better understanding of the host factors regulating virus infection/replication. Several compounds or gene silencers disrupting the rotavirus replication cycle at various stages, like virus attachment and entry, host cell lipid metabolism and homeostasis of lipid droplets, RNA transcription and replication, viral protein synthesis, assembly, and release of the virus, have been identified [<xref rid="cbf70031-bib-0149" ref-type="bibr">149</xref>]. Antiviral treatment shall serve as a complement to the vaccine. Recently, the following novel antiviral strategies against rotavirus have been developed. These are:
<list list-type="simple"><list-item><label>1.</label><p>Viruses use host machinery to replicate, assemble, and release newly synthesized virions. A host factor, the eukaryotic translation initiation factor 4F (eIF4F) complex, limits rotavirus infection by regulating the antiviral proteins IRF1 and IRF7 [<xref rid="cbf70031-bib-0150" ref-type="bibr">150</xref>]. The knockdown of the eIF4F complex using short hairpin RNA and CRISPR/Cas considerably enhanced the rotavirus infection. Suppression of the negative regulator of the eIF4F complex and programmed cell death protein 4 (PDCD4) obstructs rotavirus infection. These results highlight that the eIF4F complex is a vital host factor suppressing rotavirus replication, demonstrating promising targets for developing a novel antiviral strategy against rotavirus infection.</p></list-item><list-item><label>2.</label><p>
<italic toggle="yes">Brequinar</italic> and leflunomide, the two inhibitors of the rate&#8208;limiting enzyme of the pyrimidine biosynthesis pathway, dihydroorotate dehydrogenase, strongly inhibit rotavirus replication in intestinal cells and organoids [<xref rid="cbf70031-bib-0150" ref-type="bibr">150</xref>]. This study suggests that inhibition of pyrimidine biosynthesis suppresses rotavirus replication, thus depicting a possible approach for antiviral development against rotavirus. Gemcitabine, an anticancer drug, has been found to inhibit rotavirus infection [<xref rid="cbf70031-bib-0151" ref-type="bibr">151</xref>]. This activity of gemcitabine is associated with inhibition of pyrimidine biosynthesis.</p></list-item><list-item><label>3.</label><p>Rotavirus infection induces one of the nucleotides&#8208;binding domain leucine&#8208;rich repeat&#8208;containing receptors (NLRs), NLRP9b, which initiates the formation of the inflammasome in the intestine to prevent rotavirus replication and the harm it causes [<xref rid="cbf70031-bib-0152" ref-type="bibr">152</xref>].</p></list-item><list-item><label>4.</label><p>Rotavirus&#8208;induced intercellular calcium waves (ICWs) in intestinal enteroids are mediated by the repeated release of extracellular adenosine diphosphate (ADP), which activates P2Y1 purinergic receptors on nearby uninfected cells. Antagonists of P2Y1 receptors or their knockdown by CRISPR/Cas results in blockage of ICWs. In neonatal mice, blocking the ADP signal lowers rotavirus proliferation, prevents serotonin release and fluid secretion, and lessens the severity of diarrhea [<xref rid="cbf70031-bib-0153" ref-type="bibr">153</xref>]. Blocking paracrine signals could represent a target for antidiarrheal pharmacotherapy.</p></list-item><list-item><label>5.</label><p>VP3 has all enzymatic activities (a single protein that integrates all five enzymatic steps activities) required for capping rotavirus mRNA (a critical step for efficient translation of the viral genome) that is synthesized by the viral RNA&#8208;dependent RNA polymerase, VP1. Antiviral medications can be developed more effectively to prevent and treat rotavirus infections due to our increased understanding of the structure and functions of the VP3 protein [<xref rid="cbf70031-bib-0154" ref-type="bibr">154</xref>].</p></list-item></list>
</p></sec><sec sec-type="conclusions" id="cbf70031-sec-0320"><label>9</label><title>Conclusions and Future Directions</title><p>Since their discovery in 1973, Rotaviruses have been the prominent causal organism of life&#8208;threatening gastroenteritis in young children and calves worldwide. They show high genetic diversity because of genetic rearrangements and hetero&#8208;encapsidation and are considered a potential zoonotic agent. The absence of proper treatment against rotaviral infection has prompted researchers to develop efficacious treatment and vaccination strategies. Strategies like passive immunization, immunobiotics, and single&#8208;chain antibodies (nanobodies) have managed rotaviral&#8208;induced diarrhea. During the last five decades following rotavirus discovery, several vaccines have been developed, most of which are live&#8208;attenuated variants of naturally occurring strains developed after several passages in cell culture or by reassortment between human and animal strains. Of the seven vaccines recommended at the local or global level in approximately 120 countries, the majority of them are monovalent (five like Rotarix, Rotavac, Rotavin, Lanzhou, and RV3&#8208;BB), and two are pentavalent (RotaTeq and Rotasiil). Though two recent WHO&#8208;approved Indian rotavirus vaccines (Rotasiil and Rotavac) have been adopted widely due to their cost effectiveness and decreased cold chain storage, Rotarix is still the most widely used vaccine globally. These vaccines have reduced diarrheal severity and death rates. However, the WHO&#8208;approved live&#8208;attenuated oral rotavirus vaccines have been less successful in preventing severe gastrointestinal disease in low&#8208;income countries than in high&#8208;income countries and have also been shown to increase the incidence of intussusceptions after oral vaccination significantly. Moreover, a vaccine is still unavailable for 89 million children in several developing countries due to its high cost and limited production capacity. This necessitates next&#8208;generation rotavirus vaccines that are cost&#8208;effective, thermostable, injectable (bypass the gut and decrease the risk of intussusceptions), used without age restriction (neonatal doses or boosters), more efficacious in providing high levels of protection regardless of settings across the globe and processed within a short time, are to be developed to accelerate vaccine coverage and access to unvaccinated children and reduce diarrheal related hospitalizations. The next generation non&#8208;replicating injectable vaccines based on the RV proteins subunit vaccines and RLPs (single, double, and triple layered) have been produced in several bio&#8208;factories, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">S. cerevisiae</italic>, insect&#8208;, mammalian&#8208; and plant cells. Besides the advantages and disadvantages of each bio factory, very few studies have expressed more than one rotavirus protein, and plants have emerged as an economical and safe platform since they are readily scaled and have a minimal risk of endotoxin or human pathogen contamination. Nanoparticles have increased the low immunogenicity and stability of subunit vaccines. Plant&#8208;produced rota&#8208;VLPs composed of VP7, VP6, VP2, and NSP4 are tolerated well and induce homotypic immune responses in infants. Bacterially expressed rotavirus &#8710;VP8* subunit vaccine with P[8], P[4], or P[6] has elicited virus&#8208;neutralizing antibodies in animals on immunization intramuscularly, and vaccine potential has been improved by introducing a tetanus epitope P2 into P[8] or P[6]&#8710;VP8*. Human clinical trials on vaccination with P2&#8208;VP8&#8208;P[8] and plant&#8208;based rota&#8208;VLPs show they are safe and immunogenic and protect against rotavirus in infants. These vaccines are in the pipeline for approval. Developing these parenteral non&#8208;replicating rotavirus subunit vaccines has excellent potential to overcome several problems associated with currently marketed live attenuated rotavirus vaccines and can serve as an effective alternative. Integration of RV with Artificial Intelligence and Machine Learning, CRISPR/Cas, and RG approaches can resolve fundamental issues related to virus&#8211;host interactions and effectively develop recombinant viral strains with new genotypes/proteins as safe vaccine candidates in less time without needing prior cell culture. A variety of antiviral compounds disrupting the rotavirus infection have been developed. Nevertheless, none is currently used as an effective anti&#8208;rotavirus treatment. Further research is required to understand the disease pathogenesis and host susceptibility better to develop an effective and sustainable vaccine production, especially in plants.</p></sec><sec id="cbf70031-sec-0330"><title>Author Contributions</title><p>Collection, analysis, and interpretation of data, as well as writing the original draft: M.P., P.M., and Y.K.J. Designed figures: H.Y. Project administration, resources, writing review and editing: D.C. Conceptualization, supervision, writing&#8211;review and editing: R.J. Conceptualization, study design, writing&#8211;review and editing: P.K.J. and Y.K.A. Writing&#8211;review and editing, formal analysis: A.S., N.S., and V.K.C.</p></sec><sec sec-type="COI-statement" id="cbf70031-sec-0350"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cbf70031-suppl-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CBF-42-e70031-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="cbf70031-sec-0340"><title>Acknowledgments</title><p>Mukta Prajapati and Yachna K. Jaiwal thank the Council for Scientific and Industrial Research, New Delhi, India, and the MDU, Rohtak, India, for the Senior Research Fellowship and the University Research Scholarship, respectively. Pawan K. Jaiwal is grateful to the University Grants Commission, New Delhi, for the financial support in the form of the BSR Faculty Fellowship (18&#8208;1/2011(BSR)).</p></ack><sec sec-type="data-availability" id="cbf70031-sec-0370"><title>Data Availability Statement</title><p>The authors have nothing to report.</p></sec><ref-list content-type="cited-references" id="cbf70031-bibl-0001"><title>References</title><ref id="cbf70031-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cbf70031-cit-0001"><string-name name-style="western"><given-names>J. E.</given-names><surname>Tate</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Burton</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Boschi&#8208;Pinto</surname></string-name>, and <string-name name-style="western"><given-names>U. D.</given-names><surname>Parashar</surname></string-name>, &#8220;<article-title>World Health Organization Global Rotavirus Surveillance Network. Global, Regional, and National Estimates of Rotavirus Mortality in Children</article-title>,&#8221; <source>Clinical Infectious Diseases</source><volume>62</volume> (<year>2016</year>): <fpage>S96</fpage>&#8211;<lpage>S105</lpage>.<pub-id pub-id-type="pmid">27059362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/civ1013</pub-id><pub-id pub-id-type="pmcid">PMC11979873</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cbf70031-cit-0002"><string-name name-style="western"><given-names>K.</given-names><surname>Odagiri</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Yoshizawa</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Sakihara</surname></string-name>, et al., &#8220;<article-title>Development of Genotype&#8208;Specific Anti&#8208;Bovine Rotavirus A Immunoglobulin Yolk Based on a Current Molecular Epidemiological Analysis of Bovine Rotaviruses a Collected in Japan During 2017&#8211;2020</article-title>,&#8221; <source>Viruses</source><volume>12</volume> (<year>2020</year>): <elocation-id>1386</elocation-id>, <pub-id pub-id-type="doi">10.3390/v12121386</pub-id>.<pub-id pub-id-type="pmid">33287460</pub-id><pub-id pub-id-type="pmcid">PMC7761885</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cbf70031-cit-0003"><string-name name-style="western"><given-names>V.</given-names><surname>Vetter</surname></string-name>, <string-name name-style="western"><given-names>R. C.</given-names><surname>Gardner</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Debrus</surname></string-name>, et al., &#8220;<article-title>Established and New Rotavirus Vaccines: A Comprehensive Review for Healthcare Professionals</article-title>,&#8221; <source>Human Vaccines &amp; Immunotherapeutics</source><volume>18</volume> (<year>2022</year>): <elocation-id>1870395</elocation-id>, <pub-id pub-id-type="doi">10.1080/21645515.2020.1870395</pub-id>.<pub-id pub-id-type="pmid">33605839</pub-id><pub-id pub-id-type="pmcid">PMC8920198</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cbf70031-cit-0004"><string-name name-style="western"><given-names>G. E.</given-names><surname>Armah</surname></string-name>, <string-name name-style="western"><given-names>S. O.</given-names><surname>Sow</surname></string-name>, <string-name name-style="western"><given-names>R. F.</given-names><surname>Breiman</surname></string-name>, et al., &#8220;<article-title>Efficacy of Pentavalent Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Infants in Developing Countries in Sub&#8208;Saharan Africa: A Randomised, Double&#8208;Blind, Placebo&#8208;Controlled Trial</article-title>,&#8221; <source>Lancet</source><volume>376</volume> (<year>2010</year>): <fpage>606</fpage>&#8211;<lpage>614</lpage>.<pub-id pub-id-type="pmid">20692030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(10)60889-6</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cbf70031-cit-0005"><string-name name-style="western"><given-names>M. J.</given-names><surname>Groome</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Koen</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Fix</surname></string-name>, et al., &#8220;<article-title>Safety and Immunogenicity of a Parenteral P2&#8208;VP8&#8208;P[8] Subunit Rotavirus Vaccine in Toddlers and Infants in South Africa: A Randomised, Double&#8208;Blind, Placebo&#8208;Controlled Trial</article-title>,&#8221; <source>Lancet Infectious Diseases</source><volume>17</volume> (<year>2017</year>): <fpage>843</fpage>&#8211;<lpage>853</lpage>, <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30242-6</pub-id>.<pub-id pub-id-type="pmid">28483414</pub-id><pub-id pub-id-type="pmcid">PMC7771518</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cbf70031-cit-0006"><string-name name-style="western"><given-names>S.</given-names><surname>Ramani</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Stewart</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Laucirica</surname></string-name>, et al., &#8220;<article-title>Human Milk Oligosaccharides, Milk Microbiome and Infant Gut Microbiome Modulate Neonatal Rotavirus Infection</article-title>,&#8221; <source>Nature Communications</source><volume>9</volume> (<year>2018</year>): <fpage>5010</fpage>, <pub-id pub-id-type="doi">10.1038/s41467-018-07476-4</pub-id>.<pub-id pub-id-type="pmcid">PMC6258677</pub-id><pub-id pub-id-type="pmid">30479342</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cbf70031-cit-0007"><string-name name-style="western"><given-names>P.</given-names><surname>Pereira</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Vetter</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Standaert</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Benninghoff</surname></string-name>, &#8220;<article-title>Fifteen Years of Experience With the Oral Live&#8208;Attenuated Human Rotavirus Vaccine: Reflections on Lessons Learned</article-title>,&#8221; <source>Expert Review of Vaccines</source><volume>19</volume> (<year>2020</year>): <fpage>755</fpage>&#8211;<lpage>769</lpage>, <pub-id pub-id-type="doi">10.1080/14760584.2020.1800459</pub-id>.<pub-id pub-id-type="pmid">32729747</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cbf70031-cit-0008"><string-name name-style="western"><given-names>M.</given-names><surname>Lobato&#8208;G&#243;mez</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Alvarez</surname></string-name>, et al., &#8220;<article-title>Contributions of the International Plant Science Community to the Fight Against Human Infectious Diseases &#8211; Part 1: Epidemic and Pandemic Diseases</article-title>,&#8221; <source>Plant Biotechnology Journal</source><volume>19</volume> (<year>2021</year>): <fpage>1901</fpage>&#8211;<lpage>1920</lpage>, <pub-id pub-id-type="doi">10.1111/pbi.13657</pub-id>.<pub-id pub-id-type="pmid">34182608</pub-id><pub-id pub-id-type="pmcid">PMC8486245</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cbf70031-cit-0009"><string-name name-style="western"><given-names>S.</given-names><surname>Bhoria</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Yadav</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yadav</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chaudhary</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jaiwal</surname></string-name>, and <string-name name-style="western"><given-names>P. K.</given-names><surname>Jaiwal</surname></string-name>, &#8220;<article-title>Current Advances and Future Prospects in Production of Recombinant Insulin and Other Proteins to Treat Diabetes Mellitus</article-title>,&#8221; <source>Biotechnology Letters</source><volume>44</volume> (<year>2022</year>): <fpage>643</fpage>&#8211;<lpage>669</lpage>, <pub-id pub-id-type="doi">10.1007/s10529-022-03247-w</pub-id>.<pub-id pub-id-type="pmid">35430708</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cbf70031-cit-0010"><string-name name-style="western"><given-names>J.</given-names><surname>Yadav</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Phogat</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chaudhary</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jaiwal</surname></string-name>, and <string-name name-style="western"><given-names>P. K.</given-names><surname>Jaiwal</surname></string-name>, &#8220;<article-title>Synthesis of Plant&#8208;Based, Self&#8208;Adjuvanted, Dual Antigen Specific to <italic toggle="yes">Mycobacterium tuberculosis</italic> as a Novel Tuberculosis Subunit Vaccine That Elicits Immunogenicity in Rabbit</article-title>,&#8221; <source>Biotechnology Letters</source><volume>45</volume> (<year>2023</year>): <fpage>703</fpage>&#8211;<lpage>717</lpage>, <pub-id pub-id-type="doi">10.1007/s10529-023-03371-1</pub-id>.<pub-id pub-id-type="pmid">37074553</pub-id><pub-id pub-id-type="pmcid">PMC10113735</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cbf70031-cit-0011"><string-name name-style="western"><given-names>H.</given-names><surname>Su</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>van Eerde</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Rimstad</surname></string-name>, et al., &#8220;<article-title>Plant&#8208;Made Vaccines Against Viral Diseases in Humans and Farm Animals</article-title>,&#8221; <source>Frontiers in Plant Science</source><volume>14</volume> (<year>2023</year>): <elocation-id>1170815</elocation-id>, <pub-id pub-id-type="doi">10.3389/fpls.2023.1170815</pub-id>.<pub-id pub-id-type="pmid">37056490</pub-id><pub-id pub-id-type="pmcid">PMC10086147</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cbf70031-cit-0012"><string-name name-style="western"><given-names>U.</given-names><surname>Desselberger</surname></string-name>, &#8220;<article-title>Rotaviruses</article-title>,&#8221; <source>Virus Research</source><volume>190</volume> (<year>2014</year>): <fpage>75</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="pmid">25016036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2014.06.016</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0013"><label>13</label><mixed-citation publication-type="book" id="cbf70031-cit-0013"><collab collab-type="authors">UNICEF</collab>
, <source>Oral Rehydration Salts (ORS) and Zinc</source> (<publisher-loc>Copenhagen</publisher-loc>: <publisher-name>UNICEF</publisher-name>, <year>2016</year>).</mixed-citation></ref><ref id="cbf70031-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cbf70031-cit-0014"><string-name name-style="western"><given-names>S. A.</given-names><surname>Sarker</surname></string-name>, <string-name name-style="western"><given-names>T. H.</given-names><surname>Casswall</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Mahalanabis</surname></string-name>, et al., &#8220;<article-title>Successful Treatment of Rotavirus Diarrhea in Children With Immunoglobulin From Immunized Bovine Colostrum</article-title>,&#8221; <source>Pediatric Infectious Disease Journal</source><volume>17</volume> (<year>1998</year>): <fpage>1149</fpage>&#8211;<lpage>1154</lpage>.<pub-id pub-id-type="pmid">9877365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00006454-199812000-00010</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cbf70031-cit-0015"><string-name name-style="western"><given-names>J. W.</given-names><surname>Burns</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Siadat&#8208;Pajouh</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Krishnaney</surname></string-name>, and <string-name name-style="western"><given-names>H. B.</given-names><surname>Greenberg</surname></string-name>, &#8220;<article-title>Protective Effect of Rotavirus VP6&#8208;Specific IgA Monoclonal Antibodies That Lack Neutralizing Activity</article-title>,&#8221; <source>Science</source><volume>272</volume> (<year>1996</year>): <fpage>104</fpage>&#8211;<lpage>107</lpage>.<pub-id pub-id-type="pmid">8600516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.272.5258.104</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cbf70031-cit-0016"><string-name name-style="western"><given-names>S. A.</given-names><surname>Sarker</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Pant</surname></string-name>, <string-name name-style="western"><given-names>L. R.</given-names><surname>Juneja</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Hammarstr&#246;m</surname></string-name>, &#8220;<article-title>Successful Treatment of Rotavirus&#8208;Induced Diarrhoea in Suckling Mice With Egg Yolk Immunoglobulin</article-title>,&#8221; <source>Journal of Health, Population, and Nutrition</source><volume>25</volume> (<year>2007</year>): <fpage>465</fpage>&#8211;<lpage>468</lpage>.<pub-id pub-id-type="pmid">18402190</pub-id><pub-id pub-id-type="pmcid">PMC2754009</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cbf70031-cit-0017"><string-name name-style="western"><given-names>G. A.</given-names><surname>Preidis</surname></string-name>, <string-name name-style="western"><given-names>D. M.</given-names><surname>Saulnier</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Blutt</surname></string-name>, et al., &#8220;<article-title>Host Response to Probiotics Determined by Nutritional Status of Rotavirus&#8208;Infected Neonatal Mice</article-title>,&#8221; <source>Journal of Pediatric Gastroenterology and Nutrition</source><volume>55</volume> (<year>2012</year>): <fpage>299</fpage>&#8211;<lpage>307</lpage>.<pub-id pub-id-type="pmid">22343914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPG.0b013e31824d2548</pub-id><pub-id pub-id-type="pmcid">PMC4010314</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cbf70031-cit-0018"><string-name name-style="western"><given-names>L.</given-names><surname>Jiang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Tang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Song</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Tong</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Fan</surname></string-name>, &#8220;<article-title>Advances in the Development of Antivirals for Rotavirus Infection</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>14</volume> (<year>2023</year>): <elocation-id>1041149</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2023.1041149</pub-id>.<pub-id pub-id-type="pmid">37006293</pub-id><pub-id pub-id-type="pmcid">PMC10063883</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cbf70031-cit-0019"><string-name name-style="western"><given-names>D. H.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Song</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Bae</surname></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Han</surname></string-name>, &#8220;<article-title>Inhibitory Effect of Herbal Medicines on Rotavirus Infectivity</article-title>,&#8221; <source>Biological and Pharmaceutical Bulletin</source><volume>23</volume> (<year>2000</year>): <fpage>356</fpage>&#8211;<lpage>358</lpage>.<pub-id pub-id-type="pmid">10726895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/bpb.23.356</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cbf70031-cit-0020"><string-name name-style="western"><given-names>C.</given-names><surname>Constantin</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Neagu</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Supeanu</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Chiurciu</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Spandidos</surname></string-name>, &#8220;<article-title>IgY &#8211; Turning the Page Toward Passive Immunization in COVID&#8208;19 Infection (Review)</article-title>,&#8221; <source>Experimental and Therapeutic Medicine</source><volume>20</volume> (<year>2020</year>): <fpage>151</fpage>&#8211;<lpage>158</lpage>, <pub-id pub-id-type="doi">10.3892/etm.2020.8704</pub-id>.<pub-id pub-id-type="pmcid">PMC7282020</pub-id><pub-id pub-id-type="pmid">32536989</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cbf70031-cit-0021"><string-name name-style="western"><given-names>A.</given-names><surname>Civra</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Altomare</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Francese</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Donalisio</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Aldini</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Lembo</surname></string-name>, &#8220;<article-title>Colostrum From Cows Immunized With a Veterinary Vaccine Against Bovine Rotavirus Displays Enhanced <italic toggle="yes">In Vitro</italic> Anti&#8208;Human Rotavirus Activity</article-title>,&#8221; <source>Journal of Dairy Science</source><volume>102</volume> (<year>2019</year>): <fpage>4857</fpage>&#8211;<lpage>4869</lpage>, <pub-id pub-id-type="doi">10.3168/jds.2018-16016</pub-id>.<pub-id pub-id-type="pmid">30981494</pub-id><pub-id pub-id-type="pmcid">PMC7127701</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cbf70031-cit-0022"><string-name name-style="western"><given-names>M.</given-names><surname>Inagaki</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Yamamoto</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cairangzhuoma</surname></string-name>, et al., &#8220;<article-title>Multiple&#8208;Dose Therapy With Bovine Colostrum Confers Significant Protection Against Diarrhea in a Mouse Model of Human Rotavirus&#8208;Induced Gastrointestinal Disease</article-title>,&#8221; <source>Journal of Dairy Science</source><volume>96</volume> (<year>2013</year>): <fpage>806</fpage>&#8211;<lpage>814</lpage>.<pub-id pub-id-type="pmid">23200479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3168/jds.2012-5847</pub-id><pub-id pub-id-type="pmcid">PMC7094275</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cbf70031-cit-0023"><string-name name-style="western"><given-names>V.</given-names><surname>Parre&#241;o</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Marcoppido</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Vega</surname></string-name>, et al., &#8220;<article-title>Milk Supplemented With Immune Colostrum: Protection Against Rotavirus Diarrhea and Modulatory Effect on the Systemic and Mucosal Antibody Responses in Calves Experimentally Challenged With Bovine Rotavirus</article-title>,&#8221; <source>Veterinary Immunology and Immunopathology</source><volume>136</volume> (<year>2010</year>): <fpage>12</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">20138373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetimm.2010.01.003</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cbf70031-cit-0024"><string-name name-style="western"><given-names>J. P.</given-names><surname>Schaller</surname></string-name>, <string-name name-style="western"><given-names>L. J.</given-names><surname>Saif</surname></string-name>, <string-name name-style="western"><given-names>C. T.</given-names><surname>Cordle</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Candler</surname></string-name>, <string-name name-style="western"><given-names>T. R.</given-names><surname>Winship</surname></string-name>, and <string-name name-style="western"><given-names>K. L.</given-names><surname>Smith</surname></string-name>, &#8220;<article-title>Prevention of Human Rotavirus&#8208;Induced Diarrhea in Gnotobiotic Piglets Using Bovine Antibody</article-title>,&#8221; <source>Journal of Infectious Diseases</source><volume>165</volume> (<year>1992</year>): <fpage>623</fpage>&#8211;<lpage>630</lpage>.<pub-id pub-id-type="pmid">1313067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/165.4.623</pub-id><pub-id pub-id-type="pmcid">PMC7110050</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cbf70031-cit-0025"><string-name name-style="western"><given-names>T.</given-names><surname>Ebina</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Tsukada</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Umezu</surname></string-name>, et al., &#8220;<article-title>Gastroenteritis in Suckling Mice Caused by Human Rotavirus Can Be Prevented With Egg Yolk Immunoglobulin (IgY) and Treated With a Protein&#8208;Bound Polysaccharide Preparation (PSK)</article-title>,&#8221; <source>Microbiology and Immunology</source><volume>34</volume> (<year>1990</year>): <fpage>617</fpage>&#8211;<lpage>629</lpage>, <pub-id pub-id-type="doi">10.1111/j.1348-0421.1990.tb01037.x</pub-id>.<pub-id pub-id-type="pmid">2176268</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cbf70031-cit-0026"><string-name name-style="western"><given-names>L. H.</given-names><surname>Ulfman</surname></string-name>, <string-name name-style="western"><given-names>J. H. W.</given-names><surname>Leusen</surname></string-name>, <string-name name-style="western"><given-names>H. F. J.</given-names><surname>Savelkoul</surname></string-name>, <string-name name-style="western"><given-names>J. O.</given-names><surname>Warner</surname></string-name>, and <string-name name-style="western"><given-names>R. J. J.</given-names><surname>van Neerven</surname></string-name>, &#8220;<article-title>Effects of Bovine Immunoglobulins on Immune Function, Allergy, and Infection</article-title>,&#8221; <source>Frontiers in Nutrition</source><volume>5</volume> (<year>2018</year>): <fpage>52</fpage>.<pub-id pub-id-type="pmid">29988421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnut.2018.00052</pub-id><pub-id pub-id-type="pmcid">PMC6024018</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cbf70031-cit-0027"><string-name name-style="western"><given-names>F. T.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>B&#225;nyai</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Jiang</surname></string-name>, et al., &#8220;<article-title>Novel G9 Rotavirus Strains Co&#8208;Circulate in Children and Pigs, Taiwan</article-title>,&#8221; <source>Scientific Reports</source><volume>7</volume> (<year>2017</year>): <elocation-id>40731</elocation-id>.<pub-id pub-id-type="pmid">28098174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep40731</pub-id><pub-id pub-id-type="pmcid">PMC5241653</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cbf70031-cit-0028"><string-name name-style="western"><given-names>C.</given-names><surname>Hamers&#8208;Casterman</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Atarhouch</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Muyldermans</surname></string-name>, et al., &#8220;<article-title>Naturally Occurring Antibodies Devoid of Light Chains</article-title>,&#8221; <source>Nature</source><volume>363</volume>, no. <issue>6428</issue> (<year>1993</year>): <fpage>446</fpage>&#8211;<lpage>448</lpage>.<pub-id pub-id-type="pmid">8502296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/363446a0</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cbf70031-cit-0029"><string-name name-style="western"><given-names>C. F. C.</given-names><surname>Fernandes</surname></string-name>, <string-name name-style="western"><given-names>S. S.</given-names><surname>Pereira</surname></string-name>, <string-name name-style="western"><given-names>M. B.</given-names><surname>Luiz</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Zuliani</surname></string-name>, <string-name name-style="western"><given-names>G. P.</given-names><surname>Furtado</surname></string-name>, and <string-name name-style="western"><given-names>R. G.</given-names><surname>Stabeli</surname></string-name>, &#8220;<article-title>Camelid Single&#8208;Domain Antibodies as an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>8</volume> (<year>2017</year>): <elocation-id>653</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2017.00653</pub-id>.<pub-id pub-id-type="pmid">28649245</pub-id><pub-id pub-id-type="pmcid">PMC5465246</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cbf70031-cit-0030"><string-name name-style="western"><given-names>M.</given-names><surname>Petersson</surname></string-name>, <string-name name-style="western"><given-names>S. W.</given-names><surname>Thrane</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Gram</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Muyldermans</surname></string-name>, and <string-name name-style="western"><given-names>A. H.</given-names><surname>Laustsen</surname></string-name>, &#8220;<article-title>Orally Delivered Single&#8208;Domain Antibodies Against Gastrointestinal Pathogens</article-title>,&#8221; <source>Trends in Biotechnology</source><volume>41</volume>, no. <issue>23</issue> (<year>2023</year>): <fpage>875</fpage>&#8211;<lpage>886</lpage>, <pub-id pub-id-type="doi">10.1016/j.tibtech.2023.01.015</pub-id>.<pub-id pub-id-type="pmid">36774206</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cbf70031-cit-0031"><string-name name-style="western"><given-names>D.</given-names><surname>Tokuhara</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>&#193;lvarez</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mejima</surname></string-name>, et al., &#8220;<article-title>Rice&#8208;Based Oral Antibody Fragment Prophylaxis and Therapy Against Rotavirus Infection</article-title>,&#8221; <source>Journal of Clinical Investigation</source><volume>123</volume> (<year>2013</year>): <fpage>3829</fpage>&#8211;<lpage>3838</lpage>.<pub-id pub-id-type="pmid">23925294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI70266</pub-id><pub-id pub-id-type="pmcid">PMC3754275</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cbf70031-cit-0032"><string-name name-style="western"><given-names>N.</given-names><surname>Pant</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Hultberg</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhao</surname></string-name>, et al., &#8220;<article-title>Lactobacilli Expressing Variable Domain of Llama Heavy&#8208;Chain Antibody Fragments (Lactobodies) Confer Protection Against Rotavirus&#8208;Induced Diarrhea</article-title>,&#8221; <source>Journal of Infectious Diseases</source><volume>194</volume> (<year>2006</year>): <fpage>1580</fpage>&#8211;<lpage>1588</lpage>.<pub-id pub-id-type="pmid">17083044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/508747</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cbf70031-cit-0033"><string-name name-style="western"><given-names>N.</given-names><surname>Pant</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Marcotte</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Hermans</surname></string-name>, et al., &#8220;<article-title>Lactobacilli Producing Bispecific Llama&#8208;Derived Anti&#8208;Rotavirus Proteins <italic toggle="yes">In Vivo</italic> for Rotavirus&#8208;Induced Diarrhea</article-title>,&#8221; <source>Future Microbiology</source><volume>6</volume> (<year>2011</year>): <fpage>583</fpage>&#8211;<lpage>593</lpage>.<pub-id pub-id-type="pmid">21585264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fmb.11.32</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cbf70031-cit-0034"><string-name name-style="western"><given-names>S. A.</given-names><surname>Sarker</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>J&#228;kel</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sultana</surname></string-name>, et al., &#8220;<article-title>Anti&#8208;Rotavirus Protein Reduces Stool Output in Infants With Diarrhea: A Randomized Placebo&#8208;Controlled Trial</article-title>,&#8221; <source>Gastroenterology</source><volume>145</volume> (<year>2013</year>): <fpage>740</fpage>&#8211;<lpage>748.e8</lpage>.<pub-id pub-id-type="pmid">23831050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2013.06.053</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cbf70031-cit-0035"><string-name name-style="western"><given-names>L.</given-names><surname>Garaicoechea</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Olichon</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Marcoppido</surname></string-name>, et al., &#8220;<article-title>Llama&#8208;Derived Single&#8208;Chain Antibody Fragments Directed to Rotavirus VP6 Protein Possess Broad Neutralizing Activity <italic toggle="yes">In Vitro</italic> and Confer Protection Against Diarrhea in Mice</article-title>,&#8221; <source>Journal of Virology</source><volume>82</volume> (<year>2008</year>): <fpage>9753</fpage>&#8211;<lpage>9764</lpage>.<pub-id pub-id-type="pmid">18632867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00436-08</pub-id><pub-id pub-id-type="pmcid">PMC2546978</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cbf70031-cit-0036"><string-name name-style="western"><given-names>L.</given-names><surname>Maffey</surname></string-name>, <string-name name-style="western"><given-names>C. G.</given-names><surname>Vega</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mi&#241;o</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Garaicoechea</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Parre&#241;o</surname></string-name>, &#8220;<article-title>Anti&#8208;VP6 VHH: An Experimental Treatment for Rotavirus A&#8208;Associated Disease</article-title>,&#8221; <source>PLoS One</source><volume>11</volume> (<year>2016</year>): <elocation-id>e0162351</elocation-id>.<pub-id pub-id-type="pmid">27603013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0162351</pub-id><pub-id pub-id-type="pmcid">PMC5014449</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cbf70031-cit-0037"><string-name name-style="western"><given-names>S.</given-names><surname>Steeland</surname></string-name>, <string-name name-style="western"><given-names>R. E.</given-names><surname>Vandenbroucke</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Libert</surname></string-name>, &#8220;<article-title>Nanobodies as Therapeutics: Big Opportunities for Small Antibodies</article-title>,&#8221; <source>Drug Discovery Today</source><volume>21</volume> (<year>2016</year>): <fpage>1076</fpage>&#8211;<lpage>1113</lpage>, <pub-id pub-id-type="doi">10.1016/j.drudis.2016.04.003</pub-id>.<pub-id pub-id-type="pmid">27080147</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cbf70031-cit-0038"><string-name name-style="western"><given-names>J.</given-names><surname>Villena</surname></string-name>, <string-name name-style="western"><given-names>M. G.</given-names><surname>Vizoso&#8208;Pinto</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Kitazawa</surname></string-name>, &#8220;<article-title>Intestinal Innate Antiviral Immunity and Immunobiotics: Beneficial Effects Against Rotavirus Infection</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>7</volume> (<year>2016</year>): <elocation-id>563</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2016.00563</pub-id>.<pub-id pub-id-type="pmid">27994593</pub-id><pub-id pub-id-type="pmcid">PMC5136547</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cbf70031-cit-0039"><string-name name-style="western"><given-names>J.</given-names><surname>Villena</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Aso</surname></string-name>, <string-name name-style="western"><given-names>V. P. M. G.</given-names><surname>Rutten</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Takahashi</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>van Eden</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Kitazawa</surname></string-name>, &#8220;<article-title>Immunobiotics for the Bovine Host: Their Interaction With Intestinal Epithelial Cells and Their Effect on Antiviral Immunity</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>9</volume> (<year>2018</year>): <elocation-id>326</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2018.00326</pub-id>.<pub-id pub-id-type="pmid">29599767</pub-id><pub-id pub-id-type="pmcid">PMC5863502</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cbf70031-cit-0040"><string-name name-style="western"><given-names>Z.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Zou</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhang</surname></string-name>, et al., &#8220;<article-title>Segmented Filamentous Bacteria Prevent and Cure Rotavirus Infection</article-title>,&#8221; <source>Cell</source><volume>179</volume> (<year>2019</year>): <fpage>644</fpage>&#8211;<lpage>658.e13</lpage>.<pub-id pub-id-type="pmid">31607511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2019.09.028</pub-id><pub-id pub-id-type="pmcid">PMC7525827</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cbf70031-cit-0041"><string-name name-style="western"><given-names>A. H.</given-names><surname>Kim</surname></string-name>, <string-name name-style="western"><given-names>M. P.</given-names><surname>Hogarty</surname></string-name>, <string-name name-style="western"><given-names>V. C.</given-names><surname>Harris</surname></string-name>, and <string-name name-style="western"><given-names>M. T.</given-names><surname>Baldridge</surname></string-name>, &#8220;<article-title>The Complex Interactions Between Rotavirus and the Gut Microbiota</article-title>,&#8221; <source>Frontiers in Cellular and Infection Microbiology</source><volume>10</volume> (<year>2021</year>): <elocation-id>586751</elocation-id>, <pub-id pub-id-type="doi">10.3389/fcimb.2020.586751</pub-id>.<pub-id pub-id-type="pmid">33489932</pub-id><pub-id pub-id-type="pmcid">PMC7819889</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cbf70031-cit-0042"><string-name name-style="western"><given-names>W.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Feng</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, et al., &#8220;<article-title>Surface Display of Antigen Protein VP8* of Porcine Rotavirus on <italic toggle="yes">Bacillus subtilis</italic> Spores Using CotB as a Fusion Partner</article-title>,&#8221; <source>Molecules</source><volume>24</volume> (<year>2019</year>): <elocation-id>3793</elocation-id>, <pub-id pub-id-type="doi">10.3390/molecules24203793</pub-id>.<pub-id pub-id-type="pmid">31652492</pub-id><pub-id pub-id-type="pmcid">PMC6833084</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cbf70031-cit-0043"><string-name name-style="western"><given-names>O. S.</given-names><surname>Folorunso</surname></string-name> and <string-name name-style="western"><given-names>O. M.</given-names><surname>Sebolai</surname></string-name>, &#8220;<article-title>Overview of the Development, Impacts, and Challenges of Live&#8208;Attenuated Oral Rotavirus Vaccines</article-title>,&#8221; <source>Vaccines</source><volume>8</volume> (<year>2020</year>): <elocation-id>341</elocation-id>, <pub-id pub-id-type="doi">10.3390/vaccines8030341</pub-id>.<pub-id pub-id-type="pmid">32604982</pub-id><pub-id pub-id-type="pmcid">PMC7565912</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cbf70031-cit-0044"><string-name name-style="western"><given-names>H.</given-names><surname>Seo</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Duan</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Zhang</surname></string-name>, &#8220;<article-title>Vaccines Against Gastroenteritis, Current Progress and Challenges</article-title>,&#8221; <source>Gut Microbes</source><volume>11</volume> (<year>2020</year>): <fpage>1486</fpage>&#8211;<lpage>1517</lpage>.<pub-id pub-id-type="pmid">32552414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19490976.2020.1770666</pub-id><pub-id pub-id-type="pmcid">PMC7524147</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cbf70031-cit-0045"><string-name name-style="western"><given-names>E.</given-names><surname>Burnett</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Parashar</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Tate</surname></string-name>, &#8220;<article-title>Rotavirus Vaccines: Effectiveness, Safety, and Future Directions</article-title>,&#8221; <source>Pediatric Drugs</source><volume>20</volume> (<year>2018</year>): <fpage>223</fpage>&#8211;<lpage>233</lpage>.<pub-id pub-id-type="pmid">29388076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40272-018-0283-3</pub-id><pub-id pub-id-type="pmcid">PMC5955791</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cbf70031-cit-0046"><string-name name-style="western"><given-names>R.</given-names><surname>P&#233;rez&#8208;Ort&#237;n</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Santiso&#8208;Bell&#243;n</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Vila&#8208;Vicent</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Carmona&#8208;Vicente</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Rodr&#237;guez&#8208;D&#237;az</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Buesa</surname></string-name>, &#8220;<article-title>Rotavirus Symptomatic Infection Among Unvaccinated and Vaccinated Children in Valencia, Spain</article-title>,&#8221; <source>BMC Infectious Diseases</source><volume>19</volume> (<year>2019</year>): <fpage>998</fpage>, <pub-id pub-id-type="doi">10.1186/s12879-019-4550-x</pub-id>.<pub-id pub-id-type="pmid">31771522</pub-id><pub-id pub-id-type="pmcid">PMC6880582</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cbf70031-cit-0047"><string-name name-style="western"><given-names>G.</given-names><surname>Ramakrishnan</surname></string-name>, <string-name name-style="western"><given-names>J. Z.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Haque</surname></string-name>, and <string-name name-style="western"><given-names>W. A.</given-names><surname>Petri</surname></string-name>, &#8220;<article-title>Rotavirus Vaccine Protection in Low&#8208;Income and Middle&#8208;Income Countries</article-title>,&#8221; <source>Lancet Infectious Diseases</source><volume>19</volume> (<year>2019</year>): <fpage>673</fpage>&#8211;<lpage>674</lpage>.<pub-id pub-id-type="pmid">31178290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(19)30263-4</pub-id><pub-id pub-id-type="pmcid">PMC6871505</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0048"><label>48</label><mixed-citation publication-type="book" id="cbf70031-cit-0048"><collab collab-type="authors">UNICEF</collab>
, <italic toggle="yes">Rotavirus Vaccine: Supply Demand Update</italic> (<publisher-loc>Copenhagen</publisher-loc>: <publisher-name>UNICEF</publisher-name>, <year>2022</year>), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.unicef.org/supply/media/10841/file/Rotavirus" ext-link-type="uri">https://www.unicef.org/supply/media/10841/file/Rotavirus</ext-link>.</mixed-citation></ref><ref id="cbf70031-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="cbf70031-cit-0049"><string-name name-style="western"><given-names>P. S.</given-names><surname>Kulkarni</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Desai</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Tewari</surname></string-name>, et al., &#8220;<article-title>A Randomized Phase III Clinical Trial to Assess the Efficacy of a Bovine&#8208;Human Reassortant Pentavalent Rotavirus Vaccine in Indian Infants</article-title>,&#8221; <source>Vaccine</source><volume>35</volume>, no. <issue>45</issue> (<year>2017</year>): <fpage>6228</fpage>&#8211;<lpage>6237</lpage>.<pub-id pub-id-type="pmid">28967523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.09.014</pub-id><pub-id pub-id-type="pmcid">PMC5651219</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="cbf70031-cit-0050"><string-name name-style="western"><given-names>A.</given-names><surname>Hamidi</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Hoeksema</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Velthof</surname></string-name>, et al., &#8220;<article-title>Developing a Manufacturing Process to Deliver a Cost&#8208;Effective and Stable Liquid Human Rotavirus Vaccine</article-title>,&#8221; <source>Vaccine</source><volume>39</volume> (<year>2021</year>): <fpage>2048</fpage>&#8211;<lpage>2059</lpage>.<pub-id pub-id-type="pmid">33744044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.03.033</pub-id><pub-id pub-id-type="pmcid">PMC8062787</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="cbf70031-cit-0051"><string-name name-style="western"><given-names>D.</given-names><surname>Witte</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Handley</surname></string-name>, <string-name name-style="western"><given-names>K. C.</given-names><surname>Jere</surname></string-name>, et al., &#8220;<article-title>Neonatal Rotavirus Vaccine (RV3&#8208;BB) Immunogenicity and Safety in a Neonatal and Infant Administration Schedule in Malawi: A Randomised, Double&#8208;Blind, Four&#8208;Arm Parallel Group Dose&#8208;Ranging Study</article-title>,&#8221; <source>Lancet Infectious Diseases</source><volume>22</volume> (<year>2022</year>): <fpage>668</fpage>&#8211;<lpage>678</lpage>, <pub-id pub-id-type="doi">10.1016/S1473-3099(21)00473-4</pub-id>.<pub-id pub-id-type="pmid">35065683</pub-id><pub-id pub-id-type="pmcid">PMC9021029</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="cbf70031-cit-0052"><string-name name-style="western"><given-names>Z.&#8208;W.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>Q.&#8208;L.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>H.&#8208;S.</given-names><surname>Zhou</surname></string-name>, et al., &#8220;<article-title>Safety and Immunogenicity of a Novel Oral Hexavalent Rotavirus Vaccine: A Phase I Clinical Trial</article-title>,&#8221; <source>Human Vaccines &amp; Immunotherapeutics</source><volume>17</volume> (<year>2021</year>): <fpage>2311</fpage>&#8211;<lpage>2318</lpage>, <pub-id pub-id-type="doi">10.1080/21645515.2020.1861874</pub-id>.<pub-id pub-id-type="pmid">33545015</pub-id><pub-id pub-id-type="pmcid">PMC8189138</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="cbf70031-cit-0053"><string-name name-style="western"><given-names>C. D.</given-names><surname>Kirkwood</surname></string-name>, <string-name name-style="western"><given-names>L. F.</given-names><surname>Ma</surname></string-name>, <string-name name-style="western"><given-names>M. E.</given-names><surname>Carey</surname></string-name>, and <string-name name-style="western"><given-names>A. D.</given-names><surname>Steele</surname></string-name>, &#8220;<article-title>The Rotavirus Vaccine Development Pipeline</article-title>,&#8221; <source>Vaccine</source><volume>37</volume> (<year>2019</year>): <fpage>7328</fpage>&#8211;<lpage>7335</lpage>.<pub-id pub-id-type="pmid">28396207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.03.076</pub-id><pub-id pub-id-type="pmcid">PMC6892263</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="cbf70031-cit-0054"><string-name name-style="western"><given-names>S.</given-names><surname>Plotkin</surname></string-name>, &#8220;<article-title>History of Vaccination</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences</source><volume>111</volume> (<year>2014</year>): <fpage>12283</fpage>&#8211;<lpage>12287</lpage>, <pub-id pub-id-type="doi">10.1073/pnas.1400472111</pub-id>.<pub-id pub-id-type="pmcid">PMC4151719</pub-id><pub-id pub-id-type="pmid">25136134</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="cbf70031-cit-0055"><string-name name-style="western"><given-names>M.</given-names><surname>Brisse</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Vrba</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Kirk</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Liang</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Ly</surname></string-name>, &#8220;<article-title>Emerging Concepts and Technologies in Vaccine Development</article-title>,&#8221; <source>Frontiers in Immunology</source><volume>11</volume> (<year>2020</year>): <elocation-id>583077</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2020.583077</pub-id>.<pub-id pub-id-type="pmid">33101309</pub-id><pub-id pub-id-type="pmcid">PMC7554600</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="cbf70031-cit-0056"><string-name name-style="western"><given-names>R. L.</given-names><surname>Ward</surname></string-name> and <string-name name-style="western"><given-names>M. M.</given-names><surname>McNeal</surname></string-name>, &#8220;<article-title>VP6: A Candidate Rotavirus Vaccine</article-title>,&#8221; <source>Journal of Infectious Diseases</source><volume>202</volume> (<year>2010</year>): <fpage>S101</fpage>&#8211;<lpage>S107</lpage>.<pub-id pub-id-type="pmid">20684688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/653556</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="cbf70031-cit-0057"><string-name name-style="western"><given-names>A. D.</given-names><surname>Fix</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Harro</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>McNeal</surname></string-name>, et al., &#8220;<article-title>Safety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults</article-title>,&#8221; <source>Vaccine</source><volume>33</volume> (<year>2015</year>): <fpage>3766</fpage>&#8211;<lpage>3772</lpage>.<pub-id pub-id-type="pmid">26065919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.05.024</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="cbf70031-cit-0058"><string-name name-style="western"><given-names>X.</given-names><surname>Wen</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Wen</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Cao</surname></string-name>, et al., &#8220;<article-title>The Inclusion of a Universal Tetanus Toxoid CD4(+) T Cell Epitope P2 Significantly Enhanced the Immunogenicity of Recombinant Rotavirus Delta VP8* Subunit Parenteral Vaccines</article-title>,&#8221; <source>Vaccine</source><volume>32</volume> (<year>2014</year>): <fpage>4420</fpage>&#8211;<lpage>4427</lpage>.<pub-id pub-id-type="pmid">24962749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.06.060</pub-id><pub-id pub-id-type="pmcid">PMC4104241</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="cbf70031-cit-0059"><string-name name-style="western"><given-names>M. J.</given-names><surname>Groome</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Fairlie</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Morrison</surname></string-name>, et al., &#8220;<article-title>Safety and Immunogenicity of a Parenteral Trivalent P2&#8208;VP8 Subunit Rotavirus Vaccine: A Multisite, Randomised, Double&#8208;Blind, Placebo&#8208;Controlled Trial</article-title>,&#8221; <source>Lancet Infectious Diseases</source><volume>20</volume> (<year>2020</year>): <fpage>851</fpage>&#8211;<lpage>863</lpage>.<pub-id pub-id-type="pmid">32251641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30001-3</pub-id><pub-id pub-id-type="pmcid">PMC7322558</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="cbf70031-cit-0060"><string-name name-style="western"><given-names>K.</given-names><surname>Lakatos</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>McAdams</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>White</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Chen</surname></string-name>, &#8220;<article-title>Formulation and Preclinical Studies With a Trivalent Rotavirus P2&#8208;VP8 Subunit Vaccine</article-title>,&#8221; <source>Human Vaccines &amp; Immunotherapeutics</source><volume>16</volume> (<year>2020</year>): <fpage>1957</fpage>&#8211;<lpage>1968</lpage>.<pub-id pub-id-type="pmid">31995444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2019.1710412</pub-id><pub-id pub-id-type="pmcid">PMC7482676</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="cbf70031-cit-0061"><string-name name-style="western"><given-names>S.</given-names><surname>Agarwal</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Hickey</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Sahni</surname></string-name>, et al., &#8220;<article-title>Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens</article-title>,&#8221; <source>Journal of Pharmaceutical Sciences</source><volume>109</volume> (<year>2020</year>): <fpage>380</fpage>&#8211;<lpage>393</lpage>.<pub-id pub-id-type="pmid">31400347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2019.08.002</pub-id><pub-id pub-id-type="pmcid">PMC6941226</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="cbf70031-cit-0062"><string-name name-style="western"><given-names>N. C.</given-names><surname>Dalvie</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Brady</surname></string-name>, <string-name name-style="western"><given-names>L. E.</given-names><surname>Crowell</surname></string-name>, et al., &#8220;<article-title>Molecular Engineering Improves Antigen Quality and Enables Integrated Manufacturing of a Trivalent Subunit Vaccine Candidate for Rotavirus</article-title>,&#8221; <source>Microbial Cell Factories</source><volume>20</volume> (<year>2021</year>): <fpage>94</fpage>.<pub-id pub-id-type="pmid">33933073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12934-021-01583-6</pub-id><pub-id pub-id-type="pmcid">PMC8088319</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="cbf70031-cit-0063"><string-name name-style="western"><given-names>M. S.</given-names><surname>Hong</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kaur</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Sawant</surname></string-name>, <string-name name-style="western"><given-names>S. B.</given-names><surname>Joshi</surname></string-name>, <string-name name-style="western"><given-names>D. B.</given-names><surname>Volkin</surname></string-name>, and <string-name name-style="western"><given-names>R. D.</given-names><surname>Braatz</surname></string-name>, &#8220;<article-title>Crystallization of a Nonreplicating Rotavirus Vaccine Candidate</article-title>,&#8221; <source>Biotechnology and Bioengineering</source><volume>118</volume> (<year>2021</year>): <fpage>1750</fpage>&#8211;<lpage>1756</lpage>.<pub-id pub-id-type="pmid">33527346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bit.27699</pub-id><pub-id pub-id-type="pmcid">PMC8248096</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="cbf70031-cit-0064"><string-name name-style="western"><given-names>N.</given-names><surname>Sawant</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kaur</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Holland</surname></string-name>, et al., &#8220;<article-title>Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low&#8208;Cost, Multi&#8208;Dose Vaccine Candidates: Case&#8208;Study With Non&#8208;Replicating Rotavirus (NRRV) Vaccine Antigens</article-title>,&#8221; <source>Journal of Pharmaceutical Sciences</source><volume>110</volume> (<year>2021</year>): <fpage>1042</fpage>&#8211;<lpage>1053</lpage>.<pub-id pub-id-type="pmid">33285182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2020.11.039</pub-id><pub-id pub-id-type="pmcid">PMC7884052</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="cbf70031-cit-0065"><string-name name-style="western"><given-names>W. J.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>Y. K.</given-names><surname>Yoon</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Park</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Pansuriya</surname></string-name>, <string-name name-style="western"><given-names>Y. J.</given-names><surname>Seok</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Ganapathy</surname></string-name>, &#8220;<article-title>Rotavirus Spike Protein &#916;VP8* as a Novel Carrier Protein for Conjugate Vaccine Platform With Demonstrated Antigenic Potential for Use as Bivalent Vaccine</article-title>,&#8221; <source>Scientific Reports</source><volume>11</volume> (<year>2021</year>): <elocation-id>22037</elocation-id>, <pub-id pub-id-type="doi">10.1038/s41598-021-01549-z</pub-id>.<pub-id pub-id-type="pmid">34764353</pub-id><pub-id pub-id-type="pmcid">PMC8586335</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="cbf70031-cit-0066"><string-name name-style="western"><given-names>N.</given-names><surname>Kurokawa</surname></string-name>, <string-name name-style="western"><given-names>P. O.</given-names><surname>Lavoie</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>D'aoust</surname></string-name>, et al., &#8220;<article-title>Development and Characterization of a Plant&#8208;Derived Rotavirus&#8208;Like Particle Vaccine</article-title>,&#8221; <source>Vaccine</source><volume>39</volume> (<year>2021</year>): <fpage>4979</fpage>&#8211;<lpage>4987</lpage>.<pub-id pub-id-type="pmid">34325930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.07.039</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="cbf70031-cit-0067"><string-name name-style="western"><given-names>S.</given-names><surname>Cherepushkin</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Tsibezov</surname></string-name>, <string-name name-style="western"><given-names>A. G.</given-names><surname>Yuzhakov</surname></string-name>, et al., &#8220;<article-title>Synthesis and Characterization of Human Rotavirus A (Reoviridae: Sedoreovirinae: Rotavirus: Rotavirus A) Virus&#8208;Like Particles</article-title>,&#8221; <source>Voprosyvirusologii</source><volume>66</volume> (<year>2021</year>): <fpage>155</fpage>&#8211;<lpage>164</lpage>, <pub-id pub-id-type="doi">10.36233/0507-4088-27</pub-id>.<pub-id pub-id-type="pmid">33683066</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="cbf70031-cit-0068"><string-name name-style="western"><given-names>H.</given-names><surname>Changotra</surname></string-name> and <string-name name-style="western"><given-names>A.</given-names><surname>Vij</surname></string-name>, &#8220;<article-title>Rotavirus Virus&#8208;Like Particles (RV&#8208;VLPs) Vaccines: An Update</article-title>,&#8221; <source>Reviews in Medical Virology</source><volume>27</volume> (<year>2017</year>): <elocation-id>e1954</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rmv.1954</pub-id><pub-id pub-id-type="pmid">29048711</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="cbf70031-cit-0069"><string-name name-style="western"><given-names>N.</given-names><surname>Kurokawa</surname></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Robinson</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Bernard</surname></string-name>, et al., &#8220;<article-title>Safety and Immunogenicity of a Plant&#8208;Derived Rotavirus&#8208;Like Particle Vaccine in Adults, Toddlers, and Infants</article-title>,&#8221; <source>Vaccine</source><volume>39</volume> (<year>2021</year>): <fpage>5513</fpage>&#8211;<lpage>5523</lpage>.<pub-id pub-id-type="pmid">34454786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.08.052</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="cbf70031-cit-0070"><string-name name-style="western"><given-names>M.</given-names><surname>Tan</surname></string-name> and <string-name name-style="western"><given-names>X.</given-names><surname>Jiang</surname></string-name>, &#8220;<article-title>Histo&#8208;Blood Group Antigens: A Common Niche for Norovirus and Rotavirus</article-title>,&#8221; <source>Expert Reviews in Molecular Medicine</source><volume>16</volume> (<year>2014</year>): <elocation-id>e5</elocation-id>, <pub-id pub-id-type="doi">10.1017/erm.2014.2</pub-id>.<pub-id pub-id-type="pmid">24606759</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0071"><label>71</label><mixed-citation publication-type="miscellaneous" id="cbf70031-cit-0071"><string-name name-style="western"><given-names>A. K.</given-names><surname>Ramesh</surname></string-name>, &#8220;Study of Enteric Virus Infection and Parenteral Vaccines in the Gnotobiotic Pig Model&#8221; (Doctoral diss., Virginia Tech, <year>2020</year>), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://hdl.handle.net/10919/104356" ext-link-type="uri">http://hdl.handle.net/10919/104356</ext-link>.</mixed-citation></ref><ref id="cbf70031-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="cbf70031-cit-0072"><string-name name-style="western"><given-names>M.</given-names><surname>Xia</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Huang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Jiang</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Tan</surname></string-name>, &#8220;<article-title>Immune Response and Protective Efficacy of the S Particle Presented Rotavirus VP8* Vaccine in Mice</article-title>,&#8221; <source>Vaccine</source><volume>37</volume> (<year>2019</year>): <fpage>4103</fpage>&#8211;<lpage>4110</lpage>.<pub-id pub-id-type="pmid">31201052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.05.075</pub-id><pub-id pub-id-type="pmcid">PMC6668625</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="cbf70031-cit-0073"><string-name name-style="western"><given-names>D.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Geng</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhang</surname></string-name>, et al., &#8220;<article-title>An Effective Platform for Exploring Rotavirus Receptors by Bacterial Surface Display System</article-title>,&#8221; <source>Virologica Sinica</source><volume>35</volume> (<year>2020</year>): <fpage>103</fpage>&#8211;<lpage>109</lpage>, <pub-id pub-id-type="doi">10.1007/s12250-019-00174-5</pub-id>.<pub-id pub-id-type="pmid">31777010</pub-id><pub-id pub-id-type="pmcid">PMC7035415</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="cbf70031-cit-0074"><string-name name-style="western"><given-names>J. E.</given-names><surname>Herrmann</surname></string-name>, <string-name name-style="western"><given-names>S. C.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>E. F.</given-names><surname>Fynan</surname></string-name>, et al., &#8220;<article-title>Protection Against Rotavirus Infections by DNA Vaccination</article-title>,&#8221; <source>Journal of Infectious Diseases</source><volume>174</volume> (<year>1996</year>): <fpage>S93</fpage>&#8211;<lpage>S97</lpage>, <pub-id pub-id-type="doi">10.1093/infdis/174.Supplement_1.S93</pub-id>.<pub-id pub-id-type="pmid">8752297</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="cbf70031-cit-0075"><string-name name-style="western"><given-names>S. C.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>D. H.</given-names><surname>Jones</surname></string-name>, <string-name name-style="western"><given-names>E. F.</given-names><surname>Fynan</surname></string-name>, et al., &#8220;<article-title>Protective Immunity Induced by Oral Immunization With a Rotavirus DNA Vaccine Encapsulated in Microparticles</article-title>,&#8221; <source>Journal of Virology</source><volume>72</volume> (<year>1998</year>): <fpage>5757</fpage>&#8211;<lpage>5761</lpage>, <pub-id pub-id-type="doi">10.1128/JVI.72.7.5757-5761.1998</pub-id>.<pub-id pub-id-type="pmid">9621034</pub-id><pub-id pub-id-type="pmcid">PMC110376</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="cbf70031-cit-0076"><string-name name-style="western"><given-names>A.</given-names><surname>Garc&#237;a&#8208;D&#237;az</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>L&#243;pez&#8208;And&#250;jar</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>D&#237;az</surname></string-name>, et al., &#8220;<article-title>Nasal Immunization of Mice With a Rotavirus DNA Vaccine That Induces Protective Intestinal IgA Antibodies</article-title>,&#8221; <source>Vaccine</source><volume>23</volume> (<year>2004</year>): <fpage>489</fpage>&#8211;<lpage>498</lpage>, <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.06.018</pub-id>.<pub-id pub-id-type="pmid">15530697</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="cbf70031-cit-0077"><string-name name-style="western"><given-names>S.</given-names><surname>Roier</surname></string-name>, <string-name name-style="western"><given-names>V. M.</given-names><surname>Prasad</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>McNeal</surname></string-name>, et al., &#8220;<article-title>Novel mRNA&#8208;Based VP8* Vaccines Against Rotavirus Are Highly Immunogenic in Rodents</article-title>,&#8221; <source>bioRxiv</source> (<year>2023</year>), <pub-id pub-id-type="doi">10.1101/2023.03.29.534747</pub-id>.<pub-id pub-id-type="pmcid">PMC10739717</pub-id><pub-id pub-id-type="pmid">38129390</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="cbf70031-cit-0078"><string-name name-style="western"><given-names>P. R.</given-names><surname>Kuri</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Goswami</surname></string-name>, &#8220;<article-title>Current Update on Rotavirus <italic toggle="yes">In&#8208;Silico</italic> Multiepitope Vaccine Design</article-title>,&#8221; <source>ACS Omega</source><volume>8</volume> (<year>2023</year>): <fpage>190</fpage>&#8211;<lpage>207</lpage>, <pub-id pub-id-type="doi">10.1021/acsomega.2c07213</pub-id>.<pub-id pub-id-type="pmid">36643547</pub-id><pub-id pub-id-type="pmcid">PMC9835168</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="cbf70031-cit-0079"><string-name name-style="western"><given-names>M.</given-names><surname>Usman</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ayub</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Habib</surname></string-name>, et al., &#8220;<article-title>Vaccinomics Approach for Multi&#8208;Epitope Vaccine Design Against Group A Rotavirus Using VP4 and VP7 Proteins</article-title>,&#8221; <source>Vaccines</source><volume>11</volume> (<year>2023</year>): <elocation-id>726</elocation-id>, <pub-id pub-id-type="doi">10.3390/vaccines11040726</pub-id>.<pub-id pub-id-type="pmid">37112638</pub-id><pub-id pub-id-type="pmcid">PMC10144065</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="cbf70031-cit-0080"><string-name name-style="western"><given-names>A. D.</given-names><surname>Sharma</surname></string-name>, <string-name name-style="western"><given-names>R. K.</given-names><surname>Grewal</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Gorle</surname></string-name>, et al., &#8220;<article-title>T Cell Epitope&#8208;Based Vaccine Design While Targeting Outer Capsid Proteins of Rotavirus Strains Infecting Neonates: An Immunoinformatics Approach</article-title>,&#8221; <source>Journal of Biomolecular Structure and Dynamics</source><volume>42</volume>, no. <issue>10</issue> (<year>2024</year>): <fpage>4937</fpage>&#8211;<lpage>4955</lpage>, <pub-id pub-id-type="doi">10.1080/07391102.2023.2226721</pub-id>.<pub-id pub-id-type="pmid">37382214</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="cbf70031-cit-0081"><string-name name-style="western"><given-names>Y. D.</given-names><surname>Devi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Devi</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Gogoi</surname></string-name>, et al., &#8220;<article-title>Exploring Rotavirus Proteome to Identify Potential B&#8208; and T&#8208;Cell Epitope Using Computational Immunoinformatics</article-title>,&#8221; <source>Heliyon</source><volume>6</volume>, no. <issue>12</issue> (<year>2020</year>): <elocation-id>e05760</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.heliyon.2020.e05760</pub-id>.<pub-id pub-id-type="pmid">33426322</pub-id><pub-id pub-id-type="pmcid">PMC7779714</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="cbf70031-cit-0082"><string-name name-style="western"><given-names>Q.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Kim</surname></string-name>, et al., &#8220;<article-title>Immune Epitope Database Analysis Resource (IEDB&#8208;AR)</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>36</volume> (<year>2008</year>): <fpage>W513</fpage>&#8211;<lpage>W518</lpage>.<pub-id pub-id-type="pmid">18515843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkn254</pub-id><pub-id pub-id-type="pmcid">PMC2447801</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="cbf70031-cit-0083"><string-name name-style="western"><given-names>M.</given-names><surname>Nielsen</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Lundegaard</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Blicher</surname></string-name>, et al., &#8220;<article-title>NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA&#8208;A and &#8208;B Locus Protein of Known Sequence</article-title>,&#8221; <source>PLoS One</source><volume>2</volume> (<year>2007</year>): <elocation-id>e796</elocation-id>.<pub-id pub-id-type="pmid">17726526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0000796</pub-id><pub-id pub-id-type="pmcid">PMC1949492</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="cbf70031-cit-0084"><string-name name-style="western"><given-names>M. A.</given-names><surname>McCrae</surname></string-name> and <string-name name-style="western"><given-names>J. G.</given-names><surname>McCorquodale</surname></string-name>, &#8220;<article-title>Expression of a Major Bovine Rotavirus Neutralisation Antigen (VP7c) in <italic toggle="yes">Escherichia coli</italic>
</article-title>,&#8221; <source>Gene</source><volume>55</volume> (<year>1987</year>): <fpage>9</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">3040532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0378-1119(87)90243-5</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="cbf70031-cit-0085"><string-name name-style="western"><given-names>C. D.</given-names><surname>Rao</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Das</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Ilango</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Lalwani</surname></string-name>, <string-name name-style="western"><given-names>B. S.</given-names><surname>Rao</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Gowda</surname></string-name>, &#8220;<article-title>Comparative Nucleotide and Amino Acid Sequence Analysis of the Sequence&#8208;Specific RNA&#8208;Binding Rotavirus Non&#8208;Structural Protein NSP3</article-title>,&#8221; <source>Virology</source><volume>207</volume> (<year>1995</year>): <fpage>327</fpage>&#8211;<lpage>333</lpage>.<pub-id pub-id-type="pmid">7871749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/viro.1995.1087</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="cbf70031-cit-0086"><string-name name-style="western"><given-names>V.</given-names><surname>Enouf</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Langella</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Commissaire</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cohen</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Corthier</surname></string-name>, &#8220;<article-title>Bovine Rotavirus Nonstructural Protein 4 Produced by <italic toggle="yes">Lactococcus lactis</italic> Is Antigenic and Immunogenic</article-title>,&#8221; <source>Applied and Environmental Microbiology</source><volume>67</volume> (<year>2001</year>): <fpage>1423</fpage>&#8211;<lpage>1428</lpage>, <pub-id pub-id-type="doi">10.1128/AEM.67.4.1423-1428.2001</pub-id>.<pub-id pub-id-type="pmid">11282586</pub-id><pub-id pub-id-type="pmcid">PMC92750</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="cbf70031-cit-0087"><string-name name-style="western"><given-names>L. E.</given-names><surname>Esteban</surname></string-name>, <string-name name-style="western"><given-names>C. F.</given-names><surname>Temprana</surname></string-name>, <string-name name-style="western"><given-names>M. H.</given-names><surname>Arg&#252;elles</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Glikmann</surname></string-name>, and <string-name name-style="western"><given-names>A. A.</given-names><surname>Castello</surname></string-name>, &#8220;<article-title>Antigenicity and Immunogenicity of Rotavirus VP6 Protein Expressed on the Surface of <italic toggle="yes">Lactococcus lactis</italic>
</article-title>,&#8221; <source>BioMed Research International</source><volume>2013</volume> (<year>2013</year>): <fpage>1</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/298598</pub-id><pub-id pub-id-type="pmcid">PMC3741945</pub-id><pub-id pub-id-type="pmid">23984337</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="cbf70031-cit-0088"><string-name name-style="western"><given-names>P. H.</given-names><surname>Pouwels</surname></string-name>, <string-name name-style="western"><given-names>R. J.</given-names><surname>Leer</surname></string-name>, and <string-name name-style="western"><given-names>W. J. A.</given-names><surname>Boersma</surname></string-name>, &#8220;<article-title>The Potential of <italic toggle="yes">Lactobacillus</italic> as a Carrier for Oral Immunization: Development and Preliminary Characterization of Vector Systems for Targeted Delivery of Antigens</article-title>,&#8221; <source>Journal of Biotechnology</source><volume>44</volume> (<year>1996</year>): <fpage>183</fpage>&#8211;<lpage>192</lpage>.<pub-id pub-id-type="pmid">8717402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0168-1656(95)00140-9</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="cbf70031-cit-0089"><string-name name-style="western"><given-names>C. F.</given-names><surname>Temprana</surname></string-name>, <string-name name-style="western"><given-names>M. H.</given-names><surname>Arg&#252;elles</surname></string-name>, <string-name name-style="western"><given-names>N. M.</given-names><surname>Gutierrez</surname></string-name>, et al., &#8220;<article-title>Rotavirus VP6 Protein Mucosally Delivered by Cell Wall&#8208;Derived Particles From <italic toggle="yes">Lactococcus lactis</italic> Induces Protection Against Infection in a Murine Model</article-title>,&#8221; <source>PLoS One</source><volume>13</volume> (<year>2018</year>): <elocation-id>e0203700</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0203700</pub-id>.<pub-id pub-id-type="pmid">30192869</pub-id><pub-id pub-id-type="pmcid">PMC6128627</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="cbf70031-cit-0090"><string-name name-style="western"><given-names>H.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Xiao</surname></string-name>, et al., &#8220;<article-title>Site&#8208;Specific Integration of Rotavirus VP6 Gene in Rabbit &#946;&#8208;Casein Locus by CRISPR/Cas9 System</article-title>,&#8221; <source>In Vitro Cellular &amp; Developmental Biology &#8211; Animal</source><volume>55</volume> (<year>2019</year>): <fpage>586</fpage>&#8211;<lpage>597</lpage>.<pub-id pub-id-type="pmid">31367859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11626-019-00382-z</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="cbf70031-cit-0091"><string-name name-style="western"><given-names>W. A.</given-names><surname>Rodr&#237;guez&#8208;Limas</surname></string-name>, <string-name name-style="western"><given-names>K. E.</given-names><surname>Tyo</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Nielsen</surname></string-name>, <string-name name-style="western"><given-names>O. T.</given-names><surname>Ram&#237;rez</surname></string-name>, and <string-name name-style="western"><given-names>L. A.</given-names><surname>Palomares</surname></string-name>, &#8220;<article-title>Molecular and Process Design for Rotavirus&#8208;Like Particle Production in <italic toggle="yes">Saccharomyces cerevisiae</italic>
</article-title>,&#8221; <source>Microbial Cell Factories</source><volume>10</volume> (<year>2011</year>): <fpage>33</fpage>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.microbialcellfactories.com/content/10/1/33" ext-link-type="uri">http://www.microbialcellfactories.com/content/10/1/33</ext-link>.<pub-id pub-id-type="pmid">21569612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2859-10-33</pub-id><pub-id pub-id-type="pmcid">PMC3118324</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="cbf70031-cit-0092"><string-name name-style="western"><given-names>W. A.</given-names><surname>Rodr&#237;guez&#8208;Limas</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Pastor</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Esquivel&#8208;Soto</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Esquivel&#8208;Guadarrama</surname></string-name>, <string-name name-style="western"><given-names>O. T.</given-names><surname>Ram&#237;rez</surname></string-name>, and <string-name name-style="western"><given-names>L. A.</given-names><surname>Palomares</surname></string-name>, &#8220;<article-title>Immunogenicity and Protective Efficacy of Yeast Extracts Containing Rotavirus&#8208;Like Particles: a Potential Veterinary Vaccine</article-title>,&#8221; <source>Vaccine</source><volume>32</volume>, no. <issue>24</issue> (<year>2014</year>): <fpage>2794</fpage>&#8211;<lpage>2798</lpage>, <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.037</pub-id>.<pub-id pub-id-type="pmid">24593996</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="cbf70031-cit-0093"><string-name name-style="western"><given-names>R.</given-names><surname>Kumar</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Kumar</surname></string-name>, &#8220;<article-title>Yeast&#8208;Based Vaccines: New Perspective in Vaccine Development and Application</article-title>,&#8221; <source>FEMS Yeast Research</source><volume>19</volume> (<year>2019</year>): <elocation-id>foz007</elocation-id>, <pub-id pub-id-type="doi">10.1093/femsyr/foz007</pub-id>.<pub-id pub-id-type="pmid">30668686</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="cbf70031-cit-0094"><string-name name-style="western"><given-names>H.</given-names><surname>Bredell</surname></string-name>, <string-name name-style="western"><given-names>J. J.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>W. A.</given-names><surname>Prins</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>G&#246;rgens</surname></string-name>, and <string-name name-style="western"><given-names>W. H.</given-names><surname>van Zyl</surname></string-name>, &#8220;<article-title>Expression of Rotavirus VP6 Protein: A Comparison Amongst <italic toggle="yes">Escherichia coli, Pichia pastoris</italic> and <italic toggle="yes">Hansenula polymorpha</italic>
</article-title>,&#8221; <source>FEMS Yeast Research</source><volume>16</volume> (<year>2016</year>): <elocation-id>fow001</elocation-id>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dog.org/10.1093/femsyr/fow001" ext-link-type="uri">http://dog.org/10.1093/femsyr/fow001</ext-link>.<pub-id pub-id-type="pmid">26772798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femsyr/fow001</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="cbf70031-cit-0095"><string-name name-style="western"><given-names>T. P.</given-names><surname>McGonigal</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Turon</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Komar&#8208;Hartnett</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Kister</surname></string-name>, and <string-name name-style="western"><given-names>R. E.</given-names><surname>Smith</surname></string-name>, &#8220;<article-title>Expression of the Gene Coding for the Major Outer Capsid Protein of SA&#8208;11 Rotavirus in a Baculovirus System</article-title>,&#8221; <source>Virus Research</source><volume>23</volume> (<year>1992</year>): <fpage>135</fpage>&#8211;<lpage>150</lpage>.<pub-id pub-id-type="pmid">1318623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0168-1702(92)90073-i</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="cbf70031-cit-0096"><string-name name-style="western"><given-names>T.</given-names><surname>Dharakul</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Labbe</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Cohen</surname></string-name>, et al., &#8220;<article-title>Immunization With Baculovirus&#8208;Expressed Recombinant Rotavirus Proteins VP1, VP4, VP6, and VP7 Induces CD8+ T Lymphocytes That Mediate Clearance of Chronic Rotavirus Infection in SCID Mice</article-title>,&#8221; <source>Journal of Virology</source><volume>65</volume> (<year>1991</year>): <fpage>5928</fpage>&#8211;<lpage>5932</lpage>.<pub-id pub-id-type="pmid">1656079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.65.11.5928-5932.1991</pub-id><pub-id pub-id-type="pmcid">PMC250256</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="cbf70031-cit-0097"><string-name name-style="western"><given-names>P.</given-names><surname>Molinari</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Peralta</surname></string-name>, and <string-name name-style="western"><given-names>O.</given-names><surname>Taboga</surname></string-name>, &#8220;<article-title>Production of Rotavirus&#8208;Like Particles in <italic toggle="yes">Spodoptera frugiperda</italic> Larvae</article-title>,&#8221; <source>Journal of Virological Methods</source><volume>147</volume> (<year>2008</year>): <fpage>364</fpage>&#8211;<lpage>367</lpage>, <pub-id pub-id-type="doi">10.1016/j.jviromet.2007.09.002</pub-id>.<pub-id pub-id-type="pmid">17945356</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="cbf70031-cit-0098"><string-name name-style="western"><given-names>H. L. A.</given-names><surname>Vieira</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Est&#234;v&#227;o</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Rold&#227;o</surname></string-name>, et al., &#8220;<article-title>Triple&#8208;Layered Rotavirus VLP Production: Kinetics of Vector Replication, mRNA Stability, and Recombinant Protein Production</article-title>,&#8221; <source>Journal of Biotechnology</source><volume>120</volume> (<year>2005</year>): <fpage>72</fpage>&#8211;<lpage>82</lpage>, <pub-id pub-id-type="doi">10.1016/j.jbiotec.2005.03.026</pub-id>.<pub-id pub-id-type="pmid">16023241</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="cbf70031-cit-0099"><string-name name-style="western"><given-names>A.</given-names><surname>Rold&#227;o</surname></string-name>, <string-name name-style="western"><given-names>H. L. A.</given-names><surname>Vieira</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Charpilienne</surname></string-name>, et al., &#8220;<article-title>Modeling Rotavirus&#8208;Like Particles Production in a Baculovirus Expression Vector System: Infection Kinetics, Baculovirus DNA Replication, mRNA Synthesis and Protein Production</article-title>,&#8221; <source>Journal of Biotechnology</source><volume>128</volume> (<year>2007</year>): <fpage>875</fpage>&#8211;<lpage>894</lpage>, <pub-id pub-id-type="doi">10.1016/j.jbiotec.2007.01.003</pub-id>.<pub-id pub-id-type="pmid">17289202</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="cbf70031-cit-0100"><string-name name-style="western"><given-names>L.</given-names><surname>Yao</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Su</surname></string-name>, et al., &#8220;<article-title>Construction of a Baculovirus&#8208;Silkworm Multigene Expression System and Its Application on Producing Virus&#8208;Like Particles</article-title>,&#8221; <source>PLoS One</source><volume>7</volume> (<year>2012</year>): <elocation-id>e32510</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0032510</pub-id>.<pub-id pub-id-type="pmid">22403668</pub-id><pub-id pub-id-type="pmcid">PMC3293821</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="cbf70031-cit-0101"><string-name name-style="western"><given-names>S. A.</given-names><surname>Gonzalez</surname></string-name> and <string-name name-style="western"><given-names>J. L.</given-names><surname>Affranchino</surname></string-name>, &#8220;<article-title>Assembly of Double&#8208;Layered Virus&#8208;Like Particles in Mammalian Cells by Coexpression of Human Rotavirus VP2 and VP6</article-title>,&#8221; <source>Journal of General Virology</source><volume>76</volume> (<year>1995</year>): <fpage>2357</fpage>&#8211;<lpage>2360</lpage>.<pub-id pub-id-type="pmid">7561777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/0022-1317-76-9-2357</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="cbf70031-cit-0102"><string-name name-style="western"><given-names>E.</given-names><surname>Soler</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Parez</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Passet</surname></string-name>, et al., &#8220;<article-title>Recombinant Rotavirus Inner Core Proteins Produced in the Milk of Transgenic Rabbits Confer a High Level of Protection After Intrarectal Delivery</article-title>,&#8221; <source>Vaccine</source><volume>25</volume> (<year>2007</year>): <fpage>6373</fpage>&#8211;<lpage>6380</lpage>.<pub-id pub-id-type="pmid">17629366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.06.011</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="cbf70031-cit-0103"><string-name name-style="western"><given-names>Z.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Cui</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, et al., &#8220;<article-title>A Milk&#8208;Based Self&#8208;Assemble Rotavirus VP6&#8211;Ferritin Nanoparticle Vaccine Elicited Protection Against the Viral Infection</article-title>,&#8221; <source>Journal of Nanobiotechnology</source><volume>17</volume> (<year>2019</year>): <fpage>13</fpage>.<pub-id pub-id-type="pmid">30670042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-019-0446-6</pub-id><pub-id pub-id-type="pmcid">PMC6341625</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="cbf70031-cit-0104"><string-name name-style="western"><given-names>M.</given-names><surname>Sainger</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Jaiwal</surname></string-name>, <string-name name-style="western"><given-names>P. A.</given-names><surname>Sainger</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chaudhary</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jaiwal</surname></string-name>, and <string-name name-style="western"><given-names>P. K.</given-names><surname>Jaiwal</surname></string-name>, &#8220;<article-title>Advances in Genetic Improvement of <italic toggle="yes">Camelina sativa</italic> for Biofuel and Industrial Bioproducts</article-title>,&#8221; <source>Renewable and Sustainable Energy Reviews</source><volume>68</volume> (<year>2017</year>): <fpage>623</fpage>&#8211;<lpage>637</lpage>.</mixed-citation></ref><ref id="cbf70031-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="cbf70031-cit-0105"><string-name name-style="western"><given-names>D. S.</given-names><surname>Birla</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Malik</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Sainger</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chaudhary</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jaiwal</surname></string-name>, and <string-name name-style="western"><given-names>P. K.</given-names><surname>Jaiwal</surname></string-name>, &#8220;<article-title>Progress and Challenges in Improving the Nutritional Quality of Rice (<italic toggle="yes">Oryza sativa</italic> L.)</article-title>,&#8221; <source>Critical Reviews in Food Science and Nutrition</source><volume>57</volume> (<year>2017</year>): <fpage>2455</fpage>&#8211;<lpage>2481</lpage>.<pub-id pub-id-type="pmid">26513164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2015.1084992</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="cbf70031-cit-0106"><string-name name-style="western"><given-names>R.</given-names><surname>Fischer</surname></string-name> and <string-name name-style="western"><given-names>J. F.</given-names><surname>Buyel</surname></string-name>, &#8220;<article-title>Molecular Farming&#8212;The Slope of Enlightenment</article-title>,&#8221; <source>Biotechnology Advances</source><volume>40</volume> (<year>2020</year>): <elocation-id>107519</elocation-id>.<pub-id pub-id-type="pmid">31954848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biotechadv.2020.107519</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="cbf70031-cit-0107"><string-name name-style="western"><given-names>S.</given-names><surname>Schillberg</surname></string-name> and <string-name name-style="western"><given-names>R.</given-names><surname>Finnern</surname></string-name>, &#8220;<article-title>Plant Molecular Farming for the Production of Valuable Proteins&#8212;Critical Evaluation of Achievements and Future Challenges</article-title>,&#8221; <source>Journal of Plant Physiology</source><volume>258&#8211;259</volume> (<year>2021</year>): <elocation-id>153359</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jplph.2020.153359</pub-id><pub-id pub-id-type="pmid">33460995</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="cbf70031-cit-0108"><string-name name-style="western"><given-names>S.</given-names><surname>Schillberg</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Raven</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Fischer</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Twyman</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Schiermeyer</surname></string-name>, &#8220;<article-title>Molecular Farming of Pharmaceutical Proteins Using Plant Suspension Cell and Tissue Cultures</article-title>,&#8221; <source>Current Pharmaceutical Design</source><volume>19</volume> (<year>2013</year>): <fpage>5531</fpage>&#8211;<lpage>5542</lpage>.<pub-id pub-id-type="pmid">23394569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612811319310008</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="cbf70031-cit-0109"><string-name name-style="western"><given-names>G. J.</given-names><surname>O'Brien</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Bryant</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Voogd</surname></string-name>, <string-name name-style="western"><given-names>H. B.</given-names><surname>Greenberg</surname></string-name>, <string-name name-style="western"><given-names>R. C.</given-names><surname>Gardner</surname></string-name>, and <string-name name-style="western"><given-names>A. R.</given-names><surname>Bellamy</surname></string-name>, &#8220;<article-title>Rotavirus VP6 Expressed by PVX Vectors in <italic toggle="yes">Nicotiana benthamiana</italic> Coats PVX Rods and Also Assembles Into Viruslike Particles</article-title>,&#8221; <source>Virology</source><volume>270</volume> (<year>2000</year>): <fpage>444</fpage>&#8211;<lpage>453</lpage>, <pub-id pub-id-type="doi">10.1006/viro.2000.0314</pub-id>.<pub-id pub-id-type="pmid">10793003</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="cbf70031-cit-0110"><string-name name-style="western"><given-names>T.</given-names><surname>Matsumura</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Itchoda</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Tsunemitsu</surname></string-name>, &#8220;<article-title>Production of Immunogenic VP6 Protein of Bovine Group A Rotavirus in Transgenic Potato Plants</article-title>,&#8221; <source>Archives of Virology</source><volume>147</volume> (<year>2002</year>): <fpage>1263</fpage>&#8211;<lpage>1270</lpage>, <pub-id pub-id-type="doi">10.1007/s00705-002-0808-4</pub-id>.<pub-id pub-id-type="pmid">12111435</pub-id><pub-id pub-id-type="pmcid">PMC7086588</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="cbf70031-cit-0111"><string-name name-style="western"><given-names>J.</given-names><surname>Yu</surname></string-name> and <string-name name-style="western"><given-names>W. H. R.</given-names><surname>Langridge</surname></string-name>, &#8220;<article-title>A Plant&#8208;Based Multicomponent Vaccine Protects Mice From Enteric Diseases</article-title>,&#8221; <source>Nature Biotechnology</source><volume>19</volume> (<year>2001</year>): <fpage>548</fpage>&#8211;<lpage>552</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/89297</pub-id><pub-id pub-id-type="pmid">11385459</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="cbf70031-cit-0112"><string-name name-style="western"><given-names>Y.&#8208;Z.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>J.&#8208;T.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Z.&#8208;R.</given-names><surname>Mou</surname></string-name>, et al., &#8220;<article-title>Oral Immunization With Rotavirus VP7 Expressed in Transgenic Potatoes Induced High Titers of Mucosal Neutralizing IgA</article-title>,&#8221; <source>Virology</source><volume>313</volume> (<year>2003</year>): <fpage>337</fpage>&#8211;<lpage>342</lpage>, <pub-id pub-id-type="doi">10.1016/S0042-6822(03)00280-0</pub-id>.<pub-id pub-id-type="pmid">12954202</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="cbf70031-cit-0113"><string-name name-style="western"><given-names>A.</given-names><surname>Wigdorovitz</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mozgovoj</surname></string-name>, <string-name name-style="western"><given-names>M. J. D.</given-names><surname>Santos</surname></string-name>, et al., &#8220;<article-title>Protective Lactogenic Immunity Conferred by an Edible Peptide Vaccine to Bovine Rotavirus Produced in Transgenic Plants</article-title>,&#8221; <source>Journal of General Virology</source><volume>85</volume> (<year>2004</year>): <fpage>1825</fpage>&#8211;<lpage>1832</lpage>.<pub-id pub-id-type="pmid">15218166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/vir.0.19659-0</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="cbf70031-cit-0114"><string-name name-style="western"><given-names>D. M.</given-names><surname>P&#233;rez Filgueira</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mozgovoj</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Wigdorovitz</surname></string-name>, et al., &#8220;<article-title>Passive Protection to Bovine Rotavirus (BRV) Infection Induced by a BRV VP8* Produced in Plants Using a TMV&#8208;Based Vector</article-title>,&#8221; <source>Archives of Virology</source><volume>149</volume> (<year>2004</year>): <fpage>2337</fpage>&#8211;<lpage>2348</lpage>, <pub-id pub-id-type="doi">10.1007/s00705-004-0379-7</pub-id>.<pub-id pub-id-type="pmid">15338319</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="cbf70031-cit-0115"><string-name name-style="western"><given-names>J. L.</given-names><surname>Dong</surname></string-name>, <string-name name-style="western"><given-names>B. G.</given-names><surname>Liang</surname></string-name>, <string-name name-style="western"><given-names>Y. S.</given-names><surname>Jin</surname></string-name>, <string-name name-style="western"><given-names>W. J.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>Oral Immunization With pBsVP6&#8208;Transgenic Alfalfa Protects Mice Against Rotavirus Infection</article-title>,&#8221; <source>Virology</source><volume>339</volume> (<year>2005</year>): <fpage>153</fpage>&#8211;<lpage>163</lpage>, <pub-id pub-id-type="doi">10.1016/j.virol.2005.06.004</pub-id>.<pub-id pub-id-type="pmid">15992851</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="cbf70031-cit-0116"><string-name name-style="western"><given-names>N. W.</given-names><surname>Choi</surname></string-name>, <string-name name-style="western"><given-names>M. K.</given-names><surname>Estes</surname></string-name>, and <string-name name-style="western"><given-names>W. H. R.</given-names><surname>Langridge</surname></string-name>, &#8220;<article-title>Synthesis and Assembly of a Cholera Toxin B Subunit&#8208;Rotavirus VP7 Fusion Protein in Transgenic Potato</article-title>,&#8221; <source>Molecular Biotechnology</source><volume>31</volume> (<year>2005</year>): <fpage>193</fpage>&#8211;<lpage>202</lpage>.<pub-id pub-id-type="pmid">16230769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1385/MB:31:3:193</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="cbf70031-cit-0117"><string-name name-style="western"><given-names>S.</given-names><surname>Salda&#241;a</surname></string-name>, <string-name name-style="western"><given-names>F. E.</given-names><surname>Guadarrama</surname></string-name>, <string-name name-style="western"><given-names>T. D. J. O.</given-names><surname>Flores</surname></string-name>, et al., &#8220;<article-title>Production of Rotavirus&#8208;Like Particles in Tomato (<italic toggle="yes">Lycopersicon esculentum</italic> L.) Fruit by Expression of Capsid Proteins VP2 and VP6 and Immunological Studies</article-title>,&#8221; <source>Viral Immunology</source><volume>19</volume> (<year>2006</year>): <fpage>42</fpage>&#8211;<lpage>53</lpage>, <pub-id pub-id-type="doi">10.1089/vim.2006.19.42</pub-id>.<pub-id pub-id-type="pmid">16553549</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="cbf70031-cit-0118"><string-name name-style="western"><given-names>J.&#8208;T.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Fei</surname></string-name>, <string-name name-style="western"><given-names>Z.&#8208;R.</given-names><surname>Mou</surname></string-name>, et al., &#8220;<article-title>Immunogenicity of a Plant&#8208;Derived Edible Rotavirus Subunit Vaccine Transformed Over Fifty Generations</article-title>,&#8221; <source>Virology</source><volume>356</volume> (<year>2006</year>): <fpage>171</fpage>&#8211;<lpage>178</lpage>, <pub-id pub-id-type="doi">10.1016/j.virol.2006.07.045</pub-id>.<pub-id pub-id-type="pmid">16956640</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="cbf70031-cit-0119"><string-name name-style="western"><given-names>B.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Wang</surname></string-name>, et al., &#8220;<article-title>Oral Administration of Plant&#8208;Based Rotavirus VP6 Induces Antigen&#8208;Specific IgAs, IgGs, and Passive Protection in Mice</article-title>,&#8221; <source>Vaccine</source><volume>28</volume> (<year>2010</year>): <fpage>6021</fpage>&#8211;<lpage>6027</lpage>.<pub-id pub-id-type="pmid">20637305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.06.094</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="cbf70031-cit-0120"><string-name name-style="western"><given-names>Y.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yang</surname></string-name>, et al., &#8220;<article-title>Immunogenicity and Virus&#8208;Like Particle Formation of Rotavirus Capsid Proteins Produced in Transgenic Plants</article-title>,&#8221; <source>Science China Life Sciences</source><volume>54</volume> (<year>2011</year>): <fpage>82</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">21104033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11427-010-4104-3</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="cbf70031-cit-0121"><string-name name-style="western"><given-names>L. P.</given-names><surname>Bergeron&#8208;Sandoval</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Girard</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Ouellet</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Archambault</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Sarhan</surname></string-name>, &#8220;<article-title>Production of Human Rotavirus and <italic toggle="yes">Salmonella</italic> Antigens in Plants and Elicitation of fljB&#8208;Specific Humoral Responses in Mice</article-title>,&#8221; <source>Molecular Biotechnology</source><volume>47</volume> (<year>2011</year>): <fpage>157</fpage>&#8211;<lpage>168</lpage>.<pub-id pub-id-type="pmid">20725806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12033-010-9324-z</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0122"><label>122</label><mixed-citation publication-type="journal" id="cbf70031-cit-0122"><string-name name-style="western"><given-names>E. M.</given-names><surname>Lentz</surname></string-name>, <string-name name-style="western"><given-names>M. V.</given-names><surname>Mozgovoj</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bellido</surname></string-name>, <string-name name-style="western"><given-names>M. J. D.</given-names><surname>Santos</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Wigdorovitz</surname></string-name>, and <string-name name-style="western"><given-names>F. F.</given-names><surname>Bravo&#8208;Almonacid</surname></string-name>, &#8220;<article-title>VP8* Antigen Produced in Tobacco Transplastomic Plants Confers Protection Against Bovine Rotavirus Infection in a Suckling Mouse Model</article-title>,&#8221; <source>Journal of Biotechnology</source><volume>156</volume> (<year>2011</year>): <fpage>100</fpage>&#8211;<lpage>107</lpage>.<pub-id pub-id-type="pmid">21893114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbiotec.2011.08.023</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="cbf70031-cit-0123"><string-name name-style="western"><given-names>E. F.</given-names><surname>Alfano</surname></string-name>, <string-name name-style="western"><given-names>E. M.</given-names><surname>Lentz</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Bellido</surname></string-name>, et al., &#8220;<article-title>Expression of the Multimeric and Highly Immunogenic <italic toggle="yes">Brucella</italic> spp. Lumazine Synthase Fused to Bovine Rotavirus VP8d as a Scaffold for Antigen Production in Tobacco Chloroplasts</article-title>,&#8221; <source>Frontiers in Plant Science</source><volume>6</volume> (<year>2015</year>): <elocation-id>1170</elocation-id>, <pub-id pub-id-type="doi">10.3389/fpls.2015.01170</pub-id>.<pub-id pub-id-type="pmid">26779198</pub-id><pub-id pub-id-type="pmcid">PMC4688359</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="cbf70031-cit-0124"><string-name name-style="western"><given-names>F. F. P. G.</given-names><surname>P&#234;ra</surname></string-name>, <string-name name-style="western"><given-names>D. L. R.</given-names><surname>Mutepfa</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Khan</surname></string-name>, et al., &#8220;<article-title>Engineering and Expression of a Human Rotavirus Candidate Vaccine in <italic toggle="yes">Nicotiana benthamiana</italic>
</article-title>,&#8221; <source>Virology Journal</source><volume>12</volume> (<year>2015</year>): <fpage>205</fpage>.<pub-id pub-id-type="pmid">26626122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12985-015-0436-8</pub-id><pub-id pub-id-type="pmcid">PMC4667453</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="cbf70031-cit-0125"><string-name name-style="western"><given-names>H.</given-names><surname>Feng</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Song</surname></string-name>, et al., &#8220;<article-title>Oral Administration of a Seed&#8208;Based Bivalent Rotavirus Vaccine Containing VP6 and NSP4 Induces Specific Immune Responses in Mice</article-title>,&#8221; <source>Frontiers in Plant Science</source><volume>8</volume> (<year>2017</year>): <elocation-id>910</elocation-id>, <pub-id pub-id-type="doi">10.3389/fpls.2017.00910</pub-id>.<pub-id pub-id-type="pmid">28620404</pub-id><pub-id pub-id-type="pmcid">PMC5449476</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="cbf70031-cit-0126"><string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Guan</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Liu</surname></string-name>, et al., &#8220;<article-title>Oral Immunization With Rotavirus VP7&#8208;CTB Fusion Expressed in Transgenic <italic toggle="yes">Arabidopsis thaliana</italic> Induces Antigen&#8208;Specific IgA and IgG and Passive Protection in Mice</article-title>,&#8221; <source>Experimental and Therapeutic Medicine</source><volume>15</volume> (<year>2018</year>): <fpage>4866</fpage>&#8211;<lpage>4874</lpage>.<pub-id pub-id-type="pmid">29805507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2018.6003</pub-id><pub-id pub-id-type="pmcid">PMC5952079</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0127"><label>127</label><mixed-citation publication-type="journal" id="cbf70031-cit-0127"><string-name name-style="western"><given-names>J. F.</given-names><surname>Castillo&#8208;Esparza</surname></string-name> and <string-name name-style="western"><given-names>M. A.</given-names><surname>G&#243;mez&#8208;Lim</surname></string-name>, &#8220;<article-title>Transient Expression in Cytoplasm and Apoplast of Rotavirus VP6 Protein Fused to Anti&#8208;DEC205 Antibody in <italic toggle="yes">Nicotiana benthamiana</italic> and <italic toggle="yes">Nicotiana sylvestris</italic>
</article-title>,&#8221; <source>Molecular Biotechnology</source><volume>63</volume> (<year>2021</year>): <fpage>973</fpage>&#8211;<lpage>982</lpage>.<pub-id pub-id-type="pmid">34146324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12033-021-00359-y</pub-id><pub-id pub-id-type="pmcid">PMC8214057</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="cbf70031-cit-0128"><string-name name-style="western"><given-names>P.</given-names><surname>Malik</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Prajapati</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chaudhary</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Prasad</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jaiwal</surname></string-name>, and <string-name name-style="western"><given-names>P. K.</given-names><surname>Jaiwal</surname></string-name>, &#8220;<article-title>Production of Bovine Rotavirus VP6 Subunit Vaccine in a Transgenic Fodder Crop, Egyptian Clover (Berseem, <italic toggle="yes">Trifolium alexandrinum</italic>) That Elicits Immune Responses in Rabbit</article-title>,&#8221; <source>Molecular Biotechnology</source><volume>65</volume> (<year>2023</year>): <fpage>1432</fpage>&#8211;<lpage>1443</lpage>, <pub-id pub-id-type="doi">10.1007/s12033-022-00648-0</pub-id>.<pub-id pub-id-type="pmid">36637627</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="cbf70031-cit-0129"><string-name name-style="western"><given-names>S.</given-names><surname>Heinim&#228;ki</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Tamminen</surname></string-name>, <string-name name-style="western"><given-names>V. P.</given-names><surname>Hyt&#246;nen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Malm</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Blazevic</surname></string-name>, &#8220;<article-title>Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations With Particulate Antigens Only</article-title>,&#8221; <source>Vaccines</source><volume>8</volume> (<year>2020</year>): <elocation-id>365</elocation-id>, <pub-id pub-id-type="doi">10.3390/vaccines8030365</pub-id>.<pub-id pub-id-type="pmid">32645976</pub-id><pub-id pub-id-type="pmcid">PMC7565724</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0130"><label>130</label><mixed-citation publication-type="journal" id="cbf70031-cit-0130"><string-name name-style="western"><given-names>I.</given-names><surname>Birch&#8208;Machin</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Newell</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Hibberd</surname></string-name>, and <string-name name-style="western"><given-names>J. C.</given-names><surname>Gray</surname></string-name>, &#8220;<article-title>Accumulation of Rotavirus VP6 Protein in Chloroplasts of Transplastomic Tobacco Is Limited by Protein Stability</article-title>,&#8221; <source>Plant Biotechnology Journal</source><volume>2</volume> (<year>2004</year>): <fpage>261</fpage>&#8211;<lpage>270</lpage>.<pub-id pub-id-type="pmid">17147617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1467-7652.2004.00072.x</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="cbf70031-cit-0131"><string-name name-style="western"><given-names>P. O.</given-names><surname>Craig</surname></string-name>, <string-name name-style="western"><given-names>P. M.</given-names><surname>Berguer</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Ainciart</surname></string-name>, et al., &#8220;<article-title>Multiple Display of a Protein Domain on a Bacterial Polymeric Scaffold</article-title>,&#8221; <source>Proteins: Structure, Function, and Bioinformatics</source><volume>61</volume> (<year>2005</year>): <fpage>1089</fpage>&#8211;<lpage>1100</lpage>, <pub-id pub-id-type="doi">10.1002/prot.20635</pub-id>.<pub-id pub-id-type="pmid">16193482</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="cbf70031-cit-0132"><string-name name-style="western"><given-names>E. A.</given-names><surname>Trifonova</surname></string-name>, <string-name name-style="western"><given-names>V. A.</given-names><surname>Zenin</surname></string-name>, <string-name name-style="western"><given-names>N. A.</given-names><surname>Nikitin</surname></string-name>, et al., &#8220;<article-title>Study of Rubella Candidate Vaccine Based on a Structurally Modified Plant Virus</article-title>,&#8221; <source>Antiviral Research</source><volume>144</volume> (<year>2017</year>): <fpage>27</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">28511994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2017.05.006</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="cbf70031-cit-0133"><string-name name-style="western"><given-names>E.</given-names><surname>Donchenko</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Trifonova</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Nikitin</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Atabekov</surname></string-name>, and <string-name name-style="western"><given-names>O.</given-names><surname>Karpova</surname></string-name>, &#8220;<article-title>Alternanthera Mosaic Potexvirus: Several Features, Properties, and Application</article-title>,&#8221; <source>Advances in Virology</source><volume>2018</volume> (<year>2018</year>): <elocation-id>1973705</elocation-id>, <pub-id pub-id-type="doi">10.1155/2018/1973705</pub-id>.<pub-id pub-id-type="pmid">30018641</pub-id><pub-id pub-id-type="pmcid">PMC6029478</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="cbf70031-cit-0134"><string-name name-style="western"><given-names>E. M.</given-names><surname>Ryabchevskaya</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Evtushenko</surname></string-name>, <string-name name-style="western"><given-names>M. V.</given-names><surname>Arkhipenko</surname></string-name>, et al., &#8220;<article-title>A Recombinant Rotavirus Antigen Based on the Coat Protein of Alternanthera Mosaic Virus</article-title>,&#8221; <source>Molecular Biology</source><volume>54</volume> (<year>2020</year>): <fpage>243</fpage>&#8211;<lpage>248</lpage>, <pub-id pub-id-type="doi">10.1134/S0026893320020132</pub-id>.<pub-id pub-id-type="pmid">32431461</pub-id><pub-id pub-id-type="pmcid">PMC7222081</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0135"><label>135</label><mixed-citation publication-type="journal" id="cbf70031-cit-0135"><string-name name-style="western"><given-names>Q.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Ma</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, &#8220;<article-title>Post&#8208;Translational Modifications in Mammalian Cell Systems and Their Impact on Vaccine Immunogenicity</article-title>,&#8221; <source>Biotechnology Advances</source><volume>36</volume> (<year>2018</year>): <fpage>1567</fpage>&#8211;<lpage>1578</lpage>.</mixed-citation></ref><ref id="cbf70031-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="cbf70031-cit-0136"><string-name name-style="western"><given-names>R.</given-names><surname>Strasser</surname></string-name>, &#8220;<article-title>Plant Glycoengineering and the Impact of N&#8208;Glycosylation on Vaccine Efficacy</article-title>,&#8221; <source>Frontiers of Plant Science</source><volume>7</volume> (<year>2016</year>): <fpage>647</fpage>.</mixed-citation></ref><ref id="cbf70031-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="cbf70031-cit-0137"><string-name name-style="western"><given-names>X.</given-names><surname>Shi</surname></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Jarvis</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Wagner</surname></string-name>, &#8220;<article-title>Glycosylation in Insect Cell&#8208;Based Expression Systems and Its Effects on Vaccine Antigens</article-title>,&#8221; <source>Vaccine</source><volume>37</volume> (<year>2019</year>): <fpage>6615</fpage>&#8211;<lpage>6623</lpage>.</mixed-citation></ref><ref id="cbf70031-bib-0138"><label>138</label><mixed-citation publication-type="journal" id="cbf70031-cit-0138"><string-name name-style="western"><given-names>F.</given-names><surname>Schwarz</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Aebi</surname></string-name>, and <string-name name-style="western"><given-names>E. G.</given-names><surname>Berger</surname></string-name>, &#8220;<article-title>Glycosylation and Its Impact on Vaccine Design and Manufacturing</article-title>,&#8221; <source>Trends in Biotechnology</source><volume>38</volume> (<year>2020</year>): <fpage>936</fpage>&#8211;<lpage>947</lpage>.</mixed-citation></ref><ref id="cbf70031-bib-0139"><label>139</label><mixed-citation publication-type="journal" id="cbf70031-cit-0139"><string-name name-style="western"><given-names>A.</given-names><surname>Bizzego</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Gabrieli</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Esposito</surname></string-name>, &#8220;<article-title>Deep Neural Networks and Transfer Learning on a Multivariate Physiological Signal Dataset</article-title>,&#8221; <source>Bioengineering</source><volume>8</volume> (<year>2021</year>): <fpage>35</fpage>.<pub-id pub-id-type="pmid">33800842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/bioengineering8030035</pub-id><pub-id pub-id-type="pmcid">PMC8058952</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0140"><label>140</label><mixed-citation publication-type="journal" id="cbf70031-cit-0140"><string-name name-style="western"><given-names>C.</given-names><surname>Escalona&#8208;Noguero</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>L&#243;pez&#8208;Valls</surname></string-name>, and <string-name name-style="western"><given-names>B.</given-names><surname>Sot</surname></string-name>, &#8220;<article-title>CRISPR/Cas Technology as a Promising Weapon to Combat Viral Infections</article-title>,&#8221; <source>BioEssays</source><volume>43</volume> (<year>2021</year>): <elocation-id>2000315</elocation-id>.<pub-id pub-id-type="pmid">33569817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bies.202000315</pub-id><pub-id pub-id-type="pmcid">PMC7995209</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0141"><label>141</label><mixed-citation publication-type="journal" id="cbf70031-cit-0141"><string-name name-style="western"><given-names>G.</given-names><surname>Papa</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Venditti</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Braga</surname></string-name>, et al., &#8220;<article-title>CRISPR&#8208;Csy4&#8208;Mediated Editing of Rotavirus Double&#8208;Stranded RNA Genome</article-title>,&#8221; <source>Cell Reports</source><volume>32</volume> (<year>2020</year>): <elocation-id>108205</elocation-id>.<pub-id pub-id-type="pmid">32997981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108205</pub-id><pub-id pub-id-type="pmcid">PMC7523552</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0142"><label>142</label><mixed-citation publication-type="journal" id="cbf70031-cit-0142"><string-name name-style="western"><given-names>H.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Xiao</surname></string-name>, et al., &#8220;<article-title>Site&#8208;Specific Integration of Rotavirus VP6 Gene in Rabbit &#946;&#8208;Casein Locus by CRISPR/Cas9 System</article-title>,&#8221; <source>In Vitro Cellular &amp; Developmental Biology &#8211; Animal</source><volume>55</volume> (<year>2019</year>): <fpage>586</fpage>&#8211;<lpage>597</lpage>.<pub-id pub-id-type="pmid">31367859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11626-019-00382-z</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0143"><label>143</label><mixed-citation publication-type="journal" id="cbf70031-cit-0143"><string-name name-style="western"><given-names>N.</given-names><surname>Orr&#8208;Burks</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Murray</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Wu</surname></string-name>, et al., &#8220;<article-title>Gene&#8208;Edited Vero Cells as Rotavirus Vaccine Substrates</article-title>,&#8221; <source>Vaccine: X</source><volume>3</volume> (<year>2019</year>): <elocation-id>100045</elocation-id>.<pub-id pub-id-type="pmid">31660537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvacx.2019.100045</pub-id><pub-id pub-id-type="pmcid">PMC6806661</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0144"><label>144</label><mixed-citation publication-type="journal" id="cbf70031-cit-0144"><string-name name-style="western"><given-names>U.</given-names><surname>Desselberger</surname></string-name>, &#8220;<article-title>Reverse Genetics of Rotavirus</article-title>,&#8221; <source>Proceedings of the National Academy of Sciences</source><volume>114</volume> (<year>2017</year>): <fpage>2106</fpage>&#8211;<lpage>2108</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1700738114</pub-id><pub-id pub-id-type="pmcid">PMC5338543</pub-id><pub-id pub-id-type="pmid">28183796</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0145"><label>145</label><mixed-citation publication-type="journal" id="cbf70031-cit-0145"><string-name name-style="western"><given-names>Y.</given-names><surname>Kanai</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Onishi</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kawagishi</surname></string-name>, et al., &#8220;<article-title>Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned From Clinical Isolates of Human Rotavirus</article-title>,&#8221; <source>Journal of Virology</source><volume>95</volume> (<year>2020</year>): <elocation-id>e01374&#8208;20</elocation-id>, <pub-id pub-id-type="doi">10.1128/JVI.01374-20</pub-id>.<pub-id pub-id-type="pmid">33087468</pub-id><pub-id pub-id-type="pmcid">PMC7944460</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0146"><label>146</label><mixed-citation publication-type="journal" id="cbf70031-cit-0146"><string-name name-style="western"><given-names>U.</given-names><surname>Desselberger</surname></string-name>, &#8220;<article-title>Potential of Plasmid Only Based on Reverse Genetics of Rotavirus for Developing Next&#8208;Generation Vaccines</article-title>,&#8221; <source>Current Opinion in Virology</source><volume>44</volume> (<year>2020</year>): <fpage>6</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coviro.2020.04.004</pub-id><pub-id pub-id-type="pmid">32526696</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0147"><label>147</label><mixed-citation publication-type="journal" id="cbf70031-cit-0147"><string-name name-style="western"><given-names>A. A.</given-names><surname>Philip</surname></string-name> and <string-name name-style="western"><given-names>J. T.</given-names><surname>Patton</surname></string-name>, &#8220;<article-title>Rotavirus as an Expression Platform of Domains of the SARS&#8208;CoV&#8208;2 Spike Protein</article-title>,&#8221; <source>Vaccines</source><volume>9</volume> (<year>2021</year>): <elocation-id>449</elocation-id>, <pub-id pub-id-type="doi">10.3390/vaccines9050449</pub-id>.<pub-id pub-id-type="pmid">34063562</pub-id><pub-id pub-id-type="pmcid">PMC8147602</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0148"><label>148</label><mixed-citation publication-type="journal" id="cbf70031-cit-0148"><string-name name-style="western"><given-names>J.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Radcliffe</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Pirrone</surname></string-name>, et al., &#8220;<article-title>A Novel Rotavirus Reverse Genetics Platform Supports Flexible Insertion of Exogenous Genes and Enables Rapid Development of a High&#8208;Throughput Neutralization Assay</article-title>,&#8221; <source>Viruses</source><volume>15</volume> (<year>2023</year>): <elocation-id>2034</elocation-id>, <pub-id pub-id-type="doi">10.3390/v15102034</pub-id>.<pub-id pub-id-type="pmid">37896813</pub-id><pub-id pub-id-type="pmcid">PMC10611407</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0149"><label>149</label><mixed-citation publication-type="journal" id="cbf70031-cit-0149"><string-name name-style="western"><given-names>M. J.</given-names><surname>Tohm&#233;</surname></string-name> and <string-name name-style="western"><given-names>L. R.</given-names><surname>Delgui</surname></string-name>, &#8220;<article-title>Advances in the Development of Antiviral Compounds for Rotavirus Infections</article-title>,&#8221; <source>mBio</source><volume>12</volume> (<year>2021</year>): <elocation-id>e00111&#8208;21</elocation-id>.<pub-id pub-id-type="pmid">33975930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00111-21</pub-id><pub-id pub-id-type="pmcid">PMC8262868</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0150"><label>150</label><mixed-citation publication-type="journal" id="cbf70031-cit-0150"><string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ding</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yin</surname></string-name>, et al., &#8220;<article-title>Suppression of Pyrimidine Biosynthesis by Targeting DHODH Enzyme Robustly Inhibits Rotavirus Replication</article-title>,&#8221; <source>Antiviral Research</source><volume>167</volume> (<year>2019</year>): <fpage>35</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="pmid">30974126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2019.04.005</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0151"><label>151</label><mixed-citation publication-type="journal" id="cbf70031-cit-0151"><string-name name-style="western"><given-names>S.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Li</surname></string-name>, et al., &#8220;<article-title>Drug Screening Identifies Gemcitabine Inhibiting Rotavirus Through Alteration of Pyrimidine Nucleotide Synthesis Pathway</article-title>,&#8221; <source>Antiviral Research</source><volume>180</volume> (<year>2020</year>): <elocation-id>104823</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104823</pub-id>.<pub-id pub-id-type="pmid">32485209</pub-id><pub-id pub-id-type="pmcid">PMC7261112</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0152"><label>152</label><mixed-citation publication-type="journal" id="cbf70031-cit-0152"><string-name name-style="western"><given-names>B.</given-names><surname>Mullins</surname></string-name> and <string-name name-style="western"><given-names>J.</given-names><surname>Chen</surname></string-name>, &#8220;<article-title>NLRP9 in Innate Immunity and Inflammation</article-title>,&#8221; <source>Immunology</source><volume>162</volume> (<year>2021</year>): <fpage>262</fpage>&#8211;<lpage>267</lpage>, <pub-id pub-id-type="doi">10.1111/imm.13290</pub-id>.<pub-id pub-id-type="pmid">33283292</pub-id><pub-id pub-id-type="pmcid">PMC7884643</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0153"><label>153</label><mixed-citation publication-type="journal" id="cbf70031-cit-0153"><string-name name-style="western"><given-names>A. L.</given-names><surname>Chang&#8208;Graham</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Perry</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Engevik</surname></string-name>, et al., &#8220;<article-title>Rotavirus Induces Intercellular Calcium Waves Through ADP Signaling</article-title>,&#8221; <source>Science</source><volume>370</volume> (<year>2020</year>): <elocation-id>eabc3621</elocation-id>.<pub-id pub-id-type="pmid">33214249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc3621</pub-id><pub-id pub-id-type="pmcid">PMC7957961</pub-id></mixed-citation></ref><ref id="cbf70031-bib-0154"><label>154</label><mixed-citation publication-type="journal" id="cbf70031-cit-0154"><string-name name-style="western"><given-names>D.</given-names><surname>Kumar</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Crawford</surname></string-name>, et al., &#8220;<article-title>2.7 &#197; Cryo&#8208;EM Structure of Rotavirus Core Protein VP3, a Unique Capping Machine With a Helicase Activity</article-title>,&#8221; <source>Science Advances</source><volume>6</volume> (<year>2020</year>): <elocation-id>eaay6410</elocation-id>, <pub-id pub-id-type="doi">10.1126/sciadv.aay6410</pub-id>.<pub-id pub-id-type="pmid">32494598</pub-id><pub-id pub-id-type="pmcid">PMC7159914</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>